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Su m m a r y
(A) The EBV translounc'd lymphoblastoid, Naimlwa, cell line was used to
investigate the effects of tliree cytotoxic agents on eukaryotic UNA
replication. Cytosine arahinoside, an analogue of deoxycytidine, at a 
-ticoncentration ol 5 x 10 M was shown to inhibit UNA synthesis by 50%
3
in the Namalwa cell line as measured by the incorporation of 11-thymidine
into acid precipitable material. . A comparative study of the metabolism
of cytosine arabinoside in transformed B and T lymphoblastoid cell lines
and the protozoan, T. pyrifomis was also undertaken. AraC Inis to be
phosphorylated to its active form, araCTP, before it can exert a
cytotoxic effect. Alternatively it can be inactivated by deamination
to araU. The metabolites of araC were identified in each test system
by using thin layer chromatography. The levels of araC kinase and
araC deaminase were assayed. Both types of lymphoblastoid cells
possessed high levels of araC kinase and no araC deaminase. T. pyriformis,
on the other hand, had a low level of araC kinase and a high level of araC
-4deaminase. The latter enzyme was inhibited 100% by 10 M tetrahydro- 
uridine.
The effect of cytosine arabinoside on MIA replication was invest­
igated using sedimentation analysis of DNA on alkaline sucrose gradients. 
The results indicate that araC inhibits MIA chain elongation. A 
comparative study of the effect of aphidicolin on UNA synthesis showed
_7
that 10 M aphidicolin inhibited MIA synthesis in Namalwa cells by 50%. 
The inhibitory effect of aphidicolin on MIA chain elongation was 
demonstrated using DNA sedimentation analysis on alkaline sucrose 
gradients.
The differing effects of cyclophosphamide, phosphoramide mustard 
and hydroperoxycyclophosphamide on UNA synthesis were demonstrated.
■1
1)NA synthesis in Naina I wu cells was inhibited 20% by 5 x 10 '' M cyclo-
_3
phosphamide, 65?. by 5 x 10 M phosphoramide mustard and 90% by
_3
5 x 10 M hydroperoxycyclopbosphamide. Analysis of DNA on alkaline 
sucrose gradients indicated that the alkylating agents acted by cross- 
linking newly synthesised DNA giving unusual DNA intennediates but 
this hyjwthesis needs l.o lx> cun finned by further experiments.
(B) The imnunosuppressive effects of the glucocorticoids, clobetasol 
propionate, clobetasone butyrate and 6-a-methyl prednisolone, on the 
delayed-type hypersensitivity response to the contact sensitising 
agent oxazolone was demonstrated in CBA mice. Hie inhibitory effects 
of cytosine arabinoside, aphidicolin and 6-a-methyl prednisolone on 
DNA synthesis in P11A stimulated hunan peripheral lymphocytes were
demonstrated, 60% inhibition was obtained with 10~6 M 6-a-methyl 
—7 -8prednisolone, 10 M aphidicolin and 10 M cytosine arabinoside.
Rat peripheral lymphocytes were stimulated to undergo blastogenesis 
with both PHA and an oxazolone-rat serum albumin conjugate. The DNA 
synthetic activity induced in both cases was inhibited by 6-a-methyl 
prednisolone. 34% inhibition was obtained with 10-4 M 6-a-methyl 
prednisolone in both the PHA and conjugate stimulated rat lymphocytes.
A ims o f t h e  Pr o j e c t
There is a wide diversity of cytotoxic compounds that are 
potential or clinically used anti-cancer and imnunosuppressive drugs 
each with differing mechanisms of action. The majority of those 
drugs exert their cytotoxic effect on all proliferating cells 
therefore a potential anti-cancer agent will have an effect on normal 
tissue as well as the malignant target tissue. Because of this many 
such drugs have an inhibitory effect on the cells of the imnune 
system. In many cases those drugs which are used to treat diseases 
involving the imnune system are also potent anti-cancer drugs. Many 
such drugs act by inhibiting DNA replication in proliferating cells. 
During the course of the work described in this thesis tliree types of 
cytotoxic agents were examined and their different mechanisns of 
action compared with respect to their effects on DNA replication in 
lymphoblasts.
The effects of two inhibitors of DNA synthesis, cytosine 
arabinoside and aphidicolin, were investigated with the aim of 
discovering at what point in the DNA replicative process they exerted 
their primary effect. Both are known inhibitors of DNA polymerase a 
and would therefore be expected to inhibit DNA chain elongation. 
However it has been proposed that araC may act primarily as an 
inhibitor of initiation so it was decided to investigate this 
possibility. The metatolian of araC in lymphoblasts and a protozoan 
mcxlel system was also studied with the aim that a study of araC 
metabolism could lead to a biochemical rationale for combination 
chemotherapy of araC with other drugs that could potentiate its 
effect as an inhibitor of DNA synthesis.
A comparative study was conducted on the inhibitory effect of 
the alkylating agent cyclophosphamide and its derivalives on DNA
()
replication. The two main aims of this study wore (a) to investigate 
the differential effects of cyclophosphamide, phosphoramide mustard 
and hydroperoxycyclophosamide on DNA replication and to (b) 
investigate the hy|x>thesis that these drugs act by cross-linking 
double stranded DNA thus preventing DNA replication.
'lbe glucocorticoid steroids and their synthetic derivatives are 
used clinically as imnunosuppressants and anti-inflanmatory agents. 
The iitmunosuppressive effects of three steroids were investigated 
using an in vivo inmunologic.al assay with the aim of correlating 
activity to chemical structure. The assay used was a delayed-type 
hypersensitivity response to the contact sensitising agent oxazolone. 
An in vitro assay system using mitogen stimulated human and rat 
peripheral lymphocytes was set up in order to develop a comparable 
in vitro method for screening potential imnunosuppressants. The 
aim was to develop this system further by stimulating the lymphocytes 
to undergo blastogenesis using an oxazolone-protein conjugate thus 
providing an in vitro analogue of the in vivo UTH assay.
C H A P T E R  1
Ly m p h o c y t e  St r u c t u r e  a n d Fu n c t i o n
1.1 INTRODUCTION TO IMMUNOLOGY
The vertebrate animal has a complex defence mechanian which 
affords it protection against invasion by foreign material. This 
protection is conferred upon the animal by the sanatic tissues known 
as the lymphoreticular system (1). The fixed tissues of the lymph- 
oreticular system consist of the bone marrow, thymus, spleen, lymph 
nodes, Bursa of Fabricius (only found in birds) and the gut-associated 
lymphoid tissue. The latter includes the tonsils, snail intestinal 
Peyer's patches, the appendix and nunerous areas of lymphocyte and 
macrophage accunulation within the lamina propria of the small 
intestinal villi and between the epithelial cells of the intestinal 
mucosal surface. The bone marrow is the site of origin of the 
pluripotent stem cells which ultimately differentiate into the various 
mobile cells of the lymphoreticular system. The thymus and Bursa of 
Fabricius are classified as primary lymphoid organs, the remaining 
tissues are classified as secondary lymphoid tissues.
The mobile cells can be sub-divided into myeloid and lymphoid cells. 
The myeloid cells consist of the granulocytes, monocytes and macrophages 
and these all have phagocytic properties. Phylogentically these are 
the most primitive cells in the animal's defence sysUm and are the 
main defence mechanism in invertebrates. The lymphoid cells consist of 
the B and T lymphocytes and their sub-sets and irrmunology is generally 
regarded as being the study of the structure and function of these 
cells. It is these cells that confer the property of specific inmunity
upon an animal.
8The B lymphocytes are formed in the Bursa of Fabricius in birds 
and in the "Bursa equivalent" in manmals. The "Bursa equivalent" has 
not been fully defined in tnanmals but is probably the tone marrow.
The host's B cells respond to invasion by a foreign material (antigen), 
e.g. foreign protein or bacterium, by pnxluoing a sjxicific protein 
(antibody). Antibodies are a species of protein known as inmuno- 
globulins and have two major functions, one is to bind the antigen 
and the other to elicit secondary biological phenomena resulting in 
destruction of the antigen. This response is known as the humoral 
irrmune response.
T lymphocytes are formed in the thymus and are responsible for 
what is known as cell-mediated inmunity. They can be divided into a 
number of subsets with different properties. They do not produce 
antibodies like the B lymphocytes but interact with the other cells 
of the lymphoreticular system in a very subtle fashion thus controlling 
the inmune response. They can promote or suppress 13 cell activity, 
they secrete a variety of lymphokines and are also capable of 
destroying invading cells by the secretion of toxins. They are involved 
in the delayed-type hypersensitivity response (DTH) and in the graft- 
versus host reaction (GVH)
One other defence mechanism that animals possess is a group of 
heterogenous, low molecular weight proteins known as the interferons 
which are produecxl by infected host cells to protect non-infected cells 
from viral infection (2). It was first thought that interferon was a 
single protein but it has now been shown that there are several types 
of interferon. Lymphocytes are known to produce at least two types of 
interferon and possibly a third. Fibroblasts have also been shown to 
be capable of producing interferon. The latter can be distinguished
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from lymphocyte Interferons as it is a glycoprotein. It seems as if
interferon acts in response to the presence of double-stranded RNA,
the replicative form of RNA produced by viruses. Work with the
artificial ds.RNA poly I.poly C. has shown that interferon inhibits
protein synthesis in two ways. One method is the phosphorylation of
the protein synthesis initiation factor eIF.2 by an interferon
mediated protein kinase. The second involves degradation of messenger
RNA by an endonuclease which is activated by the unusual nucleotide 
2' 5' 2' 5'
pppA p A p A, abbreviated to 2.5A (3). Recent work on interferon 
has suggested that it migilt be a possible cancer chemotherapeutic 
agent as well as an anti-viral agent.
1.2 B AND T CELL DEVELOPMENT AND DIFFERENTIATION
All blood cells, erythrocytes, myeloid cells and lymphoid cells, 
are derived frem primitive, pluripotent haematopoietic stem cells 
formed in the bone marrow. During embryogenesis stem cells are 
produced in the yolk sac. The site of stem cell production then 
changes to the foetal liver and finally to the bone marrow where it 
remains throughout adult life. These stem cells differentiate to form 
lymphocytes in the primary lymphoid organs. The differentiated cells 
then migrate to the secondary lymphoid organs from where they enter 
the recirculating lymphocyte pool in the blood and lymphatic vessels.
Haematopoiesis, the developnent and differentiation of the blood- 
forming cells, is a complex process involving subtle interactions 
between the different cell types and haematopoietic tissues (4). All 
the different cell types originate from the same pluripotent stem cell. 
Evidence for a single stem cell has come from experiments in mice in 
which chromosome markers were induced in donor bone marrow cells by 
irradiation. Myeloid spleen colonies and B and T lymphocytes in 
reconstituted animals had the chromosome marker of a common precursor.
Evidence for the existence of pluripotent stein cells in man lias come 
fran the appearance of the Philadelphia chranosane in cells of the 
granulocytic, mononuclear phagocytic and erythroid lines in patients 
with chronic myeloid leukaemias.
ilie prcxiess of caimitment of the stem cells to a particular line 
of development is poorly understood. It is known that this process 
does come under hormonal control fran polypeptide hoimones known as 
haematopoietins (5). However a stun cell is not in itself ccmnitted 
to a line of development simply by exposure to one of the sjiecific 
haematopoietins. For example the triggering signal for erythrocyte 
production is the balance between tissue-oxygen needs and the 
capacity of the oxygen delivering system. A stem cell is not 
responsive to the erythrocyte producing haonatopoietin, erythropoietin, 
until at seme point in its development it forms an erythropoietin 
responsive stem cell which is then ccmitted to development along the 
erythroid pathway, ccnmitment may therefore be defined as the 
acquisition of responsiveness to a specific haematopoietin. 
Haematopoietins for other cell lines are the CSA factor (colony 
stimulating activity) for granulocytes, thymopoietin for T lymphocytes 
and bursopoietin for B lymphocytes, produced in the thymus and Bursa 
respectively. A non-selective inducing agent found in all tissues is 
the polypeptide ubiquitin, this is not a physiological inducing 
hormone. All these polypeptides act by increasing cyclic AMP levels 
in the precursor cells. Other agents have also been shown to be 
capable of non-selectively inducing lymphocyte differentiation. These 
include cyclic AMP, dibutyryl cyclic AMP, adrenaline, bacterial 
endotoxin, cholera toxin and poly(A:U) all of which act by raising 
intracellular cyclic AMP levels. All of these agents act as positive 
controls in haematopoietic development.
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development and differentiation.
As well as the positive controls there are a number of negative 
feedback controls and interactions between the different cell 
populations. Negative feedback control is thought to be produced by 
chalones. Chalones are defined as tissue specific, species non­
specific, products of differentiated cells that selectively inhibit 
early cells of the same lineage. This type of negative feedback 
control has been postulated for granulocytopoiesis though its 
existence has not been fully established. Another form of negative 
control of myeloid cell development .that has been reported is the 
existence of neutrophil derived factors that inhibit cells producing 
CSA. Prostaglandin involvement has also been demonstrated, PGEj and 
PGEg have been shown to be inhibitors of granulocyte proliferation 
whereas F prostaglandins are stimulatory.
There is also extensive interaction between the different cell 
lines, e.g. CSA is produced by lymphocytes, monocytes and macrophages, 
and prostaglandins are produced by monocytes and macrophages. It has 
also been suggested that erythropoiesis is modulated by T cell inter­
action. Another form of cell-cell interaction is that between 
proliferating haematopoietic cells and the strcmal cells of the blood 
forming organs. The rate of stem cell replication and differentiation 
is partly determined by factors derived from the organ in which the 
cells are situated. These factors are collectively referred to as the 
haematopoietic inductive microenvironment and may be under seme form 
of genetic control.
1.3 B CELL STRUCTURE AND FUNCTION
The differentiation of B lymphocytes from pluripotential stan cells 
to fully mature antibody-secreting cells can be divided into two stages. 
The first stage consists of the differentiation of the cells within the 
primary lymphoid organs (see Section 1.2). This stage is known as
i:»
l'l
clonal development and results in the formation of inniunoccmpetent B 
lymphocytes. These celIs carry specific cell surface markers that can 
be used to differentiate them frem T lymphocytes. These markers are 
very useful as to all intents and purposes all lymphocytes look the 
same when viewed under the 1 itillL microscope having a characteristic 
round appearance consisting of very little cytoplasm surrounding a 
large nucleus which occupies most of the cell volume. The cell 
surface markers fall into three categories and can lxj used to identify 
sub-populations of B lymphocytes in -the circulation. The principle 
categories are surface irmiunoglobulin molecules, receptors for the Fc 
portion of the inmunoglobulin molecule and cells with receptors for the 
third component of complement (C,^). Often B lymphocytes express two of 
these markers and occasionally three. These markers may represent 
different stages in the sequential maturation of B lymphocytes or they 
may denote discrete populations of B lymphocytes (6).
The second stage of B lymphocyte development is the antigen- 
induced differentiation of B ' ohocytes to mature plasma cells and 
memory cells. The second stage is referred to as clonal selection by 
antigen. When the inmunoglobulin bearing B cell binds to an antigen 
the cells are stimulated to undergo either clonal expansion giving rise 
to daughter memory cells for that particular antigen or they differ­
entiate directly into mature, specific antibody-secreting plasma cells. 
The manory cells have a long life span of several months or years in 
contrast to the plasma cells which are relatively short lived having 
half-lives that can be measured in days.
An antigen can be described as an invading foreign particle within 
the host animal which elicits an immune response. The invading particle 
has to fulfil certain requirements for it to have antigenic properties. 
It must be a large particle with a molecular weight generally greater
If)
than 5,000. 'Hie ixrlential antigen must have a rigid structure and 
the antigenic determinant (that part of the molecule recognised by the 
antibody) has to be of a consistent shape and charge pattern. Anti­
gens must also have a high degree of internal complexity and are 
often multivalent, i.e. having more than one antigenic determinant. 
Small molecules can be coupled to large carrier molecules such as 
proteins to produce antigens. Small molecules that can act in this 
fashion are called haptens and are non-iimunogenic when not coupled 
to a carrier.
Antibodies are a class of proteins known as immmoglobulins. 
Imnunoglobulins are made up of equal numbers of heavy and light 
polypeptide chains with a general formula (II2Ij2 )n • These chains are 
held together by non-covalent forces and interchain disulphide bridges. 
Each chain is made up of a number of loops called domains. The 'N1 
terminal domain has a variable amino acid sequence compared with the 
other domains. This variable region represents the antigen binding 
site and confers specificity upon the antibody. As well as a complex 
two-dimensional structure iumunoglobulins have a complex three- 
dimensional structure. The polypeptide chains of each domain are 
folded into a series of anti-parallel folds forming two surfaces held 
together by a disulphide bridge. This basic shape allows non- 
covalent interactions between pairs of domains thus holding the 
structure rigid.
As well as binding to specific antigens the inmunoglobulins have 
other important biological, or adjunctive, functions to perform as 
part of their role in the humoral inmune response. One of these 
functions is the fixation and activation of the compliment system. Hie 
complement system is a group of serun proteins that acts as the primary 
hunoral mediator of the antibody-antigen reaction. The activation of
Ill
the amplement system procédés via a cascade ol' triggered enzyme 
systems that ultimately cause coll lysis. Another im|x>rtanL biological 
function is the transfer of ijiniinoglobulins across epithelial membranes. 
'Ibis is of importance in providing antibodies for the external surfaces 
of tin' Uxly e.g. the alimentary, respiraLory ;uul reproductive tracts. 
They can also U' transferred across the placenta lion mother to foetus, 
a function which is of particular importance in the protection of the 
newly-born.
1.4 T CELL STRUCTURE AND FUNCTION
T lymphocytes are the primary mediators in cell mediated immunity 
and can be distinguished from B lymphocytes by differences in their 
surface membrane. One obvious difference is the lack of iimiunoglobulins 
on the surface membrane of T cells. There are also a number of 
distinctive cell surface markers including certain alloantigens. These 
have been mainly studied in mice because of the availability of a large 
nunber of inbred strains. Such antigens are the Thy 1 and Ly 1,2,3 and 
5 antigens, the other member of the series, Ly 4, is also present on B 
lymphocytes. These antigens can be identified by their reaction with 
specific antisera. Human T lymphocytes also possess surface receptors 
for sheep red blood cells. Hie sheep erythrocytes bind to the T cell 
surface forming a rosette of red cells around a central lymphoid cell. 
Hie rosette test has proved to be a useful marker for himan T lympho­
cytes.
Hie classification and characterisation of the rrjany T cell sub­
populations is very complex because their morphological differences are 
somewhat unclear. Hiey are best distinguished by their specific 
functions. Hie sub-populations of T lymphocytes are helper cells, 
suppressor cells, cytotoxic T cells, killer cells and natural killer 
cells (6). Hie helper T lymphocytes function as "helpers" in inducing
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antibody responses, The synthesis of antibodies by 11 lyrnptiocytes is 
critically dependent on the presence of adequate numl>ers of helper 
cells. The opposite function is performed by suppressor cells which 
act by limit inti specific iinnune responses such as the antibody-antigen 
respt >nse.
Cytotoxic T cells are specifically sensitised to kill target cells 
bearing antigens that have been induced by virus, bacterial or 
parasitic infections. Tbe cytotoxic response of T lymphocytes to 
persistent viral infection is of great importance. Most individuals 
are infected at sane time in their lives with Herpes simplex, 
cytanegalovirus or Epstein-Barr virus. Normally transient illness 
occurs after primary infection but after that persistent infection 
is of little clinical consequence. Defects in this aspect of inmunity 
can have serious consequences e.g. children with severe cytomegalo­
virus infections or lymphoproliterative disorders such as infectious 
mononucleosis and lymphcma after EBV infection.
Killer cells are a distinct sub-population of lymphoid cells 
capable of killing target cells sensitised with antibodies to their 
cell surface antigens. This phenanenon is called antibody-dependent 
cell-mediated cytotoxicity (ADCC). Killer cells have seme B cell 
characteristics, such as receptors for and surface inmunoglobulins, 
and sane T cell characteristics such as rosette formation with sheep 
erythrocytes. Killer cells therefore do not fit easily into any 
category though they appear to be of thymic origin.
Natural killer cells (NK) have been identified as a population of 
lymphoid cells capable of lysing or damaging a variety of malignant 
target cells in vitro. Tliis has lead to suggestions that they may 
play a role in tumour surveillance (7). However more recent evidence 
suggests that NK cells play an integral role in T cell and non-T cell
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interactions and may have an inmunoregulatory role (8). It has been 
shown that NK activity can lx; augmented by interferon and that their 
primary role may lx- as a surveillance mechanian directed against 
viruses. Like killer cells they appear to lx; of T cell lineage having 
weak affinity receptors foi- sheep erythrocytes though this is a 
controversial point as they also ixssess Fc receptors, a characteristic 
of B lymphocytes.
1.5 CELL INTERACTIONS IN THE IMMUNE RESPONSE
'Hie imnune response is under strict regulatory control via a 
series of cellular interactions. One such example is the control of 
haematopoiesis (see Section 1.2). The control of both hunoral and cell- 
mediated inmunity is also governed by the interactions of different 
lymphocyte populations. The humoral, B lymphocyte mediated, imrnine 
response is controlled by T lymphocyte helper and suppressor cells 
(see Section 1.4). The cell-mediated iinnune response is itself 
controlled by the release of chemical mediators known as lymphokines (6).
Lymphokines are non-iirmunoglobulin mediators produced by 
activated lymphocytes which produce their effect by acting on the 
cell-mediated iirmune response (9). There are many different lymphokines 
and it is not yet known exactly what activity each lymphokine possesses 
and much work has still to be done in the physiology and biochemistry 
of lymphokine secretion (10). It is known that they are released in 
minute amounts and that their activity is relatively intense.
One of the first lymphokines to be discovered was macrophage 
migration inhibition factor (MIF). Its function is to inhibit the 
migration of normal macrophages. A number of other lymphokines have 
been demonstrated in mouse sera, these include a bacteriostatic factor, 
a timour inhibiting factor, a lymphotoxin, a mitogenic factor and a
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mixed lymphocyte reaction suppressor factor. Both B and T cells sixtn 
to be involved in lymphokine release. In the case of HIF evidence 
suggests that T cells are initially important in the antigen 
sensitisation stage and once sensitised T and B cells interact to 
produce Mil1’. The interaction of interferon with lymphocyte's also 
suggests its involvement in inmunorcgulation. All this emphasises 
the complexity of imnunoregulatory control and the large degree of 
integration between the various components of the irrmune system.
1.6 THE USE OF IMMUNOSUPPRESSIVE DRUGS
Inmunosuppressive drugs are agents which depress or suppress the 
development of one aspect of the inmune response (11, 12). The 
majority of these drugs exert their effect by interfering with the 
growth of rapidly dividing cells and are therefore not specifically 
directed against inrmine function. Itmiunosuppressive agents are often 
active at doses close to their toxic level and therefore can produce 
a number of undesirable side effects. This means the use of such drugs 
has to be carefully considered and it is essential to determine the 
best ackninistration regimen which will permit maxirnim inmunosuppressive 
activity with the least toxicity.
The mechanisms of the different types of inmunosuppressive agents 
differ widely. Alkylating agents such as chlorambucil and cyclo­
phosphamide act by crosslinking macrcmolecules such as DNA thus 
preventing cell replication. The antimetabolites such as cytosine 
arabinoside and methotrexate resemble natural enzyme substrates and 
compete with the natural substrates for enzyme active sites. Cytosine 
arabinoside is an inhibitor of DNA polymerase a and methotrexate is an 
inhibitor pf tetrahydrofolate reductase which results in the depletion 
of tetrahydrofolate, a cofactor for the enzyme thymidylate synthetase. 
The mechanian of action of corticosteroids is still unresolved but they
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appear to act by suppressing UNA and HNA synthesis. Sane antibiotics 
and plant alkaloids and cytotoxic antisera to lymphocytes also act as 
inmunosuppressants.
Imnunosuppressive drugs are list'd as chemotherapeutic agents in a 
nimber of diseases involving the irmiune res|x>nse (12, 13). They are 
widely used in the treatment of inflammatory diseases though sometimes, 
as in the case of corticosteroids, the anti-inflairmatory effect is not 
necessarily linked to the inmunosuppressive effect. Cyclophosphamide 
and chlorambucil have been used in the treatment of systemic lupus 
eryethanatosus. Rheumatoid arthritis has been treated with methotrexate, 
cyclophosphamide and azathioprine. Psoriasis has been effectively 
treated with methotrexate and alkylating agents.
Another major use of immunosuppressants is in transplant surgery. 
Here their ability to suppress the immune response is used to prolong 
graft survival in patients receiving organ transplants and skin grafts. 
The corticosteroids have been particularly useful for this purpose. A 
new canpound which has enormous potential in this field is the recently 
discovered fungal metabolite cyclosporin A which is a specific inhibitor 
of cell-mediated immunity.
Many drugs with imnunosuppressive activity are used in the treatment 
of tumours and cancers as a result of their non-specific action on 
rapidly metabolising cells (14, 15). In many cases of cancer chemo­
therapy one of the undesirable side effects of the drugs used is their 
imnunosuppressive effect. It is this difficulty in finding selective 
drugs which makes cancer chemotherapy so difficult as any drug affecting 
cell metabolism will also act on normal cells as well as malignant cells. 
It is the seriousness of these diseases which justifies using such 
drastic treatment. One form of cancer in which the immunosuppressive 
property is desirable are those cancers of the immune system i.e. the
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leukaemias and lymphomas discusscxl below.
1.7 LEUKAEMIAS AND LYMPHOMAS
Leukaemias and lymphcmas are both malignant neoplastic diseases of 
the cells involved in the immune response and usually arise from the 
clonal proliferation of one cell type. Their main difference is 
anatomic rather than pathogenic e.g. chronic lymphocytic leukaemia and 
lymphocytic lymphoma may be abnormalities of the same B cell (16). 
Lymphcmas are solid tunours and are’anatomically restricted to the 
lymphoid tissues. The two major categories of lymphoma are the 
Hodgkin's and non-Hodgkin's lymphomas. There is no completely 
satisfactory definition for Hodgkin's lymphcmas but they can be 
morphologically defined as malignant neoplasms which arise in sane 
lymph nodes, often spreading to others, composed of neoplastic and 
normal cells inteimingled in a uniquely complicated way. Non- 
Hodgkin's lymphomas are defined as all other solid lymphoreticular 
neoplaans and they consist almost entirely of neoplastic cells.
Leukaemias differ from lymphanas in that a significant nunber of 
the malignant cells are constantly present in the blood or bone marrow. 
Leukaemia is associated with abnormal leucocyte counts, anaemia and 
thrombocytopenia. Death usually occurs as a result of infection or 
haemorrhage. The two major classifications of leukaemia are the 
myeloid and lymphoid leukaemias derived from neoplastic myeloid and 
lymphoid cell lines respectively. These can be further sub-divided 
into the acute and chronic leukaemias. The acute leukaemias are 
rapidly fatal diseases, the average time interval from onset to death 
in untreated cases being two to four months. The chronic leukaemias 
are diseases of longer duration of around three to six years between 
onset and death. These classifications must be considered as 
generalisations as not all lymphomas and leukaemias can be so neatly
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characterise*! (17).
Many leukaemias and lynphonas exhibit visible, non-randan, 
chranosanal rearrangements (18, 19). About 90% of chronic myeloid 
leukaemias shew a translocation from chromosome 22 to 9 which creates 
the shortened 22 chrunosune known as the Philadelphia ctmmosunc.
There is frequent involvement of chranosane 14 abnormalities in B cell 
neoplasms as in Burkitt's lymphoma. In murine T cell leukaemias 
trisomy at chrunosome 15 is often observe*!. It is thought that these 
translocations may be the specific genetic change require*! for the 
transition of pre-neoplastic cells to neoplastic cells. It is not yet 
certain what the initiators for leukaemia and lymphoma development are. 
In the case of Burkitt's lymphoma it is known to be a virus, the 
Epstein-Barr virus (EBV); this is also the case in some murine 
leukaemias (20). There is no direct evidence for virus involvement in 
Inman leukaemias though the possible involvement of RNA viruses has 
been indicated by the presence of the enzyme reverse transcriptase in 
some leukaemic cell types (21, 22, 23). Other possible initiators are 
chemical carcinogens and radiation.
There are a number of different approaches to therapy, the aim of
which is to induce remission a state in which all clinical and 
J, wwui
laboratory signs of the have disappeared. Types of therapy include 
bone marrow transplants, radiation therapy, chemotherapy and inmuno- 
therapy. The latter can take the form of imnunisation against a timour 
cell type, passive transfer of antisera or cells with anti-tunour 
activity and non-selective stimulation of the inrnune'response with 
drugs (24). Chemotherapy often takes the form of multi-drug regimens 
consisting of a number of drugs acting in different ways (25, 26, 27). 
Chemotherapy is often supplemented with radiation therapy e.g. in the 
treatment of acute leukaemias irradiation of the central nervous 
system is carried out to prevent the onset of meningitis (28). Many
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of the drugs usexl are the same as those described in Section 1.6. 
Cyclophosphamide is used to treat Burkitt's lymphana and cytosine 
arabinoside is used in combination with drugs such as daunorubicin, 
prednisolone and methotrexate in the treatment of myeloid leukaemias.
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C H A P T E R  2
Eu k a r y o t i c  DMA Sy n t h e s i s
2.1 HISTORICAL PERSPECTIVE
The complexity of the mechanism of DNA synthesis has become 
increasingly apparent since the double helical structure of DNA was 
first elucidated by the X-ray diffraction studies of Watson and 
Crick. The DNA molecule consists of two polynucleotide chains 
intertwined in a helical fashion. The backbone of the two chains 
consists of deoxyribose units linked by 3', 5'-phosphodiester bridges. 
The two chains are held together by hydrogen bonding between 
complementary base pairs of cytosine and guanine, and adenine and 
thymine. Each stand has a polarity caused by the phosphodiester bond 
between C-3' and C-5' atoms of two neighbouring nucleosides, the two 
conplementary strands having opposite polarities.
A great deal of our understanding of the biosynthesis of this 
macrcmolecule has come from work on prokaryotes, mainly E. ooli which 
has a single circular chrcmoscme a much simpler system when compared 
to the multi-chromosome system of eukaryotes. It was by using this 
organisn that Meselsohn and Stahl demonstrated the semi-conservative 
nature of DNA synthesis, i.e. that newly synthesised DNA molecules 
consist of one newly synthesised daughter strand and one parental 
strand. The opposite polarities of the two strands presented problems 
when explaining the mechanism of DNA replication, either the two 
strands are synthesised by two separate polymerizing activities or by 
some more complicated process. This problem was solved by Okazaki 
who found that one strand, the leading strand, is synthesised 
continuously in the same direction as the movement of the replication
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fork whereas the other, lading, strand is synthesised discontinuously 
in sliort pieces in the opposite direction. These short pieces are 
then joined together to give net synthesis in the same direction as 
the leading strand (29). The direction of synthesis has been shown 
to be in the 5' to 3' direction along the new DNA strand.
Fran this it becanes apparent that the enzymatic machinery 
involved in DNA synthesis is extremely complex (30). Besides the 
existence of a polymerizing activity there has to lie a mechanian for 
unwinding and separating the strands of the helix, for priming and 
initiating the process, ligating the Okazaki fragments on the lagging 
strand and for termination. The whole mechanian has to proceed at a 
rate compatible with cell growth and close to 100% accuracy. The 
process in E. aoli is known to require at least a dozen different 
proteins all involved with the control and synthesis of new DNA 
molecules.
The first of these proteins to be discovered was the DNA polymerase I 
of E. ooli. This enzyme can use nicked duplex DNA, duplex DNA 
containing large gaps or a primed single strand of DNA as a tanplate.
As well as possessing polymerizing activity it also has 3' to 5' 
exonuclease activity and 5' to 3' exonuclease activity. It was 
originally thought to be the major enzyme of DNA replication until a 
mutant was isolated defective in this enzyme yet still capable of 
replication. This lead to the discovery of DNA polymerase III. This 
enzyme is made up of at least four subunits and exists in two main 
forms, the polIII enzyme and the holoenzyme consisting of polIII and 
c.opolymerase III. The holoenzyme is the functional enzyme in E. coli 
DNA synthesis. It can only use single stranded DNA as a tanplate and 
possesses 3' to 5' exonuclease activity. This exonuclease activity 
is part of a proof-reading mechanian for removal of misnatched bases.
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A third I)NA polymerase has been found in E. ooli, polymerase II. The 
role of this enzyme is not clear but it may be involv<*l in DNA repair.
Tlie other proteins involved in E. ooli DNA synthesis have been 
identified and their roles established by using bacteriophages such as 
0X174, col ipliage Ml If and (54 as proltes. These phages have much smaller 
and simpler chromosomes than E. ooli. These phages depend on the 
enzymes of E. ooli for their replication and each phage has been used 
to investigate a different part of the DNA synthesis machinery of 
£. ooli. The life cycle of 0X174 is shown in Fig. 2.1 and a list 
of the proteins involved in the conversion of 0X174 SS-DNA to RF-DNA is 
shea\t i in Fig. 2.2. 'Hie cisA protein is peculiar to the life cycle of 
0X174. The other proteins can all be assigned a role in the 
replication of £’. ooli DNA (see Fig. 2.3) (31).
A leading strand started at the origin of replication of the 
chrcmoscme advances continuously, its progress being made possible by 
the unwinding action of them) irotein. Binding protein stablises the 
single stranded DNA so it can act as a template while the bared 
opposite strand becomes the template for the discontinuous synthesis 
of the lagging strand. Delivery of the promoter dnaB protein by the 
preprinting proteins dnaC, protein i and protein n prepares the tanplate 
for priming. Proteins dnaB and dnaC are used stoichicmetrically whereas 
proteins i and n are used catalytically. The primase, dnaG, synthesises 
a short segment of RNA to serve as a primer for the covalent extension 
by DNA polymerase III haloenzyme. Elongation may average 1000 nucleo­
tides or so. Progressive movement of the dnaB protein in the 5 ’ to 3' 
direction of the leading strand enables it to follow the progress of 
the replicating fork also enabling primase to make successive 
discontinuous initiations of the lagging strand. DNA polymerase I 
r«moves the RNA primer by its 5' to 3' exonuclease activity and fills 
in the gaps on the lagging strand. The ends of the discontinuous
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F i g  2 . 1  L i f e  c y c l e  o f  0X17*1. Th e  c i r c u l a r  s i n g l e  s t r a n d e d  DNA 
chrom osom e i s  c o p i e d  t o  E i v o  t h e  d o u b l e  s t r a n d e d ,  r e p l i c a t i v e  
( R F )  f o r m .  T h e  o r i g i n a l  s t r a n d  i n  d e s i g n a t e d  (- f )  an d t h e  n e w ly  
s y n t h e s i s e d  s t r a n d  ( - ) .  T h e  ( - )  s t r a n d  i s  u s e d  a t e m p l a t e  to  
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*Ste Table 5-3 for more details.
•Normal protein level was increased this many times by introducing a plasmid or phage vector containing the encoding gene
The proto in.; in tfXiV'i DMA r c . l  ic . i t ln n  inFig ?-.? ur.cd ce_LL
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F i g  2 . 3  H y p o t h e t i c a l  ochc-mo f o r  t h e  r e p l i c a t i o n  f o r k  o f  the  
li»_c o l i  ch ro m o s o m e .
segments are thon sealed by DNA ligase activity uniting the nascent 
f raiments into an intact duplex.
2.2 ORGANISATION OF THE EUKARYOTIC CHROMOSOME
The eukaryol ic chranosano is much larger Lh;ui a prokaryotic 
chrcmosane. This increase in size is concomitant with an increase in 
complexity and organisation. The prokaryotic chromosome replicates as 
a whole unit starting at a unique origin and proceeding until the 
whole unit has been copied, this unit of replication is called a 
replicon. Eukaryotic chromosomes do not replicate as single elements. 
Instead different sections of a chromosome are replicated at different 
periods of the S phase of the cell cycle, i.e. eukaryotic chromosomes 
contain more than one replicon or replication unit. This form of DNA 
replication requires a more sophisticated level of organisation than 
exists on a prokaryotic chromosome (32).
The DNA of the eukaryotic chranoscme is organised into repeating 
structural nucleoprotein units called nucleosomcs of about 200 base 
pairs in length canplexed with histones (33). The nucleosome can be 
sub-divided into a core particle and a linker region. Hie nucleosome 
core consists of approximately 140 base pairs wound around a histone 
octamer containing two each of the histones H2A, H2B, H3 and H4.
Histone HI associates with a further 60 base pairs to form the linker 
and appears to play a role in the higher order packing of chromatin. 
There is also a complex range of local variations in the distribution 
of non-histone proteins along the length of the chromosome.
Nucleoscmes can be formed in vitro f ran histones and DNA by 
dialysis against salt solutions the speed of formation depending on 
ionic concentration. Two proteins have been found in the eukaryotic 
nucleus which allow nucleoscme core assembly to proceed rapidly in vitro,
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these are topoiscmerase I (nicking-closing enzyme) and nucleoplaanin, 
an acidic, thermostable protein (34). It is thought that these 
proteins may act together by competing against or masking the strong 
electrostatic interactions between histones and DNA thus allowing 
asstmhly to occur without aggregation and precipitation as occurs in 
salt solutions. There is as yet no direct evidence that these two 
proteins act as assembly factors in vivo but indirect evidence seems 
to support their involvement in nucleoscme assembly. The nucleoscme 
structure is integrated into the helical structure of the DNA molecule.
It is thought that the helix is then super-coiled to form the close 
packed structure of the eukaryotic chromosome.
The control of chromosome replication is organised on several 
levels all of which may be regulated in part by chromatin structure (35). 
There is a degree of tenporal control at the level of the chromosome 
in that certain sections of the chromosome are replicated at defined 
times in S phase. This degree of control is more apparent in lower 
eukaryotes. The next level of control is exerted on a cluster of 100 
replication units or less. Such clusters replicate synchronously as 
a whole section of UNA within the chromosome. The third level of 
organisation is the replication unit itself. A replication unit is a 
stretch of DNA replicated by two adjacent growing points which share 
a cannon origin and which move in opposite directions fran the origin. 
The initiation of replication unit synthesis also appears to be subject 
to tcmijoral control. After initiation new daughter strands are 
synthesisexi, at least one strand is synthesised discontinuously as 
Okazaki fragments which are subsequently ligated. Nucleosome size 
may govern the initiation of Okazaki fragments whereas the temporal 
control of initiation on replication units and clusters may be 
controlled by higher orders of chrcmatin structure.
2 .3  NUCLEOTIUE METABOLISM
Tlio first step in DNA biosynthesis is the production of the 
nucleotide precursors (36). These are made available to the DNA 
synthesis machinery via two main pathways, Ilu.* ./<? novo biosynthesis 
pathways and the salvage pathways. The first type of pathway 
utilises ribose-5'-phosphate, certain amino acids, carton dioxide and 
amnonia. These are combined in a series of successive reactions to 
form the free nucleotide-5'-monophosphates. There are two separate 
de novo pathways, one for purine synthesis and one for pyrimidine 
synthesis (Fig. 2.4 and Fig. 2.5).. In eukaryotes several of the 
enzymes for dc novo synthesis are linked into a single multifunctional 
unit whereas in prokaryotes such as E. ooli the enzymes can be 
extracted in soluble form.
The nucleotides formed in this way are ribonucleotides which then 
have to be converted to the deoxyritose form before they can participate 
in DNA synthesis. The enzyme responsible for this conversion is 
ritonucleoside diphosphate reductase. It catalyses the following 
reaction:
ritoNDP + reductant-lSlOg --- * deoxyritoNDP + reductant-(S-S)
The cofactor supplying the enzyme with the pair of sulphydryl groups is 
thioredoxin. An alternative reductant found in E. ooli mutants lacking 
thioredoxin is glutathione coupled to a protein glut.arodoxin. This 
enzymes replaces the 2 1 -Oil group of rilxxse with the hydrogen atom to 
give the deoxyritose sugar present in dooxyritonuoleotidos.
The nucleotide deoxythymidine, the nucleotide unique to DNA, is 
formed iron dUMP by the enzyme thymidylate synthetase. This enzyme 
transfers a methyl group fran the coenzyme methylene tetrahydrofolate 
to deoxyuridylate to give deoxythymidylatc*. The coenzyme is
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regenerated by the enzymes dihydrofolate reductase, which catalyses 
the? formation of tetrahydrofolate, and serine hydroxymethyltransfora.se 
which converts tetrahydrofolate to methylene tetrahydrofolate. The 
source of dUMP is dLTlV produced by the action of the enzyme dlTIPase.
The salvage pathways use tin; free buses and nucleosides ultimately 
produced by the breakdown of nucleic acids to provide an alternative 
source of precursors which can supplement de novo synthesis. This is 
essential, where due to mutation or the inherent genetic make-up of 
the cell, certain enzymes in de novo synthesis are lacking. When such 
a situation exists in pathogens, but not in the host's metabolign, 
these differences can be exploited as a rationale for the use of 
certain chemotherapeutic agents. As well as providing precursors for 
DNA synthesis salvage pathways may also serve important disposal or 
detoxification functions and play an important role in the drug 
metabolism of nucleoside and base analogues used in chemotherapy. A 
list of the inportant salvage reactions is shown in Fig. 2.6.
The nucleoside-5'-monophosphates do not participate directly in 
DNA synthesis and have to be first converted to the 5'-triphosphates, 
the substrates for the DNA polymerase enzymes. The monophosphates 
are first converted to diphosphates by base specific kinases. These 
kinases will however act on either ribose or deoxyribose nucleotides. 
The general reaction is:
NMP + ATP ---- »■ NDP + ADP
Diphosphate synthesis is favoured by the rapid regeneration of ATP by 
oxidative and substrate-level phosphorylation. The diphosphates are 
converted to triphosphates by ubiquitous, non-specific kinases. The 
enzymes show no preference for any particular base or sugar. This 
lack of specificity also applies to the donor triphosphate but this
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is generally ATP.
The synthesis of 1)N A precursors is under strict regulatory control 
and nucleotide pool size plays an important role in the regulation of 
DNA synthesis (37). There are two important points of regulation in 
purine nucleotide synthesis. The initial ccmnilinent to purine synthesis 
is under feedback regulation. The end products of the pathway AMI5, ADP, 
ATP and Gf.IP, GDP and GTP inhibit the enzyme amidophosphoribosyl 
transferase which condenses PRPP with glutamine to give phospho- 
ribosylamine. The second point of regulation occurs where the pathway 
diverges to form either adenylate or guanylate from inosinate. This 
point is under feedback control from ATP and GTP. If GTP is in 
excess more adenylate is formed and vice versa. The enzyme aspartate 
transcarbamylase is the key controlling enzyme in pyrimidine biosynthesis 
in E. aoli . This enzyme is controlled by feedback inhibition iron CTP 
and feedback activation from ATP thus balancing the synthesis of 
purine and pyrimidine nucleotides with one another.
Another important regulatory site for the production of DNA 
precursors is the enzyme ribonucleoside diphosphate reductase. This 
enzyme is under strict allosteric control responding to the metabolic 
needs of the cell, ATP acts as a positive effector whereas dATP acts 
as a negative effector when binding at the overall activity sites. ■
When ATP or dATP bind at the substrate specificity sites reduction of 
UDP and CDP is favoured. Binding of dTIP stimulates GDP reduction and 
binding of dGTP stimulates ADP reduction thus giving fine control over 
the availability of specific DNA precursors.
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2.4 INITIATION OF I)NA SYNTHESIS
Growing cells go through a cyclic sequence of events known as 
the cell cycle. These can be siirmarised as G^ - the post mitotic phase, 
S- the DNA synthetic phase, G^- the post synthetic phase and M- the 
mitotic phase. '11« control of entry into S phase Iran Gj is the first 
regulatory point for DNA synthesis and is hypothesised to be controlled 
by cytoplaanic factors. A requirement for protein synthesis for the 
entry into S phase lias been demonstrated indicating that progression 
frcm Gj to S phase is controlled by a regulatory protein synthesised 
during G^ and which acts as a positive effector to de-repress DNA 
replication (38).
The initiation of synthesis of replication units during S phase 
also requires protein synthesis (39, 40, 41) and evidence points 
towards the existence of a DNA binding protein which stimulates DNA 
synthesis and probably acts as a helix-destabilising protein. One 
protein of this type is the T antigen produced by SV40 virus (32, 42). 
This protein is required for the initiation of viral DNA replication 
and for the induction of cellular DNA synthesis. Other DNA binding 
proteins have been discovered for other viruses.
In most cases eukaryotic DNA replication is initiated at an 
origin within the replication unit and proceeds bidirectionally by 
the movonent of two replication forks towards two termini. Recent 
evidence has suggested that in sane instances replication may proceed 
unidirectionally. Proteins are probably involved in regulation at 
this level as initiation of unidirectional replication is preferred 
when normal replication is impeded by protein synthesis inhibitors. 
Attempts have bum made to identify the origin of replication. These 
origins usually have a superhelical conformation and perhaps have a 
specific base sequence. In general initiation sequences setm to be
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located within larger DNA sepjnonts that contain palindromes or tandem 
repeats of unique? DNA length. A 73 base pair palindrome? has bex;n 
identified using restriction enzyme analysis as the point of origin of 
SV40 virus chromosome replication (39).
There is indirect evidence for a role for UNA in the initiation 
of eukaryotic DNA synthesis (32, 38, 42). Short chain DNA intermediates 
have been found in cells infected with SV40 virus in hunan lymphocytes 
and a number of nuurmalian cell lines containing short pieces of RNA at 
the 5' end. These RNA pieces are usually 8-11 nucleotides long and 
linked by 3', 5' bonds to DNA. The 5' end of the RNA sequence is not 
unique but can consist of either adenine or guanine residues.
Analysis of RNA-DNA junctions reveals that all four cannon ribonucleo­
tides and deoxyritonneleotides are present with about the same frequency.
There is little direct evidence for RNA involvement in initiation. 
Work on an isolated HoLa cell nuclei system has however shown a 
necessity for RNA polymerase I or an RNA polymerase I type enzyme for 
initiation of DNA synthesis (43). There is also a requirement for 
ribonucleotide triphosphates as a substrate for this enzyme. It is 
also suggested that other protein factors are involved in initiating DNA 
synthesis in this system. These include a heat-labile factor and a 
factor that can be removed frem the nuclei by salt extraction. A role 
for these proteins has not been suggested but their existence seems to 
fit the pattern already indicated for the initiation of replication.
2.5 ELONGATION
The elongation of replicating eukaryotic DNA, once initiation has 
occurred, takes place in three stages (42). The primary event is the 
formation of 4-7S single stranded DNA segments resulting from the 
initiation of replication units, these are the Okazaki fragments. The
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secondary elongation process proceeds through two major size classes, 
a 6-26 S segment and a 20-100 S sopjnent arising from the arrangement 
oi replication units either singly or in clusters. The third stage 
is the formation of ehromosanal DNA from the joining together of the 
rtplicufion units. Klongalion of eukaryotic PNA, like prokaryotic DNA, 
is a suni-conservative process and proceeds in the 5' to 3' direction. 
However there is sane debate as to whether or not the process is semi- 
discontinuous as described for E. ooli or fully discontinuous, i.e. 
there is no leading or lagging strand but both are synthesised from 
short Okazaki fragments. Recent evidence is in favour of eukaryotic 
DNA synthesis being totally discontinuous (35, 42).
Like prokaryotic DNA synthesis the involvement of several different 
proteins has been indicated though, as yet, their functions are not so 
well defined (32, 44). There is evidence for a strand separating 
protein in eukaryotes that binds to single stranded DNA. There is also 
an unwinding enzyme or nicking-closing enzyme that can relax the 
superhelical DNA formed by strand separation. The major proteins 
involved in eukaryotic DNA synthesis and the most well characterised 
are the DNA polymerases (45, 46, 47).
There are three DNA polymerases in higher eukaryotes that have 
been characterised by their size, tanplate specificity and drug 
sensitivity and have been designated a, 6 and y (48). The main 
polymerase involved in normal mamnalian DNA replication is DNA 
polymerase a. This enzyme, a large 5-8 S protein, is located in the 
nucleus (49) and is sensitive to aphidicolin, araCTP and araATP, and 
the sulphydryl reagent N-ethylmaleimide (47, 48). Polymerase a prefers 
RNA primed DNA as a template. Evidence that it is the major 
replicative enzyme first came from observations of the marked rise in 
levels of this enzyme during cell replication. It is this enzyme? that
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synthesises the Okazaki size fragments of DNA. It is generally thought 
that nucleosnmos govern the- size of Okazaki pieces hut there is evidence 
that suggests it may bo the DNA polymerase enzyme itself (50).
DNA pulymorase (< is a smaller, 3-4 S, protein and is resistant to 
N-elhylmaleimide, aphidicolin and aral'IV (47, 51). It cannot use HNA 
primed DNA as a template but will utilise activated (nicked) DNA and 
needs free 3’-Oil teimini as primers. The mode of DNA chain elongation 
by this enzyme appears to lie distributive i.e. the enzyme molecule 
might leave the template at the 3’ end of the growing chain after 
polymerization of one or more nucleotides and then reassociate with the 
template primer in a randan fashion. The suggested role for this 
enzyme is as a repair enzyme for d[imaged DNA.
DNA polymerase y is predominantly an extranuclear enzyme and is 
found in organelles such as mitochondria and chloroplasts though it is 
found in low levels in the nucleus. Its properties are similar to 
those of DNA polymerase a with regards to inhibitor sensitivity (48, 51). 
Its mechanism of action may be different to that of the other DNA 
polymerases as a result of its specific role in organelle DNA synthesis. 
It is the enzyme involved in adenovirus replication and it is studies on 
this virus that indicate a strand displacement mechanism of DNA synthesis 
similar to the rolling circle mechanian in bacteriophages. This • 
gives some indication as to its possible role in the nucleus, a 
strand displacement mechanism would allow for gene amplification of 
certain parts of the chrcmoscme e.g. ribosomal genes.
After the addition of deoxynucleotides to the RNA primer by DNA 
polymerase a the RNA primer is removed by an RNAase like enzyme 
called RNAasell (42). This is followed by DNA gap filling. This is 
carried out by DNA polymerase n rather than by another polymerase as 
in ooli. The Okazaki fragments when fully formed are .joined
together by an ATP dependent ligase enzyme.
Tliere are no exonucloa.se activities associated with the a or 6 
enzymes as there is with the.* prokaryotic polymerases so there is no 
obvious proof readint; mechaninn in eukaryotes of the tvjh* found in 
prokaryotes. This implies that the high fidelity of 1>NA replication 
relies on the ability of the enzyme to copy the template accurately.
A separate exonuclease activity has been found associated with DNA 
polymerase 3 and this may participate in repair.
Several forms of DNA polymerase a have been found, varying in 
their size. In rabbit bone marrow these have been called , a0 and 
6 (52). The two a polymerases have molecular weights 215,000 and 
100,000 respectively and 6 has a molecular weight of 122,000. The 
DNA polymerase 6 enzyme possesses 3' to 5' exonuclease activity so it 
is possible that this is the form of DNA polymerase o used in noimal 
replication thus providing it with a possible proof-reading function.
2.6 TERMINATION
There are two possible mechanisms for the termination of 
replication unit synthesis (38, 42). Termination could take place 
when two replication forks from adjacent replication units meet or. . 
there could be definite termination sites coded by specific nucleotide 
sequences. Evidence against the existence of specific termini comes 
from DNA fibre autoradiography studies on SV40 and polyoma viruses.
In such cases where there is defective DNA i.e. during replication of 
viral DNA, chromosomal translocations, inversions or deletions, normal 
termination has still been observed, such occurrences would be 
impossible*if termination was controlled by specific sequences.
Contrary to this is the fact that there is precise tonixiral and
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spatial regulation of initiation and termination on widely separated, 
individual and tandcmly arranged replication units. Such regulated DNA 
replication implies a specific control of initiation and termination 
and in fact termination sequences have been identified in seme viral DNA 
moUx:ulc.s. It is tlieivloiv |x>ssil)le that structurally and functionally 
similar initiation-termination sequences are present on adjoining 
replication units of chromosomal DNA.
2.7 CHROMATIN ASSEMBLY
ENA synthesis proceeds as a component of chromatin replication. 
Concurrent with ENA replication is the unwinding of nucleosomal DNA in 
front of the replication fork and reassanbly of nucleoscmes behind the 
replication fork. Nucleosomes are assembled after the ligation of 
Okazaki fragements into nascent DNA chains. As there are only small 
histone pools in eukaryotic cells, histone synthesis has to be tightly 
coupled to DNA synthesis, therefore if one process is inhibited the 
rate of synthesis of the other is decreased. Newly synthesised DNA is 
rapidly associated with the histones into core particles to form 
nascent chrcmatin. Histone octamer assanbly is conservative so that 
during chromatin replication when nucleosome nunbers double half of 
the nucleoscmes are made up of old histones and half are made up of 
new histones. There is no mixing of old and new histones in a 
nucleosane octamer. The nucleosomes nearest the replication fork 
comprising the nascent chrcmatin are different to those in mature 
chromatin therefore newly synthesised nucleoscmes must go through a 
maturation stage during chronatin assanbly. Ibis maturation process 
may involve stepwise addition of histones to nascent DNA and may also 
reflect chemical modification of the histones.
The mechanism by which newly synthesised and parental nucloosomos 
are distributed and packaged with nascent DNA during chromatin replication
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is not yet clear. There are two main models for chrunatin assnnbly, 
the conservative; ohremutin replication nKxlel and the cooperative 
randan model. Conservative chromatin assembly predicts that parental 
nucleosomes are to be found on only one daughter strand of DNA whilst 
t Ik * other consists entirely of newly made nuclensancs. The experi­
mental evidence does not sup|x>rt this concept and the alternative 
hypothesis proposes that there is cooperative and randan distribution 
of new and old nucloosomes between the daughter strands. This model 
requires that equal numbers of new and preformed nucleosanes be 
distributed to both growing DNA helices. The present experimental 
evidence supports the latter hypothesis for chromatin assembly (32, 42).
2.8 DNA AND CANCER
Induction of cancer can be correlated with changes in nucleotide 
sequence and gene expression caused by a carcinogen or mutagen. The 
repair of damaged UNA appears to be fundamental in preventing these 
genetic changes caused by local damage to the nuclear DNA and a great 
deal of work has been done to try to relate the repair of DNA lesions 
with carcinogenesis (53, 54, 55). The repair of damaged DNA involves 
a succession of reactions which include the excision of the abnormal 
base, removal of an adjacent sequence of DNA by exonuclease action, 
resynthesis of the removed section and finally ligation of the 
resynthesised DNA to the original molecule (53).
The possible connection between DNA repair and carcinogenesis 
was first suggested by studies on the hereditary disease, xeroderma 
pigmentosa (XP) which exhibits a genetic defect leading to a defect 
in the excision-repair system (19, 55). This disease is characterised 
by a sensitivity to ultraviolet light. Ultraviolet light causes the 
formation of dimers between adjacent thymidines causing local
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distortion in the I)NA double helix resulting in skin cancers. XP 
patients suffer an age-specific incidence of skin cancer that is 
several thousand time's higher than normal and they frequently die 
of malignant melanoma.
One obvious contradiction within this theory is the fact that 
though the defect in DNA repair in XP patients is found in all 
tissues there is only an increased incidence in skin cancer but not 
in the incidence of other cannon fatal cancers. This suggests that 
most cannon fatal cancers are not caused by local DNA lesions of the 
kind that can lx? repaired by the DNA repair mechanian as was first 
proposed. An alternative origin of cancer must be found. In the 
case of Bloom's syndrome, an inherited disease that does appear to 
be associated with an increased incidence of cannon cancers, there 
is a high frequency of chromosomal aberrations and exchanges. Many 
leukaemias and lymphomas also show chrcmosunal aberrations, it 
therefore seems as if many cancers arise as a result of large 
chromosomal rearrangements or transpositions (19).
The regions of transposed DNA are known as transposons and their 
reshuffling within the DNA molecule is brought about by reccmbinational 
enzymes called transposases. Tins form of genetic rearrangement has 
been identified in lower eukaryotes and prokaryotes. It is not yet 
known if it plays a role in vertebrate development though it is known 
that antibody diversity is generated by specific transpositions during 
the differential ion of B lymphocytes. Though localised changes in DNA 
structure do give rise to seme cancers as in the case of skin cancers 
it now seems as if many cannon fatal cancers arise as a result of 
genetic transpositions and that many carcinogens may be promoters of 
cancer rather than initiating cancers by producing localised DNA
lesions.
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C H A P T E R  3
Me t a b o l i s m  o f  Cy t o s i n e  Ar a b i n o s i d e
3.1 METABOLISM OF CYTOSINE AKABINOSIIJE
Cytosine arabinoside (1—3—1) arabinofuranosyl cytosine) is a 
synthetic nucleoside which differs from the naturally occurring 
nucleosides, cytidine and deoxycytidine, in a substitution of the 
sugar arabinose for ribose or deoxyribose (56). It is one of the 
most effective and widely used antimetabolite drugs for the treatment 
of acute myeloid leukaemia giving complete remission rates of 25% 
when used alone and 50% or more when used in combination with other 
drugs such as daunorubicin, 6 thioguanine and alkylating agents (57,
58, 59, 60). Though the drug shows in vitro anti-viral activity, 
clinical tests have indicated that it is of little clinical use as 
an anti-viral agent (61, 62, 63). It also lias marked inmunosuppressive 
effects but is not used clinically as an inmunosuppressant. The 
developnent of combination chemotherapy regimens of araC with other 
drugs has usually come about as a result of empirical clinical 
trials (64-68). It may be possible by studying the mechanian of 
action of this drug, its metabolian and the development of resistance 
to the drug by neoplastic cells to develop a biochemical rationale 
for combination chemotherapy. This chapter deals with a study of araC 
metabolian by seme of the salvage enzymes involved in nucleotide 
metabolism, and the possibility of combination therapy of araC with 
other agents based on these studies is discussed.
The active form of the drug is the triphosphate but as this 
cannot cross the cell membrane the drug has to be acininistered as 
the nucleoside (69). AraC is rapidly transported into the cell by
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a facilitated diffusion process similar to that used for transporting 
the naturally occurring nucleosides into the cell. Here the drug is 
phosphorylated by a series of kinase reactions to the triphosphate, 
the rate limiting step being the conversion to the monophosphate (70). 
Alternatively the drug can be inactivated by deamination to uracil 
arabinoside (71, 72). The Lherajxjutic activity of the drug therefore 
depends on the balance that exists between the intracellular levels of 
these two enzymes.
In many instances tumour cells have been shown to develop 
resistance to the drug. There are a number of theoretically possible 
medianians for this resistance. These include (a) impaired transport 
into the cell, (b) impaired intracellular phosphorylation, (c) rapid 
deamination, (d) increased intracellular pools of the competing 
metabolite dCTP, (e) an altered form of the target enzyme, DNA 
polymerase, (f) variation in the plaana level of the intact drug,
(g) competition between the normal metabolite and antimetabolite for 
the activating enzyme. The major reasons for drug resistance which 
have been suggested on the basis of experimental evidence are either 
low levels of the kinase responsible for converting the drug to the 
monophosphate (71), and/or high levels of the deaminase enzyme (72, 73) 
and/or increased intracellular pools of competing metabolites (74, 75). 
The activity of the drug is therefore dependent on the intracellular 
levels of the enzymes involved in its metabolism, primarily the kinase 
and deaminase. ItecenL work has shown that alterations in the 
regulation of the enzyme CIV synthetase may be involved in drug 
resistance (76). This enzyme is controlled by feedback inhibition 
from CIV. In cases when the enzyme is altered so that this feedback 
regulation is lost the CIV pool increases and this leads to an increase 
in dCIV levels. This results in a decreased sensitivity of the target 
cell to the drug due to the increased levels of the competing
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nucleotide, dCTP.
Of the two major enzymes involved the kinase appears to be the 
most important one in determining the intracellular levels of araCTP. 
It is the level of the latter that determines the therapeutic efficacy 
of araC. This enzyme is the rate determining step in araC activation 
rather than transport of the nucleoside into the cell or the 
phosphorylation of the monophosphate to the di- and tri-phosphates. 
High levels of kinase have been found in leukocytes from patients with 
acute myeloid leukaemia (72). This correlates well with the fact that 
araC is most active against this type of leukaemia. Alternatively in 
cell lines tested for their in vitro response to araC those resistant 
to the drug are those with low levels of this enzyme.
The enzyme responsible for the phosphorylation of araC to araQlP 
is the same enzyme that is responsible for the phosphorylation of 
deoxycytidine to dCMP (77, 78, 79). The two act as competitive 
inhibitors for each other thus suggesting that araC, biochemically 
speaking, is an analogue of deoxycytidine rather than cytidine. The 
enzyme is under allosteric control by dCIP, high levels of dCIP will 
inhibit the kinase. Deoxycytidine triphosphate also acts as 
a positive effector for the enzyme cytidylate deaminase. This 
converts dCMP to dUMP and can likewise deaminate araCMP thus acting 
against activation by the kinase and resulting in inactivation of the 
drug (80). Levels of dCIP can be controlled by inhibiting the enzyme 
ribonucleotide diphosphate reductase. Inhibition of this enzyme by 
inhibitors such as hydroxyurea will decrease the levels of dCIP.
Other inhibitors acting at other stages of the salvage pathways such 
as alanosine and doazauridine will also decrease dt'IP levels thus 
potentiating the phosphorylation of araC.
Cytidine deaminase, the enzyme responsible for the deamination
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of araC to araU, is found in the liver, kidney, granulocytes, red 
blood cells and some tumours (81). The enzyme levels in nonnal 
granulocytes are higher than those in acute and chronic myeloid 
leukaemic cells, this may reflect an increase; in enzyme levels with 
granulocyte maturat ion. The deiunina.se apiienrs to confer resistance 
to araC in some eases of leukaemia. In a Lest carried out on 
patients, those that responded well to araC therapy had correspond­
ingly low deaminase levels whereas those with high levels showed 
poor response to araC (73). In some cases deaminase levels increased 
during araC therapy and this corresponded with increased resistance 
to the drug implying that araC may induce the enzyme. Contrary to 
the clinical situation deaminase levels appear to have little effect 
on araC resistance in experimental tumour systems.
Tiie enzyme; has been isolated and well characterised in granulocytes 
especially with regard to its inhibition by the uridine analogue 
tetrahydrouridine (81). Tetrahydrouridine lias been shown to be a 
potent inhibitor of cytidine deaminase (82). It is thought to be a 
transition state inhibitor resanbling one of the intermediates in the 
reaction mechanism (81). TOU has been shown to potentiate araC in 
sane in vitro situations, e.g. in L1210 leukaemic mice and sane murine 
tunours with high deaminase levels and sufficient kinase levels to 
activate araC (83, 84). Its possible role in combination chemotherapy 
with araC in the clinical situation has been demonstrated with some 
success especially with araC treatment of acute myeloid leukaemia 
though the tests are not altogether conclusive (85, 86). More 
recently other uridine analogues have been found that inhibit both 
cytidine and cytidylate deaminase, e.g. 3 deazauridine, which may 
prove to be effective in protecting araC from deamination (87).
One alternative method of preventing deamination other than the
dooxycytldino
cytosino arabi nor]do
cyclocytidine
Fig 5.2 Deoxycytidino and annloeuos
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use of inhibitors is to synthesise further analogues of araC that 
are resistant to deamination. Such analogues include a series of N4 
acyl derivatives with long chain saturated fatty acids (88, 89, 90) 
and conjugates of araC and steroids such as prednisolone and cortisol 
(91). Another, more generally uscxl method, is to adninister the drug 
as a continuous infusion so that the high levels will overcome the 
effect of deactivation. One method of enhancing this effect is to 
use the araC derivative cyclocytidine. This is slowly hydrolysed in vivo 
to give cytosine arabinoside thus achieving a sustained slow 
release of the active form of the drug (56).
3.2 LYMPHOBLASTOID CELL LINES
Transformed cells are cells derived from normal tissue that have 
undergone a stable hereditable change so that they can be continuously 
cultured in vitvo. lire two cell lines used here are both derived from 
lymphocytes. The major lymphoblastoid cell line that has been used is 
a B cell line transformed by the Epstein-Barr virus and derived from a 
Burkitt's-type lymphoma (20). Part of the EB virus gencme is 
incorporated into the genetic material of the transformed cells, the 
cells then produce EBV directed antigens each of which serves a 
specific function in the replication of the infected cell and 
subsequent viral replication (92). The major antigens are the 
nuclear antigen (EBNA), the early and late membrane antigens (EMA and 
LMA), the early antigen complex (EA), viral capsid antigen (VCA) and 
the lymphocyte-detected nxmbrane antigen (LYLMA). EBNA is the only 
antigen present in all EBV transformed B cell lines and is necessary 
for the continued growth of tlie infected cells. MA, EA and VCA are 
only expressed in cell lines that produce EBV. The cell line grown 
in this laboratory, the Namalwa cell line, only produces EBNA and is 
therefore a non-producer cell line, i.e. it is not possible for this
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particular cell line to produce now, infectious EB viruses thus 
making it an ideal cell line for use in the laboratory. This cell 
line is relatively easy to grow compared with many other cell lines 
and provides a useful model systim for the study of imnunosuppressive 
and anti-cancer drugs.
The other cell line used in these studies is a T cell line 
derived frcm an acute lymphocytic leukaemia (93). This lymphoblast 
cell line, the CCRF-CEM cell line, was originally isolated from the 
peripheral blood of a female child suffering from acute childhood 
leukaemia. This T cell line was used as part of a comparative study 
of cytosine arabinoside metabolism.
3.3 TETRAHYMKNA PYRIFORMIS
Tetrahymena pyriformis is a ciliated protozoan normally found 
inhabiting fresli water environments (94). It is pyriform or pear 
shaped with an average cell size of 50 x 30 |im dependent upon 
environmental conditions. Tetrahymena possess typical eukaryotic 
organelles such as mitochondria, rough and smooth endoplasmic 
reticulum, nucleus and lysosomes. TYiey also contain food vacuoles 
and microbodies called peroxisomes, responsible for oxidising a- 
hydroxy and a amino acids and metabolising lipids to glycogen via 
the glyoxylate cycle, which are not found in higher eukaryotes.
Many strains of Tetvahymena also contain a diploid micronucleus.
This plays a role in the protozoans sexual reproductive cycle.
Tliose strains that are amicronucleate reproduce only by vegetative, 
mitotic growth. The mac.ronucleus is polyploid carrying several copies 
of the genome. It is the genetic information carried in the macro­
nucleus that determines the phenotype of the protozoan.
The strain used in the work described in this chapter is the
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amicronucLeate strain, T. pyrifomia w. This strain, which is only 
capable of vegetative growth, can lx; grown easily and rapidly in the 
laboratory in both defined and complex media (95). If necessary 
cultures can lx; induced to divide synchronously milking it a suitable 
orgiuiisn for cell cycle studies. As it possesses many typical 
eukaryotic characteristics it can lx; used as a model system for the 
study of eukaryotic metabolism both in whole cell and cell free 
systems. It has been used extensively in this latoratory for studying 
DNA, RNA and cyclic nucleotide metabolian. Because it has been well 
characterised biochemically it was used as a control system in a 
comparative study of cytosine arabinoside metabolism.
3.4 MATERIALS AND METHODS 
3.4.1 Materials
Namalwa and OCRF-CEM lymphoblast cell lines were obtained 
frem the Department of Biological Sciences, University of Warwick,
T. pyriformis strain L1630/IW was obtained from the Culture Centre 
of algae and protozoa, Cambridge. RPMI-1640 medium and new born 
calf serum were obtained from Flow Laboratories and proteose peptone 
and yeast extract from DIFCO Laboratories. Glutamine, penicillin, 
streptomycin and cytosine arabinoside were obtained from Sigma 
Chemical Company, trypan blue from BDH Chemicals and tetrahydrouridine 
and calf thymus DNA from Calbiochem. Prefilled DOWEX50 colunns were 
obtained frexn Biorad Laboratories, PEI-F cellulose thin layer 
chromatography plates from Merck and DEAE cellulose DE81 chromato­
graphy paper and Whatman No. 1 chromatography paper from Whatman Ltd.
3 3( H-methyl] thymidine and 5- H cytosine B-D arabinoside were obtained 
from the Radicxdemical Centre, Amersham.
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3.4.2 Culture of lymphoblastold cell lines
Nama.1v/a and OCRF-CEM cells were grown under aseptic conditions 
at 37°C in Hepes buffered RPMI-1640 medium supplemented with 10% new­
born calf serum, L-glutamine (300 mg/1), penicillin (100 u/ml) and 
streptomycin (100 iig/ml). Cultures of 50 ml or more were grown in 2 1 
roller bottles, smaller volunes were grown in stationary cultures.
Hie cells were grown to a density of 1.2 x 10° cells/ml and then 
passaged to give a final cell concentration of 0.6 x 10^ cells/ml, 
the average doubling time being three days. At regular intervals of 
about 10-14 days the cells were harvested by centrifugation at 100 g,
5 minutes, 18-20°C and resuspended completely in fresh medium.
Regular supplementation with L-glutamine was also essential as it is 
rapidly degraded under normal culture conditions. The cells were 
counted and their viability determined using the trypan blue 
exclusion test. A 0.5 ml aliquot of cells was diluted with 0.5 mis 
0.4% trypan blue in 0.9% saline and then counted in a Neubauer 
haemocytometer. Dead cells are stained blue whereas live cells remain 
unstained due to their ability to pump out the dye.
3.4.3 Culture of T. pyrifomis
Tetrahymena pyriformis was grown under aseptic conditions in 2% 
proteose peptone, 0.1% yeast extract, 0.5% glucose and 5 ug/ml ferric 
chloride all made up in tap water. 50 ml static cultures were grown 
in 250 ml conical flasks in the dark at roc in temperature and sub­
cultured weekly by addition of a 0.2 ml inoculun of old cultures into 
50 ml fresh mediun.
Hie stock cultures were used to inoculate 400 ml cultures in 2 1 
conical flasks, the desired volime of cell inoculim was calculated 
from the following equation:
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y .v
v = volume of inoculum required (ml) 
y = desired final cell concentration in cells/ml 
V = final culture volume (400 ml) 
x = cell concentration of stock culture
t = time in hours from time of inoculation to the time when 
the cells are required. -
The 400 ml cultures were incubated at 28°C in an orbital shaker 
operating at a rate of 150 oscillations/minute. Under these conditions 
the average doubling time for the cells was three hours. The cells 
were counted by fixing an aliquot of cells with an equal volune of 20% 
formalin in 0.01 M phosphate buffer pH 7 and then counting in a 
Neubauer hacmocytaneter.
3
3.4.4 Measurement of H-thymidine incorporation by
lymphoblasts
1 ml cultim>s of Namalwa cells, 103 *6 *10cells/ml, were incubated in
10 ml Sterilin tissue culture tubes at 37°C for four hours with 5 pCi
3
[ H-methyl] thymidine, sp. act. 47 Ci/mmol. Cytosine arabinoside and 
tetrahydrouridine were both dissolved in PBS and added to the cultures 
to give the required final concentration. After incubation the 
cultures were diluted with 5 mis cold PBS and centrifuged at 200 g,
10 minutes, 0-4°C. The supernatant was discarded and the precipitate 
was resuspended in 200 pi calf thymus DNA, 1 mg/ml in 5 mM NaOll, and 
500 pi of cold 5% TCA added. The acid insoluble precipitate was 
collected by centrifugation at 200 g, 5 minutes, 0-4°C and washed in 
the same way with a further 500 pi cold 5% TCA. The precipitate was
v =
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then dissolved in 500 til 0.5 M NaOll and 200 til aliquots removed and 
added to 8 mis scintillation fluid (Toluene 600 mis: ethoxyethanol 
400 mis, PIO 4 g/1, P0TOP 0.2 g/1). 'Die samples were left overnight 
to remove any chemiluminescence caused by the sodium hydroxide. Tie 
nidioactivi ty of the smnples was l hen counted on a Packard Tri-Curb 
2425 liquid scintillation spcclmncler. Results are shown :is the 
percentage of maximum thymidine incorporation into acid precipitable 
material.
3.4.5 Identification of araC metabolites
1 ml cultures of Namalwa and CCRF-CEM cells, 106 cell/ml, were
incubated with 5 tiCi 5-3H cytosine 6-D arabinoside, sp. act. 26 Ci/mmol,
-4both in the presence and absence of 10 M THU for 0, 0.5, 1, 2, 3 and 
4 hours. At the end of the incubation period the cultures were washed 
in 5 mis cold PCS and the precipitate resuspended in 500 yl cold 5%
TCA. The acid insoluble precipitate was removed by centrifugation at 
200 g, 5 minutes, 0-4°C and 15 yl of the supernatant applied to pre­
pared PEI-F cellulose thin layer chromatography plates (96). For 
T. pyriformis 30 ml cultures of log phase cells, 2-4 x 10 cell/ml, 
were incubated at 28°C in a shaking water bath with 20 yCi 
3H-cytosine arabinoside with or without 10-4 M THU. 1 ml aliquots 
were ranoved atO, 0.5, 1, 2, 3 and 4 hours and treated as described 
for the lymphoblastoid cells.
'Oie plales wore prepared by first running the plates in 10% 
sodium chloride for 5 ems and then transferring to distilled water 
without drying and allowed to run until the solvent front ran off 
the edge of the plate. The plates were then dried for two hours in 
air and run again in distilled water until the solvent front ran off 
the edge. The plates wore then left to dry overnight in air.
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The plates, containing the s;imples, were then placed in 
distilled water until the solvent front had risen 5 uns. They were 
then transferred without drying to an acid solvent of 1 M lithium 
chloride, 1 M formic acid where they were run for a further 5 cms.
Tlie plates were then nmoved and dried in air.
After drying the plates were cut into 1 cm squares and placed in 
scintillation vials with 0.5 ml 1 M LiCl, 1 M H000H and left at room 
temperature for two hours. Toluene, ethoxyethanol, PPO, POPQP 
scintillant was then added (12 nds) and radioactivity counted as 
previously described. The metabolites were identified by running 
standards simultaneously with the samples. The position of the 
standards on the Tl/C plates was determined by their ability to 
fluoresce under UV light of wavelength 254 nm.
3.4.6 AraC deaminase assay
Cell homogenates of both lymphoblastoid cell lines and T. pyriformis
were prepared in 0.001 M EDTA, 0.002 M PIT, 0.05 M Tris-HCl pH 8 buffer.
6 5Lymplrablastoid cells, 10 cells/ml, and T. pyriformis, 2-4 x 10 cells/
ml, were harvested as previously described, washed in cold PBS, and
the pellet resuspended in the homogenising buffer. The cells were
then homogenised in a motor driven Potter-Elvejhem hcmogeniser at 4°C,
the degree of cell breakage was monitored using a light microscope.
The ability of these cell homogenates to deaminate araC to araU
was assayed using the method described below. As the substrate used
in this assay was araC the enzyme is described as araC deaminase though
the enzyme is probably isofunctional with cytidine deaminase.
3
The assay mixture contained 100 yl cell homogenate, 50 pi H-araC,
5 yCi/ml at a final concentration of 5 x 10 M, and 100 ul homogenis­
ing buffer or 75 |il buffer plus 25 yl tetrahydrouridine to give the
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required final concentration. The assay mixture was incubated at 37°C 
for the lymphoblast homogenates and 28°C for the Tetmhymena 
homogenates. The incubation was stopped by the addition of 250 pi 
3 M HC1 and the resultant precipitate removed by centrifugation for 
10 minutes in a UTL mieroangle l>ench centrifuge. The su|x'rnatants 
were then placid on top of 4 <in pro— filled co I urn is packed with 
DOWKX 50W-X8 200-400 (97) and allowed to sink into the column bed.
The columns were then eluted first with 2.5 ml of the homogenising 
buffer to remove the arabinosyl uridine fonned in the reaction. Hie 
araC bound to the columns was then removed by eluting with 2.5 ml 3 M 
amnonia. The columns were then washed several times with distilled 
water to prepare them for further use. 200 pi aliquots were removed 
from the eluates and added to 8 mis of Toluene, ethoxyethanol, PPO, 
P0P0P scintillant and radioactivity determined as previously described.
The compounds eluted from the colunns were identified using 
descending paper chromatography. Samples from selected eluates were 
spotted on to Whatman No. 1 chromatography paper and run for 10 cms 
in isobutyric acid, anmonia, water (66:1:33). The chromatogram was 
then dried in air and cut into 1 cm squares and placed in scintillation 
vials with 0.5 mis 3 M HC1 and left at room temperature for two hours. 
Toluene, ethoxyethanol, PPO, POPOP scintillant (12 mis) was then added 
and the radioactivity of the samples determined. Hie products of the 
reaction were identified by running standards simultaneously with the 
samples on the chromatogram. All protein determinations were 
carried out by Liu? method according to Lowry (98) using Ixrvine so run 
albumin as a standard.
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3.4.7 A raC kinase assay
Cell homogenates prepared as described in 3.4.6 were assayed 
for their ability to pliosphorylate araC to araCMP. As in the case 
of the dcroninase assay the substrate used was araC therefore the 
en/.yme is desrrilied as araC kinase though it is probably iso­
functional with deoxycytidine kinase. The assay incubation mixture 
contained 100 pi cell homogenate, 100 pi assay cocktail and 50 pi 
^H-araC, 5 pCi/ml at a final concentration of 5 x 10 ° M. The 
assay mixture was incubated at 37°C for the lymphoblast homogenates 
and 28°C for the Tetrahymena homogenates. The assay cocktail was 
made up of equal volimes of the following components plus two 
volumes of distilled water:
ATP 0.14 M 
MgCl2 0.07 M 
2 Mercaptoethanol 0.14 M 
Sodium fluoride 0.07 M
Final concentration 0.01 M 
Final concentration 0.005 M 
Final concentration 0.01 M 
Final concentration 0.05 M
Homogenising buffer (Tris HCl pH 8 0.05 M, 0.001 M EDTA, 
0.002 M DIT)
The assay mixture was incubated for up to thirty minutes and 
stopped by heating for three minutes in a boiling water bath. The 
resultant precipitate was removed by centrifugation for ten minutes 
in a BTL micro-angle bench centrifuge. 25 pi samples were removed 
from the supernatant and pipetted on to DF.AE (DE81) 1.5 cm filter 
squares (71, 98). The filter squares were then washed for 
10 minutes in 500 ml 0.001 M ammonium formate followed by 
45 minute and 20 minute washes in 250-500 ml distilled water leaving 
radioactive araCMP bound to the filter squares. The filter squares 
were then placed in scintillation vials with 1 ml 0.5 M NaCl in 
1 M HC1 for 10 minutes with occasional shaking. Scintillation
fluid (10 mis of Toluene 50% v/v, Triton X-100 50% v/v, PTO 5 g/1,
PQPOP 0.2 g/1) w ; l s  then added and the radioactivity of the samples 
detennined. 11 le products of the assay were characterised using thin 
layer chromatography on PKI-F cellulose plates using the conditions 
desorilxKl in 3.4.4 (A.M. Coles, l’h.l). dissertation, University of 
Warwick, 1081).
3.5 RESULTS
3.5.1 The effect of cytosine arabinoside and tetra-
3
hydrouridine on 11-thymidine incorporation by 
Namalwa cells
The incorporation of [^11-methyl] thymidine into acid preciptable 
material was used as a measure of DNA synthesis. Cytosine arabinoside, 
a known inhibitor of DNA synthesis (see Chapter 4), inhibited the
3
incorporation of H-thymidine into acid precipitable material by 
Namalwa cells, the greater the concentration of araC the greater the 
degree of inhibition until maximim inhibition was obtained.
Increasing concentrations of tetrahydrouridine had a negligible effect
3
on H-thymidine incorporation of Namalwa cells. THU should increase
the inhibitory effect of araC when used in combination with araC if
the latter is inactivated by deamination. The effect of increasing
concentrations of THU while maintaining araC concentrations constant 
-9at 5 x 10 M was investigated. This concentration of araC gave 
approximately 50% inhibition of thymidine incorporation by Namalwa 
cells in the absence of THU. 111U however had a negligible effect on 
araC inhibition at this concentration. It remained at approximately 
50% with all the 111U concentrations used.
In
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Drug c o ne  ( M l
Fig 3.3 The inhibition of ^H-thymidlne uptake in Namalwa cells 
hy (□) cytosine arabinosido, (v ) totrahydrouridino and (o) 
tetrohydrouridine in the presence of 5xlr>“9M cytosine 
arabinosido. Results are shown as the percentage inhibition 
of maximum thymidine incorp >reti <n into .veld procipitable 
material a» described in Error bars represent S.E., n=3.
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3.5.2 T he metabolism of cytosine arabinoside by
T. p y viformio i)
The products from the incubation of T. pyrifovrnia over a four 
hour period with *l[-cytosino araitinoside are shown on the thin-layer 
chromatogram profiles (figs. 3.4, 3.5). Within tin* first hour Uiere 
was rapid conversion of araC to araU. There was little phospliorylated 
product formed from either of the two nucleosides within that period. 
There was an increased assimilation of araC after that time though 
this wits still accompanied by rapid deamination. After the full four 
hour period there was some increase in the amounts of the phosphates 
formed though aralflP predominated over araCTP. These results indicate 
the presence of a very active deaminase enzyme but very low kinase 
activity.
-4The incubation procedure was repeated in the presence of 10 M 
tetrahydrouridine. The presence of the uridine analogue lead to a 
marked decrease in the araU levels within the first hour. There were 
few phosphorylated products formed within that period. As the 
incubation continued there was an increase in the level of araCIP and 
a steady uptake of araC. There was no format ion of araU or aral/IP.
It therefore appears as if the TUU completely inhibited the deamination 
of araC. There was no increase in the degree of phosphorylation but 
the product in this case was only araCIP, rather than a mixture of 
aral/IP and araCTP, resulting in increased intracellular levels of the 
drug.
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3.5.3 Metabolism of cytosine arabinoside by 
lymphoblastoid cell lines
The thin-layer chromatogram profile produced by the incubation 
3
of H-araC with Namalwa cells sirus a steady increase in araCIP levels 
throughout a four hour period suggesting that the araC was 
phosphorylated rapidly as it entered the cell. There was no 
indication of the formation of araU or its phosphorylated derivatives 
suggesting the absence of any araC deaminase activity fs«“
-4The incubation was repeated in the presence of 10 M THU.
3
H u s  had a negligible effect on the metabolian of the H-araC
giving a thin-layer chromatogram profile of araC metabolites similar
to that produced without THU. The same procedure was also carried
out using the CCRF-CHl cell line both in the presence and absence of
THU. These incubation procedures gave similar results to those
3obtained fran the incubation of ‘H-araC with Namalwa cells. The
3
profile shown for the incubation of H-araC with Namalwa cells is 
representative of similar profiles obtained from the series of 
experiments described above.
3.5.4 Characterisation of the araC deaminase assay 
using T. pyriforints
The principle of the assay relies upon the ion exchange 
properties of the DOWEX 50 columns. The sulphonate groups on the 
colunn matrix bind the amino group of cytosine arabinoside allowing 
the deaminated uracil arabinoside to pass through. Hie cytosine 
arabinoside is then eluted fran the colunn by washing with 3 M 
amnonia solution which displaces the bound araC. In the first 
characterisation experiment the T. pyriformis cell homogenate was 
incubated with the 11-araC as described in "Materials and Methods"
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for 0, 15 , 30 , 45 and 60 minutes. The incubation mixture, after 
treatment with 3 M 1IC1 was carefully pipetted on to the columns and 
eluted as described. Samples were taken from the buffer and 
anmonia washes for radioactivity determinations. As can be seen in 
Figure 3.7 the radioactivity in the buffer wash increased with a 
corresponding decrease in the radioactivity in the anmonia wash. The 
total amount of radioactivity remained constant throughout.
Samples were taken from both washes from the 0 and 60 minute 
incubations and spotted on to Whatman No. 1 chromatography paper as 
described in "Materials and Methods" in order to identify the 
radioactive products in each wash at the beginning and end of the 
assay. At 0 minutes there was no radioactive product in the buffer 
wash as would be expected from Fig. 3.7. In the amnonia wash the 
only radioactive compound was the substrate, ^H-araC. After a
60 minute incubation there was a large amount of '^ ll-araU in the
3 3buffer wash and again no H-araC. There was some residual H-araC
in the anmonia wash.
These two results indicate the validity of the method as an assay 
for araC deaminase. Both sets of results are representative results 
from a series of similar experiments.
A time course for the assay was performed in order to find out 
over what period the reaction was linear with time so that the 
specific activity could be calculated and also so that suitable 
conditions could be determined for assays on lymphoblast homogenates. 
The results of this assay are shown in Fig. 3.9 The other experiment 
carried out to characterise the assay was performed in order to 
determine the inhibitory effect of tetrahydrouridine on the reaction. 
Figure 3.10 shows the inhibitory effect of increasing concentrations 
of niU  on the reaction. THU was used in subsequent araC deaminase
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an d ( v ) I s  t h e  t o t a l  r a d i o a c t i v i t y  from  t h e  two 
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F i g  3 . 8  C h a r a c t e r i s a t i o n  , f  t h e  a r a C  d e a m i n a s e  a s s a y  ( I I ) .  The  
a s  a y  p r o d u c t s  e l u t e d  from  t l ie  iXJWj^a  50  c o l u m n s  w ere i d e n t i f i e d  by 
d e s c e n d i n g  p a p e r  c h r o m a t o g r a p h y  a s  d e s c r i b e d  i n  3 « h . 6 .  T h e  p r o f i l e s  
shown a r e  f o r  s a m p l e s  t a k e n  f r o m  (A )  t h e  b u f f e r  wash a f t e r  O m i n u t e s  
i n c u b a t i o n ,  ( B )  t h e  b u f f e r  w a s h  a f t e r  6<"> m i n u t e s  i n c u b a t i o n ,  ( C )  th e  
ammonia w ash  a f t e r  O m i n u t e s  i u c u b . t i o n  and ( 0 )  t h e  ammonia wash  
a f t e r  6o m i n u t  s  i n c u b a t i o n .
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assays with the lymphoblast cell homogenates as an additional 
control. Inhibition of enzyme activity i>y '11IU was taken as a 
further confirmation of the presence of the anC deaminase enzyme.
3.5.5 Comparison of a raC kinase and araC deaminase 
levels in different cell types
AraC deaminase and kinase assays were performed on cell 
homogenates of Nawalwa and OCRF-CEM cells and T. pyriformis as 
described in "Materials and Methods". The results from these 
assays show that only T. pyriformis possesses araC deaminase 
activity. T1IU inhibited araC deaminase in T. pyriformis but had 
no effect on the assay when lymphoblast cell homogenates were used. 
All the cell homogenates possess kinase activity, however the 
kinase activity in T. pyriformis is 1000X lower than that found in 
the lymphoblast cell homogenates. These results are consistent with 
the results obtained from the identification of araC metabolites 
using PEI thin layer chromatography.
3.6 DISCUSSION
The initial results indicate that araC is a potent inhibitor of
DNA synthesis in Namalwa cells with 50% inhibition of thymidine
incorporation into acid precipitable material being obtained with 
-95 x 10 M araC. Tetrahydrouridine has little effect on thymidine
incorporation and no effect on the inhibition of thymidine incorpora-
• -9tion by 5 x 10 M araC. If araC were being inactivated by a 
deaminase then the inhibitory effect of araC should be increased by 
the presence of a deaminase inhibitor such as tetrahydrouridine.
This suggests (i) that 11IU inhibition of araC deaminase activity in 
Namalwa cells has negligible effect on araC inhibition or (ii) there 
is negligible araC deaminase activity in Namalwa cells. Subsequent
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experiments were performed in an attempt to clarify this situation.
The metabolisn of araC by T. pyriformis has been well 
characterised in this laboratory (M.A.N. Benhura, Ph.D. dissertation, 
University of Warwick, 1979). It is capable of rapidly deaminating 
araC and this deaminase activity is readily inhibited by Till). AraC 
has a poor inhibitory effect on T. pyriformis growth, this corresponds 
with a weak ability to convert araC to its phosphorylated derivatives. 
Tliese findings have been confiimed in the control experiments carried 
out, both in the identification of the T. pyriformis metabolites of 
araC and in tie characterisation of the araC deaminase assay using 
T. pyriformis cell homogenates.
Using these control experiments as references for comparison a 
study of the metabolisn of araC in a T and B lymphoblastoid cell 
line was carried out. In studies on the metabolisn of araC in the 
Namalwa, B cell, line it was found that araC was rapidly converted 
to the active triphosphate but there was no apparent conversion of 
araC to araU. The rapid phosphorylation of the drug to the active 
form correlates well with its high inhibitory effect on thymidine 
incorporation in Namalwa cells. The lack of araU among the araC 
metabolites further suggests that the absence of an araC deaminase 
as indicated by the negligible effect of T11U on thymidine 
incorporation. It also appears as if the CCRF-CEM, T cell, line can 
rapidly convert araC to araCIP. There is no apparent deamination of 
araC to araU. Tetrahydrouridine has no effect on araC metabolism in 
either cell line as would be expected if there was no deaminase 
activity present. The direct assays for both the kinase and deaminase 
enzymes confirms the presence of the araC kinase enzyme in the 
lymphoblast cells and the absence of the deaminase enzyme. They 
also show the expected high deaminase levels and low kinase levels in 
T. pyriformis.
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These results indicate that the levels of the enzymes in the 
activation and inactivation pathways are crucial for araC to have a 
useful inhibitory effect. The level of the deaminase enzyme can 
have an important effect on the inhibitory effect of araC but it 
may bo possible to overcome this by the combination of the drug 
witli a deaminase inhibitor such as 11IU. Ultimately however it 
appears as if the overriding factor is the level of the kinase 
enzyme. If this enzyme has only a low activity even inhibition of 
inactivating enzymes will only slightly affect the levels of the 
active phosphorylated form of the drug as is the case with 
T. pyriformia. However when kinase levels are high the drug can 
act as a potent inhibitor as illustrated by its effect on Namalwa 
cells.
These results have two further important consequences, one 
from a practical point of view with regards to the clinical use of 
araC and the other with regards to experimental studies on araC. 
These results suggest that araC may have a high therapeutic value 
as an anti-lymphocytic leukaemia and anti-lymphoma drug as well as 
being a potent drug in the treatment of myeloid leukaemias. Also 
the high kinase levels and low deaminase levels in the Namalwa cell 
lines and the potent effect of araC on this cell line make it a 
useful model system for the study of the mechanisn of action of draC 
and its effect on eukaryotic DNA synthesis.
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C H A P T E R  A
The Mechanism Of Action Of Cytosine Arabinoside
4.1 INTRODUCTION
Cytosine arabinoside is a known inhibitor of DNA synthesis 
(69,100). It has been shown to inhibit DNA synthesis in a number of 
eukaryotic cell systuns such as mouse L cells (99,101), hamster 
aabryo cells (102), PUA stimulated human lymphocytes (103) and rat 
liver (104). It has also been shown to be an inhibitor of E. coli 
DNA synthesis (104, 105) acting as an inhibitor of DNA polymerase III. 
AraC also inhibits RNA polymerase (106), reverse transcriptase of RNA 
viruses (96, 107), and glycolipid and glycoprotein synthesis (108), but 
its major mode of action has now been confirmed as ¡ui inhibitor of DNA 
synthesis.
Directly related to this observed effect on DNA synthesis is the 
observation that araC exerts its effect specifically during the S phase 
of the cell cycle (99, 109). The maximum sensitivity of synchronised 
mouse lymphoma cells to cytosine arabinoside occurs in early S phase 
(110). This knowledge has been used in in vitro studies on drug 
scheduling using drug regimens composed of araC in canbination with 
other cell cycle specific drugs such as hydroxyurea and methotrexate 
(110, 111, 112, 113, 114). It has been found that improved therapeutic 
effects can be obtained when the scheduling of the drugs is directly 
related to cell cycle kinetics so that the drugs are administered 
during that part of the cell cycle where they have a maximum effect. 
This type of study has been extended to the in vivo situation in 
leukacmic mice by optimising the time of drug aclministration to suit 
the natural circadian activity of the mice (115).
8:j
The molecular mechanise by which araC inhibits DNA synthesis has 
not yet been fully resolved. One of the earliest proposed hypotheses 
was that araC inhibited the reduction of CDP to dCDP by the enzyme 
ribonucleotide reductase, thus blocking the production of dCTP and 
preventing DNA synthesis (11(3). However this hypothesis has now been 
discounted (U9, 117). Another proposed hypothesis was that DNA 
synthesis was inhibited by the incorporation of araCTP into the 3 '-OH 
termini of newly synthesised DNA strands causing premature termination 
of DNA replication. However it has’been shown that araC, though 
incorporated into replicating DNA, was incorporated into internucleo­
tide linkages. It was therefore not blocking the further addition of 
nucleotides to the growing MIA strand (101) and therefore could not be 
acting as an inhibitor by inducing premature termination.
The favoured, and most likely, hypothesis is that araCTP is an 
inhibitor of the eukaryotic DNA polymerase (96, 118, 119). Studies 
on cell-free systems and the isolated DNA polymerase enzymes have shown 
that the drug is a ccmpetitive inhibitor of DNA polymerase a with 
respect to dCTP and non-competitive with respect to dATP, dGTP and dTTP. 
DNA polymerase 6 is also slightly inhibited by araCTP, but is much less 
sensitive to the inhibitor than DNA polymerase a (23, 47, 120, 121, 122). 
This is in agreement with the fact that araC inhibits normal DNA 
replication, which is carried out by DNA polymerase a, rather than DNA 
repair synthesis, which is carried out by DNA polymerase 6.
A similar pattern of inhibition is observed with adenosine 
arabinoside, the only difference being that DNA polymerase a is not so 
sensitive to araA inhibition as it is to araC (123, 124). AraA is a 
ccmpetitive intribitor of DNA polymerase a with respect to dATP but 
non-canpetitive with respect to dCTP, dGIP and dTTP. One explanation 
for this is the concept of plural binding sites for the triphosphates
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on the enzyme within the catalytic region so that the binding of a 
triphosphate at one site does not affect the binding of a triphosphate 
at another site. An alternative explanation is that the inhibitors 
may inhibit the action of the enzyme by binding at a Site removed fron 
the catalytic region and inhibiting the enzyme in an, as yet, unknown 
way (124).
If araCTP is an inhibitor of the replicative enzyme, DNA 
polymerase a, then it should inhibit the further elongation of newly 
initiated DNA chains. Several studies have been carried out using 
either whole cells or isolated nuclei systems in order to analyse 
the DNA produced under noimal replicating conditions and in the presence 
of inhibitors sucli as cytosine arabinoside. Sedimentation analyses 
using such techniques as alkaline sucrose density gradient 
centrifugation and caesium chloride buoyant density centrifugation 
have been carried out so as to determine the size-class of DNA 
produced under different conditions. DNA is synthesised in short 
discrete lengths and ligated to give fully formed DNA as described 
in Chapter 2. Inhibition of DNA synthesis at different points in the 
replication process, i.e. initiation, elongation, termination and 
ligation, each lead to the accumulation of specific size-classes of 
DNA which can be identified using sedimentation analysis. Several 
workers have shown that the incubation of cell cultures or isolated 
nuclei with araC leads to the accumulation of low molecular weight DNA 
intermediates as would be expected if araC was inhibiting chain 
elongation (125, 126, 127).
Contrary to this expected behaviour of the DNA replication process 
in the presence of araC, Fridland has suggested that both araCTP and 
araATP inhibit the initiation process of DNA replication (128, 129).
He has demonstrated that, tlx; incubation of OCRF-CTM lymphoblasts with
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low concentrations of araC, 0.03 nM-0.05 uM, causes inhibition of the 
initiation process. This is shown by the accumulation of high 
molecular weight DNA intermediates in the presence of araC with a 
concomitant decrease in the amount of low molecular weight intermediates. 
It is suggested that araC may inhibit an enzyme involved in replicon 
initiation.
Aiother effect of araC on initiation has been proposed by Woodcock 
(130). He suggests that though araC is a potent inhibitor of DNA 
synthesis this is not enough to account for the cytotoxicity and cell 
death caused by araC treatment. This is supported by the fact that 
DNA synthesis in vitro can recover frem araC inhibition and cells can 
regain the ability to synthesise new DNA chains after the removal of 
araC. It is proposed that cytotoxicity is a complex secondary 
phenomenon of the araC inhibition of DNA synthesis. Cytosine arabinoside 
causc>s damage to the DNA and severe chromosomal aberrations. The 
proposed mechanian by which this is achieved is that after receiving a 
pulse of araC, cells that have had their DNA replicative machinery 
inhibited, can re-initiate DNA synthesis in DNA segnents that have 
already been replicated earlier in the S phase. This would mean that 
newly synthesised daughter duplexes would have two accompanying short 
DNA duplexes associated with than resulting in abnormal sections of 
replicating DNA which could in turn lead to DNA damage and chromosomal 
aberrations. This double replication of DNA segnents following araC 
induced inhibition of DNA synthesis is not an effect of araC itself 
but a result of inhibiting DNA synthesis in the middle of replicon 
replication and therefore could be produced by other inhibitors of 
DNA synthesis. Similar effects have been observed with hydroxyurea.
The aim ofthe work in this chapter is to investigate the point in 
the DNA replication process where araC exerts its inhibitory effect,
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i.e. initiation or elongation. The technique of alkaline surcrose 
density gradient centrifugation is used to identify the intermediates 
of DNA replication and the effect of araC on their synthesis.
4.2 MATERIALS AND METHODS
4.2.1 Materials
Namalwa cells were cultured as described in 3.4.2. Sarkosyl NL35
was obtained from Ciba Geigy. Whatman 2.5 cm GF/C glass microfibre
14 3filters were obtained from Whatman Limited 2- C thymidine.[ H-methyl],
3
thymidine and 5- H cytosine-B-D-arabinoside were obtained from the 
Radiochemical Centre, Amersham. Cytosine arabinoside was obtained from 
the Signa Chemical Company.
4.2.2 Cell incubation and labelling procedures
All incubations were carried out in Hepes buffered RPMI-1640 medium
0
using 20 ml cultures of Namalwa cells, 10 cells/ml. Hie 20 ml
14cultures were preincubated with 0.25 pCi, 2- C thymidine, sp. act.
21 Ci/irmol, for 24 hours. The cells were then resuspended in fresh
3
medium and then incubated with 20 pCi [ H-methyl] thymidine, sp. act.
25 Ci/nmol, under the following conditions
3
A(l) 4 hour incubation with H-thymidine.
3 -9(2) 4 hour incubation with H-thymidine in the presence of 5 x 10 M araC.
3
B(l) 15, 30 and 60 minute incubations with H-thymidine.
3
(2) 15, 30 and GO minute incubations with H-lhymidine in the presence 
of 5'x 10 9 M araC.
The following incubation procedure was also carried out in order to
look at the possible incorporation of araC into intracellular DNA.
0
3 x 20 ml cultures of Namalwa cells, 10 cells/ml, were incubated for
4 IhHirs with 0.25 pCi 2- C thymidine. One culture was simultaneously
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3 -4incubated with 20 pCi H-araC, sp. act. 26 Ci/mnol and 10 M cold
araC lor 4 hours. The other two cultures were incubated with 20 pCio  _ 4
H-araC and 10 M cold araC for the final 60 and 30 minutes of the 
4 hour incubation.
4.2.3 Sedimentat ion analysis on alkaline sucrose 
gradients
After incubation the cells were harvested by centrifugation at 
100 g, 5 minutes, 18-20°C and then washed with cold PUS and resuspended 
in 3 mis of 0.9%NaCl, 0.01 M KCN, 0.008 M EUTA, 0.05 M potassium 
phosphate buffer pH 7.2. To this was added 500 pi Sarkosyl NL35 
(35% Sarkosyl) to give a final concentration of 5% Sarkosyl. This was 
layered on to 5-20% alkaline sucrose gradients (sucrose in 10 mM EDTA, 
0.2 M NaOH, 0.2 M NaCl) prepared on a 6 ml cushion of 60% sucrose and 
left overnight for the cells to lyse and the gradients to equilibrate. 
The gradients were centrifuged in an MSE 3 x 65 ml aluminum swing out 
rotor on an MSE Prepspin 65 ultracentrifuge at 22,000 r.p.m. (90,000 g) 
for 18 hours at 20°C. At the end of the 18 hour spin the centrifuge 
was allowed to stop with the brake off so as not to disturb the 
gradients. Fractions, volime 2 mis, were collected fran the bottom of 
the gradient using a fine needle attached to an LKB 2120 varioperpex 
peristaltic pump and an LKB 2112 redirac fraction collector. 100 pi 
calf thymus DNA, 1 mg/ml in 5 mM NaiOH, and 2 mis cold 10% TCA were 
added to the fractions. The fractions were left to stand overnight 
in the cold, 4°C. The acid-insoluble precipitates were collected by 
filtration on to Whatman GF/C glass microfibre filters and washed 
twice with 5 mis ethanol and dried in a warm oven. Scintillation 
fluid, 8 mis of Toluene, PPO 5 g/1, POPOP 0.2 g/1, was added to the 
discs and radioactivity determined for both H and C (see Appendix I). 
Sedimentation coefficient values were calculated by the method of 
McEwen (see Ap|x?ndix II). All gradient profiles shown are
8K
representative profiles obtained from a nunber of similar experiments.
4.3 RESULTS
4.3.1 The effect of araC on D N A synthesis in Namalwa 
cells
14Namalwa cells, prelabelled with C-thymidine for a period of
3
24 hours, were incubated for 4 hours with H-thymidine in the presence
-9of 5 x 10 M araC and in the absence of araC. This concentration
of araC is that which gave 50% inhibition of thymidine incorporation
into acid precipitable material (see 3.5.1). The DNA produced under
these conditions was analysed on alkaline sucrose gradients, the
profiles obtained frem these gradients are shown in Fig. 4.1. Fran
14these results it can be seen that C-thymidine has been incorporated
3
into 25 S DNA. After a 4 hour incubation the H-thymidine was also 
found in 25 S DNA though the size of the 25 S peak was decreased by 
the presence of araC. No smaller size-classes of DNA were detected 
under these conditions.
In order to analyse these results quantitatively it was assumed
that the area under the peaks (see Fig. 4.1) was proportional to the
amount of labelled thymidine incorporated into a particular size-class
of DNA and that the amount incorporated was proportional to the amount
of DNA in that size-class. It was also observed that the area under the 
1425 S C peak was approximately the same in all of the gradients 
obtained from a particular set of incubation conditions. To refine
the; data On ‘^ 11-thymidine incorporation the areas under the control peaks 
ol ^i^lhymidine incorporation were all normalised by introducing a 
normalisation factor. Using this normalisation factor, the areas under 
the H peaks were calculated and corrected where necessary. The ratios 
of the areas under the **H peaks for the different incubation conditions,
8!)
in this case with and without araC, should give an indication of the 
extent of the inhibition by araC. The positions of the peaks should 
indicate the site of inhibition by indicating which size-classes of 
DNA intermediates accumulated under a given set of conditions. The 
calculations for the gradients shown in Fig. 4.1 are given below. 
Similar calculations were used in the foilwing sections to provide 
quantitative comparisons of the results obtained fran sedimentation 
analyses from a number of different experiments.
14Area under the 25 S C peak obtained
2
in the absence of araC = 10.8 cm (1)
14Area under the 25 S C peak obtained
2
in the presence of araC = 9.4 cm (2)
The normalisation factor is obtained by 
dividing (1) by (2)
3
Area under the 25 S li peak obtained 
in the absence of araC
3
Area under the 25 S H peak obtained 
in the presence of araC
Corrected value for (4) = 2.25 x 1.14
= 1.14
= 6.25 cm2
= 2.25 cm2 
= 2.6 cm2
(3)
(4)
(5)
-9The degree of inhibition obtained with 5 x 10 M araC can be obtained 
from the values of (3) and (5)
The percentage inhibition obtained = 100 - (ftÌ5 X 100)
= 58%
This value is comparable with that value obtained for the 
inhibition of 211-thymidine incorporation into acid precipitatile material 
by 5 x 10 ^ M araC (see Fig. 5.3).
3 14Occasionally very high counts for both H-thymidine and C-thymidine
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wore found in the 6O'" sucrose cushion. This probably was due to the 
pelleting of unlysed eel Is or fully formixl high molecular weight DNA. 
The centrifugation conditions list'd were designed to look at the 
synthesis of low molecular weight I)NA pieces.
4.3.2 The e ffeet of araC on the synthesis of primary 
DNA pieces
Namalwa cells, prelabelled over a period of 24 hours with ^C-
thymidine, were pulsed with 1^1-thymidine for 15, 30 and 60 minutes
and the DNA produced analysed on alkaline sucrose gradients (see 
14Fig. 4.2). All the C-thymidine was found in the 25 S peak. After 
a 15 minute pulse, ^li-thymidine was found in 4 S DNA and 25 S DNA.
40(1 of the total "*11-thymidine incorporated into DNA was found in the 
4 S peak and 60% in the 25 S peak. After a 30 minute pulse H- 
thymidine was found in 4 S, 12 S and 25 S DNA. The percentage of the 
total ^H-thymidine incorporated in each peak was 13%, 8% and 79%
3
respectively. After a 60 minute pulse the H-thymidine was found
3
predominantly in the 25 S peak, 92.5% of the total H-thymidine 
incorporated was found in this peak, 2.5% was found in the 4 S peak 
and 5% in the 12 S peak. The 4 S peak represents the primary,
Okazaki, pieces of DNA formpd as a result of the initiation of the 
synthesis of new replication uhits. Hie 12 S and 25 S peaks probably 
represent the DNA produced in the secondary elongation process arising 
from the arrangement of replication units either singly or in 
clusters (see Chapter 2).
3
This experiment was repeated but this time the H-thymidine
-9pulses were carried out in the presence of 5 x 10 M araC. The
gradient profiles obtained are shown in Fig. 4.3. After a 15 minute
3 3pulse H-thymidine is only found in the 4Speak. The amount of 11-
thymidine in this peak is only 15%. of the total 'll-thymidine
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incorporated into DNA after a 15 minute pulse without-araC. After a
30 minute pulse the 3H-thymidine is found in the 4 S and 12 S peak,
75% of the total in the 12 S peak ;uid 25% in the 4 S peak. The total
thymidine tncor|x>rated is 00%, of that found after a 30 minute pulse in
the absence of uraC. After a 60 minute pulse in the presence of araC
the profile obtained is similar to that obtained after a 4 hour
incubation with H-thymidine in the presence of araC, i.e. the majority 
3
of the H-thymidine, 82%, is found in the 25 S peak. The rest is
evenly distributed throughout the 4 S and 12 S peaks. The heights of
these two peaks are so anall as to be almost negligible. The total 
3
H-thymidine incorporated after the 60 minute pulse is 68% of that 
found in the absence of araC representing a 42%, inhibition of DNA 
synthesis.
The formation of h u h11 pieces of DNA in the presence of araC 
indicates that the initiation of DNA synthesis has not been inhibited. 
The rate of elongation 1ms decreased in the presence of araC but has 
not been totally inhibited. This is to be expected as the araC 
concentration used was very low and was expected to only give 50% 
inhibition of DNA synthesis.
4.3.3 The incorporation of araC into newly synthesised 
DNA
14Namalwa cells were incubated with C-thymidine for 4 hours and
with 20 viCi 3lI-araC at a final concentration of 10 4 M araC for the
last 60 and 30 minutes of the 4 hour incubation. One culture was 
14 3incubated with C-thymidine and H-araC simultaneously for 4 hours. 
Hie DNA produced was analysed on alkaline sucrose gradients. The 
gradient profiles obtained are shown in Fig. 4.4.
44C-thytnidine was found in the 4 S, 12 S and 25 S peaks after a
9f>
4 hour incubation during which ^II-araC had boon added for the last
1430 minutes. Most of the C-thymidine, 74%, was found in the 25 S
peak, 23% was found in the 12 S peak and 3% in the 4 S peak. The
3
H-araC was found evenly distributed between the 4 S and 12 S peaks.
After a similar 4 hour incubation, but with ‘11-araC present for the
14last 60 minutes of Liu; incubation, again nost of the C-thymidine,
81%, was found in the 25 S peak, 14% was found in 12 S DNA and 5% in
4 S DNA, i.e. a similar distribution to that found after a
30 minute exposure to araC. The araC was evenly distributed between
the 4 S and 12 S peaks. After a simultaneous 4 hour incubation with
14 -4 3 14C-thymidine and 10 M H-araC the C-thymidine was only found in
4 S and 12 S UNA, about 70% in the 4 S and 30% in the 12 S DNA. The
14total amount of incorporated C-thymidine under these conditions 
was also only 17% of that under the other two sets of incubation 
conditions, i.e. there was an 83% inhibition of 1^C-thymidine
3
incorporation. Again the H-araC was found evenly distributed
3
throughout the 4 S and 12 S peaks but the amount of H-araC
incorporated after the 30 and 60 minute incubations was only 30% of
3
that found in the 4 hour exposure to H-araC.
It therefore appears as if araC has been incorporated into low 
molecular weight DNA, i.e. 4 S and 12 S. This again implies that araC 
has not inhibited the initiation of the synthesis of primary pieces 
of DNA. However araC has inhibited the synthesis of 25 S DNA. It 
therefore appears as if araC has inhibited the further elongation or 
ligation of DNA between the 12 S and 25 S stages under these conditions 
of high araC concentration.
í ) ( ¡
pni
r®? ---
IZl .
c  ~l
X
*>2-^ 0-~ "
• i
r •
r* ♦ >
1
:r: o Ô
t í A .r — I •
4> 4 ■* 41
t :  . i
c> -r  R 4-Ì
( ) •R
(O
• f l r l  O •iH HÌ • •H
*M O  rC •; CO f R
* k* 4-> r> <u
R  O  R n »»  C. o
« r. ; . . C  Ì • * r : i
3 « R
i>J *‘M O
• * r o
r / 
.1 !
•» 1 ♦>
k: n
•. i . i «1»
( f .
r  » » r
R
■J y KA • t
• i
( ) ; i *> « i
M r> r 1 « * . C o
•'* R :.1 c: r R
»;* O ki f-i R
L i R  -3 •r-l r-l
f  *. Ci ò ti
R C. « o •H
O  C> .3 T1 X  c.
rs x : R O 4-» .J
W 4 » R •-J ,R ( ’
4-> 9% •<-<C « -4- •> r""* 4>
R  <■ * f* « c: •H .)
•• \ c* U (. 4->
r 1 r •o R
. C c l J u» R R  r -4 a
¿ í  H  r< R O O  .j V.
rH 4-> tí •H Vh I- 4 H
«4  .\¿ : T l R  rj " Î
.r •H r*x n O
n  -4-> k: o 4->
-3- f*-4 G R
• ti  >■> G c> •»
- I  R  R -U o r  1 >i
4-> 1 :i tí •
to  v : «•< O R  O
•H V  VJ R •r4 R •
r«« o  r  H as «.-4 f* -3
< Y
ocL«no r XÎ1
''n— cr—
X C H >
Î
u - C  / '
1 A
IUl1 3
Fr
ac
ti
on
 
no
. 
Bo
ff
of
n
97
4.4 DISCUSSION
The major mode of action of cytosine arabinoside is generally 
considered to be its inhibitory effect on the enzyme DNA polymerase a. 
This being the case one would e.\|X'ct araC to inhibit tho elongation 
process of DNA synthesis its it is an inhibitor of the elongation 
enzyme. This is supported by the work of Wist et al. , Heligren et al. 
and Dijkwel and Wanka (125, 126, 127). However Fridland has proposed 
that the primary effect of araC, observable at low concentrations of 
the drug, is to inhibit the initiation of new replicons (128, 129).
The results presented here are examined in the light of these two 
hypotheses.
The concentration of araC used in the following experiments 
-9(5 x 10 M) was chosen so that DNA synthesis was only partially
inhibited. When lymphoblasts were incubated for 4 hours with 
-9 35 x 10 M araC, all the H-labelled thymidine was found in the 25 S DNA 
region. This was the same result as in the control experiment without 
araC. However in the presence of the drug the 25 S peak was 58% 
analler indicating a partial inhibition of DNA synthesis. Wien the
3
cells were pulsed with H-thymidine for 15, 30 and 60 minutes in the 
presence of araC the rate of elongation was markedly inhibited 
compared to the control experiments without araC. However though the 
initiation process was slowed down under these conditions, it was by 
no means completely inhibited, whereas Fridland however reported the 
complete inhibition of initiation with 5 x 10~8 M araC (129). The 
decreased rate of eLongation from 4 S to 12 S to 25 S may represent 
an inhibition of the ligation process though this may be a secondary 
result of the slowing down of elongation by the inhibition of the 
polymerising activity of DNA polymerase a.
3 14
Tile incubation of Namalwa cells with ' 11-araC and C-lhymidine
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resulted in the incorporation of araC into 4 S and 12 S DNA. This
14also coincides with the incorporation of C-thymidine into 4 S and 
12 S DNA suggesting that they are both incorporated into the same
growing DNA chains. The araC concentration used in this third set 
-4ol experiments, 10 M, was clioson so as to give complete inhibition 
of DNA synthesis so that a more pronounced effect on the gradient
3
profiles could lie produced. The incorporation of Il-araC into the 
4 S and 12 S peaks again indicates that initiation has not been
3
inhibited to any great extent. When the H-araC was incubated with 
14the C-thymidine for 4 hours there was a complete inhibition of 
incorporation into 25 S DNA indicating a complete inhibition of the 
elongation process without an affect on the synthesis of 4 S and 12 S 
DNA showing that there was no significant inhibition of the 
initiation process even at this high concentration of araC.
Presumably the araC is incorporated into DNA in place of deoxycytidine.
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Ç H A P î  E R 5
J h e _N e c h a n i s m  O f Ac t i o n  O f A p h i d i c o l i n
5.1 INTRODUCTION
Aphidicolin is a tetracyclic, diterpenoid antibiotic produced by 
the mould Cephalosporiwn aphidicola Petch (131). It Is a non-polar, 
water insoluble compound. Original studies on its biological activity 
showed that it was active against Herpes virus. Later work has shown 
that its anti-viral activity extends to other DNA viruses including 
SV40 and Vaccinia viruses (132, 133), but not Adenovirus (134). It 
also inhibits DNA synthesis in lymphocytes (135), IleLa cells (136), 
and other mamnalian cells. It has no effect on E. ooli DNA synthesis.
The principal mode of action of aphidicolin seems to be as an 
inhibitor of mamnalian DNA polymerase a and certain DNA virus 
induced DNA polymerases involved in viral replication. It has no 
effect on DNA polymerase 6 or DNA polymerase y. It therefore generally 
only affects normal, S phase, DNA replication and has little or no 
effect on DNA repair replication (132, 138). Inhibition studies have 
shown that it is a competitive inhibitor of DNA polymerase a with 
respect to dCIP, its inhibitory effect being reversed by the addition 
of excess dCTP (137, 138). It is a non-competitive inhibitor with 
respect to dGIP, clATP and dTIP.
However the picture is not as clear as depicted above. Seki et al., 
have sliown that aphidicolin can inhibit DNA repair synthesis in 
lymphocytes induced by UV irradiation or N-methyl-N'-nitro-N-nitroso 
guanidine (139). It is proposed, as a result of this evidence, that 
DNA polymerase u may play a role in DNA reixiir replication. A possible
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explanation tor this discrepancy is that the UNA polymerase involved 
in repair may not lx; the s:imo lor al l types of DNA damage or that there 
may be species differences in the repair enzymes involved. It is also 
suggested that the inhibition of DNA polymerase u may not be simple 
canjx'titive inhibit ion with res|>eef to d(TP tint is a tyjx? of rnixed- 
inhibition of competitive and non-cut|xjtiLivu inhibition.
The competitive inhibition of DNA polymerase a by aphidicolin is 
similar to that observed with araOP. Unfortunately this affords no 
clue as to the mechanism of action of aphidicolin as the chemical 
structure of aphidicolin is totally dissimilar to that of araCIP and 
NMR studies have shown that aphidicolin cannot form hydrogen bonds 
with guanine. It has been proposed by Oguro et al., that there are 
separate binding sites for the four nucleotide triphosphates because 
(a) aphidicolin is only a competitive inhibitor with respect to dCTP 
and (b) studies using poly(dC).(dG)12 and poly(dA).(dT)1 2 1 g as 
templates for DNA polymerase a show a reduced sensitivity to 
aphidicolin using dGTP and dTIP respectively as the labelled substrates 
for 111 A polymerase a assays compared with activated DNA as a template- 
primer using dTIP as the labelled substrate. If there were not separate 
binding sites the degree of inhibition would be the same in all cases 
(138). Non-ccmpetitive inhibition with respect to dNTPs other than 
dCTP can be explained by the slower breakdown of the ternary enzyme- 
dOTP-aphidicolin complex. There are two possibilities for the 
aphidicolin binding site. The drug may bind competitively with dCTP 
at the dCTP binding site or it may bind at a site other than the 
catalytic'site and compete with dCTP by an, as yet, unknown mechaninn. 
The aphidicolin binding site may be in a hydrophobic region of the 
enzyme molecule as it is a non-polar compound.
Aphidicolin, because of its specificity for eukaryotic DNA
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polymerase a, is a useful tool for studying eukaryotic UNA replication. 
In this chapter its effect on thymidine incorporation in Namalwa cells 
is investigated. This is used as a preliminary study leading to an 
investigation of its effect on UNA synthesis in Namalwa lymphoblastoid 
cells.
5.2 MATERIALS ANU METHODS
5.2.1 Materials
Aphidicolin was a gift fran Ur G Coles, I.C.I. Pharmaceuticals,
Alderly Edge. The source of all other materials used was the same as 
described in 4.2.1.
5.2.2 The effect of aphidicolin on thymidine incorporation 
in Namalwa cells
1 ml cultures of Namalwa cells, 10® cells/ml, weie incubated at 37°C
3
for four hours with T H-methyl] thymidine, sp. act. 47 Ci/mnol, as 
described in 3.4.4. Aphidicolin, dissolved in 0MS0, was added at final 
concentrations of 0, 10_®, 10®, 5 x 10 ®, 10 ^ , 5 x 10 7 , 10 6 and 
10 M, so that the final concentration of DMSO was not greater than 1%.
The incorporation of radioactive thymidine into acid précipitable 
material was assayed as described in 3.4.4. Results are shown as the 
percentage of maximun thymidine incorporation into acid précipitable 
material.
5.2.3 Cell incubation and labelling procedures for 
sedimentation analysis
All incubations were carried out in Hopes buffered RPMI-1640 mediun
g
using 20 ml cultures of Namalwa cells, 10 cells/ml. The 20 ml
14cultures were preincubated for 24 hours with 0.25 pCi C-thymidine, 
sp. act. 21 Ci/mnol. The cells were then resuspended in fresh medium
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and incubated with 20 pCi [^H-methylJ thymidine, sp. act. 20 Ci/mnol, 
under the following conditions:
3
(1) 4 hour incubation with H-thymidine.
3 -7(2) 4 tour incubation with H-thymidine in the presence of 10 M
aphidicolin.
(3) 15, 30 and 60 minute incubations with ^H-thymidine in the presence
_7
of 10 M aphidicolin.
Sedimentation analysis on 5-20% alkaline sucrose gradients was carried 
out as described in 4.2.3.
5.3 RESULTS
3
5.3.1 The effect of aphidicolin on H-thymidine 
incorporation by Namalwa cells
The effect of increasing concentrations of aphidicolin on the
3
incorporation of H-thymidine into acid precipitable material is 
shown in Fig. 5.2 Aphidicolin is not such a potent inhibitor of DNA 
synthesis in Namalwa cells as cytosine arabinoside but it is still 
effective at low concentrations. 50% inhibition of thymidine
_7
incorporation is obtained with 10 M aphidicolin. Inhibition was seen
—8with concentrations as low as 10 M and 100% inhibition was attained
_5
with 10 M aphidicolin.
5.3.2 The effect of aphidicolin on DNA synthesis in 
Namalwa cells
14Namalwa cells, prelabelled with C-thymidine, were incubated
3 -7for 4 hours with H-thymidine in the presence of 10 M aphidicolin
and in the absence of aphidicolin. The concentration of aphidicolin
used is that which gave 50% inhibition of thymidine incorporation into
acid precipitable material (see 5.3.1). The DNA produced under these
In I
Fie i>«2 The inhibition of ''H-thymidine upt.k- in N n m a l c o l l s  by 
aphidieolln. Results or'.- shown no th : poreontec« inhibition of 
maximum thymidine incorporation into acid pr< cipitnbl c material as 
describ' d in Rrror born rnpror nt r.R. t n=3*
cp
m
IO!)
r‘i(' Alk.'1! i rò:  i:ncrn"i! donr:i ty rr > l i  ni. o. l i t r i  furd-ion ot' Ih«
proiluo tr. of fl.iìiitlv.n. p i  1 UN A r.yntlPv i' " iI t  » ?.'■ hour 
prolneuh••tion v/itli 'o-thymidino (n) f >1 l o v  I by a /| li >ur pulro 
with Jll-thynldi no (o), A, in tho pr> li>• • • of |f'“ 'H nph1 dlcolin 
• »mi, li, without. u phidi.no l i n* Oí ■••ni i • ■ ri l. 01 ly:lo •.» •: r*-i *1 •ut •• 
doscribod in R'-dimentation )/■ from loft to ridili*
ior.
conditions was analysed on alkaline sucrose gradients. The gradient
14profiles are shown in Fig. 5.3. All the C-thymidine was 
incorporated into 25 S DNA. After the 4 hour incubation all the 1^1- 
thymidine was also found in 25 S DNA in experiments both with and without 
aphidicolin. The size of the 1^1-thymidine 25 S peak formed in the 
presence of aphidicolin was 54% smaller than that produced in the 
control incubation without aphidicolin. This indicates 54%
_7
inhibition of DNA synthesis in Namalwa cells treated with 10 M 
aphidicolin. There was no thymidine incorporation into 4 S or 12 S 
DNA under these conditions.
5.3.3 The effect of aphidicolin on the synthesis of DNA 
primary pieces
14Namalwa cells, prelabelled with C-thymidine, were pulsed with 
3 -7H-thymidine in the presence of 10 M aphidicolin for 15, 30 and 60
minutes and the DNA produced analysed on alkaline sucrose gradients
14(see Fig. 5.4). All the incorporated C-thymidine was found in 25 S
3
DNA. After a 15 minute pulse a anall amount of H-thymidine was found 
in the 4 S and 12 S DNA peaks, 45% of the total 3H-thymidine incorpor­
ated was found in the 4 S peak and 55% in the 12 S peak. The total 
3
amount of H-thymidine incorporated is 32% of that obtained under 
similar conditions with no drug present (see Fig. 4.2). After a 
30 minute pulse the total amount of thymidine incorporated had 
increased, but radioactivity was still only found in 4 S and 12 S DNA 
regions. 60% was found in 4S DNA and 40%, in 12 S DNA. The total 
amount of.thymidine incorporated under these conditions was 46% of 
that found under similar conditions with no drug present. At the end
3
of the 60 minute pulse the majority of the H-thymidine, 82%, was 
found in the 25 S peak and 18% in the 4 S peak. There was no
3
incorporation of thymidine into 12 S DNA. The total amount of H- 
thymidine ineoriJoraUxl into DNA was 47%, of that found in the control
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without any drug present. This represents a 53% inhibition of DNA 
-7synthesis with 10 M aphidicolin.
5.4 DISCUSSION
Aphidicolin is a known inhibitor of DNA polymerase a. This 
property of aphidicolin has been used as a tool to study DNA 
synthesis. Being an inhibitor DNA polymerase a it should only 
affect the elongation process of DNA synthesis. It therefore provides 
a useful comparison for the study of the inhibition of DNA synthesis 
with araC.
The result shown in Fig. 5.2 demonstrates the inhibition of DNA 
synthesis in Namalwa cells by aphidicolin as measured by the incorp­
oration of radioactive thymidine into acid precipitable material. 50%
_7
inhibition was obtained with 10 M aphidicolin. This concentration 
of drug was chosen for the study of the effect of aphidicolin on the 
process of DNA synthesis. This degree of inhibition was the same as 
that given by the araC concentration used in the experiments described 
in 4.3.1 and 4.3.2 thus allowing direct comparisors to be made.
3
After a four hour incubation of lymphoblasts with H-thymidine in
_7
the presence of 10 M aphidicolin all the labelled thymidine was 
found in 25 S DNA (Fig. 5.3). A similar result was achieved by 
repeating the experiment without aphidicolin. However the presence 
of the drug decreased the size of the H-thymidine 25 S peak by 54%. 
This indicaUd an inhibition of DNA synthesis of the order of 50% as 
would be predicted iron the thymidine incorporation study (5.3.1).
14 3When the C-thymidine prelabelled cells were pulsed with H-
_7
thymidine for 15, 30 and 60 minutes in the presence of 10 M 
aphidicolin the rate of elongation was inhibited compared with the 
control experiments without drug (Fig. 4.2). There was a decrease in
the rate of initiation l>ut this was probably the result of the
decreased rate of elongation. The gradient profiles produced under
these conditions (Fig. 5.4) were similar to those produced under
-9similar conditions with 5 x 10 M araC. This suggests that the 
mochanisn of inhibition of the two drugs may lx> simi lur. As 
aphidicolin is an inhibitor of the elongation enzyme, 1)NA polymerase 
a, it is proposed that araC is also primarily an inhibitor of DNA 
chain elongation.
10!)
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C H A P T E R  6
Cyclophosphamide And DNA Synthesis
6.1 Till?: MKCIIAN ISM O K A C T ION OF CYCLOPHOSPHAMIDE
Cyclophosphamide is a widely used, potent, anti-cancer drug and 
is of the class of drugs known as the alkylating agents. It is a 
phosphoramide derivative of the nitrogen mustards, a group of potent 
and very toxic alkylating reagents. Nitrogen mustards alkylate by a 
two step process. The first stage is the rapid cyclisation of the 
molecule to give an ethyleneiinnonium ion. The second step is slower 
and is an S^2 alkylating step. This is the rate determining step in 
the alkylation mechanism. Phosphoramide mustards probably alkylate 
via the same mechanism as the nitrogen mustards (140). The postulated 
mechanism of alkylation of phosphoramide mustard is shown in Fig. 6.1.
Cyclophosphamide itself is inactive as an alkylating agent and 
has to be first metabolised to an active form (14, 141). The 
principal site of activation is the liver where cyclophosphamide is 
metabolised by oxidative microsomal enzymes. The major metabolites 
of cyclophosphamide are shown in Fig. 6.2. The first activation step 
is the oxidation of the phosphoramide ring to produce 4-hydroxycyclo- 
phosphamide. This compound can then be detoxified by further 
oxidation to the inactive 4-ketocyclophosphamide. Alternatively the 
4-hydroxycyclophosihnmide can tautanerise to the open chain aldehyde, 
aldophosphamide. This can also undergo further oxidation to give 
carboxyphosphamide. Tire ketocyclophosphamide and carboxyphosphamide 
are the major urinary metaboli tos excreted by the body and represent 
lii% and f>0% respectively of the administered drug. Alternatively the 
aldophosphamide can Ire cleaved non-enzymatically via spontaneous
111
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B elimination of acrolein to give phosphoramide mustard, the postulated 
active foim of the drug. The metabolian of cyclophosphamide can be 
altered by drugs affecting microsomal metabolism, e.g. phenobarbitone 
increases microsomal enzyme activity in rats giving accelerated 
production of the? alkylating metal«lites, whereas the antibiotic 
chroramphenicol inhibits microsomal enzymes and produces the reverse 
effect (14).
The alkylating activity of phosphoramide mustard cannot alone 
account for the potency of cyclophosphamide. It is thought that seme 
of the metabolites of cyclophosphamide such as 4-hydroxycyclophosph- 
amide, aldophosphamide and iminophosphamide may act as carriers of 
phosphoramide mustard which, on entering the target cell, can release 
phosphoramide mustard (141).
Phosphoramide mustard is a non-specific alkylating agent and the 
exact target of the di\ig is not known, however the favoured target is 
DNA (142). It is thought that phosphoramide mustard, being a 
bifunctional alkylating agent, can cross-link the two strands of the 
DNA double helix thus preventing DNA replication. Because of its 
non-specific action cyclophosphamide is not cell-cycle specific like 
the other inhibitors of DNA synthesis, araC and aphidicolin, that 
have already been examined. This lack of specificity makes it 
difficult to explain the observéd tunour cell specificity of cyclo- 
ptosphamide over normal cells. Two main theories have been proposed 
to account for this (141). On«' theory proposes that cyclophosphamide 
and its metabolites are bound by thiols, probably proteins, giving 
increased metabolic stability so that entry into target celle is 
facilitated. This thiol binding also enables the metabolites to be 
directed to specific sites in the cells and gives a delayed release 
of phosphoramide mustard into the target cell. The other hypothesis
li:*
VII vili IX
Fig 6.? The motabolism of cyclo«hosph:imldo. Cyelophoephamido 
(I), h, hydroxycyclophosphami lo (II), hydrop ro:y- 
cyclophosphantide (III), lt, ketocyclophosi'humide (IV), 
aldophonphumi.de (V), iminophoRpha lido (VI) phosph ir iraido 
mustard (VII), acroi ein (Vili), cnrboxyphosphamide (IX)
proposes that cyclophosphamide and its metabolites are selectively 
detoxified by normal cells thus rendering than inactive. This 
detoxification mechanism is thought not to exist in tiinour cells 
thus milking them susceptible to the alkylating agents.
Several derivatives of cyclophosphamide have Ix'on synthesised 
in this laboratory including the non-physiological derivative 
hydroperoxy-cyclophosphamide (see Fig. 6.2). This spontaneously 
decomposes in water to the activated, hydroxy, form of the drug (143) 
thus providing an active form of the drug that can be used in in vitro 
studies. Extensive work has been-carried out in this laboratory on the 
effect of cyclophosphamide and its derivatives on cyclic nucleotide 
metabolism, and RNA and protein synthesis. This chapter looks at 
the effect of cyclophosphamide and its derivatives on the DNA 
synthesis of the transformed lymphoblastoid cell line.
6.2 MATERIALS AND METHODS
6.2.1 Materials
Cyclophosphamide was obtained fran Boehringer Mannheim. Phosphor- 
amide mustard (cyclohexylamine salt) was obtained fran NIH, Bethesda, 
Maryland. Hydroperoxycyclophosphamide was synthesised by L.A. Fitton 
and G.J. Hunter, Department of Chemistry and Molecular Sciences, 
University of Warwick. All other materials were obtained as 
described in 4.2.1.
6.2.2 The effect of alkylating agents on thymidine 
incorporation in Namalwa cells
1 ml cultures of Namalwa cells, 10 cells/ml,were incubated at 
37°C for one hour with l^H-methyl] thymidine, sp. act. 47 Ci/mnol.
All the alkylating agents, dissolved in PBS, were added to give the
Ilf)
-f> -4 -4following final concentrations: 0, 10 ,10 , 5 x 10 , 10 * and
_3
5 x 10 M. The incorporation of radioactive thymidine into acid 
précipitable material was assay<d as described in 3.4.4. Results are 
shown as the percentage of maxi mini thymidine incorporation into acid 
précipitable material.
6.2.3 Cell incubation and labelling procedures for 
sedimentation analysis
All incubations were carried out in Hopes buffered RTMI 1640
medium using 20 ml cultures of Namalwa cells, 106 cell/ml. The 20 ml
' 14cultures were preincubated for 24 hours with 0.25 aCi C-thymidine,
sp. act. 21 Ci /nmol. The cells were then resuspended in fresh medium
3
and cinbuated for one hour with 20 yCi [ H-methyll thymidine,
-3 -3sp. act. 25 Ci/tmiol and (1) 10 M cyclophosphamide (2) 10 M
_3
phosphoramide mustard (3) 10 M hydroperoxycyclophosphamide and 
(4) without drug. Sedimentation analysis on 5-20% alkaline sucrose 
gradients was carried out as described in 4.2.3.
6.3 RESULTS
3
6.3.1 The effect of alkylating agents on H-thymidine 
incorporation by Namalwa cells
The effect of cyclophosphamide, phosphoramide mustard and
3
hydroperoxycyclophosphamide on H-thymidine incorporation into acid 
preciptable material is shown in Fig. 6.3. The jx>riod of incubation 
for these assays was one hour, rather than four hours as described 
in 3.4.4, as phosphoramide mustard is rapidly degraded in aqueous
3
solution. Cyclophosphamide has little effect on H-thymidine
incorporation into acid précipitable material. Only 20% inhibition 
-3was obtained with 5 x 10 M cyclophosphamide which was the maximun 
concentration used. Phosphonimide mustard lias a greater effect than
%
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FI g 6.3 T h u  Inhibition of thymidine uptake: in' flemalKn cells 
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hydroporoMycycloph'ir.phamidc (v). Ronulto nre shorn nr the 
percentage inhibition of maximum thymidine incorporation into 
acid proct pi tab1 o m" turial as described 3«,i«h. !rror barn 
represent S.M., n=3
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cyclophosphamide. As the concentration of phosphoramide mustard
increases so inhibition increases starting at 18% inhibition with
-4 -310 M up to 60% inhibition with 5 x 10 M. The greatest inhibitory
-4effect was seen with hydroperoxycyclophosphamide. 10 M hydroper- 
oxycyclophosphamide gave 35% inhibition and as the drug concentration 
increased so the degree of inhibition increased so that 90%
_3
inhibition was obtained with 5 x 10 M of the compound.
6.3.2 The effect of alkylating agents on DNA synthesis 
in Namalwa cells
• 14Four cultures of Namalwa cells, prelabelled with C-thymidine,
3
were incubated for 1 hour with H-thymidine and (A) without drug,
-3 -3(B) with 10 M cyclophosphamide, (C) 10 M phosphoramide mustard and 
-3(D) 10 M hydroperoxycyclophosphamide. The DNA produced was analysed 
on alkaline sucrose gradients. The gradient profiles obtained are 
shown in Fig. 6.4a and 6.4b. il-thymidine was only incorporated into 
25 S DNA when the Namalwa cells were incubated in the absence of the
_3
alkylating agents. When the cells were incubated with 10 M 
3
cyclophosphamide H-thymidine was incorporated into 4 S, 12 S and 
25 S DNA. 69% of the label was incorporated into 25 S DNA. 15% 
into 12 S DNA and 16% into 4 S DNA.
_3
When the cells were incubated with 10 M phosphoramide mustard 
3
H-thymidine was incorporated into 4 S and 25 S DNA. There was also 
3
H-thymidine in a 19 S DNA peak that had not been previously observed
3
in any of the other gradient analyses. 64% of the H-thymidine was in 
25 S DNA, 11% in 4 S DNA and 25% in 19 S DNA. When the cultures were
_3
incubated with 10 M hydroperoxycyclophosphamide all the incorporated 
3H-thymidine was found in the 19-20 S DNA peak. The 25 S 14C-thymidine
peak was also broader.
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'Hie control incubation wits not performed at the same Lime as the 
incubations with the alkylating agents as three gradients was the 
maximum number that could be run at any one time in the rotor used. 
Because of this a quantitative comparison between the four gradient 
profiles shown was not carried out as it was decided that this would 
not be valid under the eircunstanees (see 4.3.1).
6.4 DISCUSSION
The three alkylating agents have different effects on thymidine 
incorporation by Namalwa cells. Cyclophosphamide has little effect. 
This is to be expected because the drug has to be metabolised by 
oxidative enzymes in order to produce the activated, hydroxy, form 
of the drug. Phosphoramide mustard is an active alkylating agent
3
and therefore inhibits the incorporation of H-thymidine into acid 
precipitable material as shown in Fig. 6.3. The synthetic derivative 
of cyclophosphamide, hydroperoxycyclophosphamide, has an even greater 
inhibitory effect on thymidine incorporation than phosphoramide mustard. 
The hydroperoxy compound rapidly decomposes in water to give the 
activated, hydroxy, from of cyclophosphamide. This is then slowly 
degraded to phosphoramide mustard and acrolein. However the hydro­
peroxy compound has a greater net effect than phosphoramide mustard 
on its own. This implies that the action of the drug is not a simple 
alkylating effect by the phosphoramide mustard formed as a result of 
its degradation. The synthetic derivative must have other effects in 
order to produce the observed response. The hydro|>eroxy ccmpound may 
be metabolise*! to other derivatives which may themselves act as 
alkylating agents or may be more easily transjxjrtexi across the 
Namalwa cell membrane than phosphoramide! mustard (sex? 6.1). The 
concentrations of all the drugs required to produce an inhibitory 
effect is mue:h greater than those eronce-ntrat ions of araC and aphidi- 
colin m i u i m l  Io inhibit Lhymieline incorporation. This is probably
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because ol' tlie non-specific action of the alkylating agents compared 
with the specific UNA synthesis inliibitors.
It is thought that the alkylating agents a m  cross-link double 
stranded DNA and in this way prevent DNA replication. Cyclophosphamide 
appears to slow down the rate of DNA elongation. This is indicated by 
the accumulation of low molecular weight intermediates, 4 S and 12 S, 
after the sedimentation analysis of the DNA produced by Namalwa cells
_3
in the presence of 10 M cyclophosphamide (see Fig. 6.4a). However 
the inhibition of DNA synthesis, even at this high concentration, is 
not very significant.
Phosphoramide mustard inhibited DNA elongation as indicated by 
the accumulation of low molecular weight DNA intermediates. Another 
effect was also observed, this was the accimulation of a 19 S DNA
_3
intermediate. When the Namalwa cells were incubated with 10 M
hydroperoxycyclophosphamide the only DNA formed was in the 19 S
peak. This unusual peak is probably the result of the cross-linking
of DNA by the alkylating agents and this may explain the formation of
this unusual class of DNA intermediate. The cross-linking of DNA
would produce DNA intermediates of an unusual size and would also
prevent the strands frem separating on the gradients as is normally
14the case on alkaline sucrose gradients. The broadening of the C- 
thymidine 25 S peak may also be a result of the alkylation of preformed 
25 S DNA. However before such a hypothesis could be established 
further, more detailed, experiments should be performed in order to 
establish that binding of the alkylating agents to faNA occurs in this 
fashion (see General Discussion).
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C H A P T E R  7
The Immunosuppressive Activity of Glucocorticoids:- 
in vivo Studies
7.1 INTRODUCTION
Steroids make an important contribution to the control and 
regulation of the body's metabolism’in their role as naturally 
occurring hormones. They are secreted by a number of tissues 
throughout the body and serve a number of functions. The major 
classes of steroid hormones are (1) the mineralocorticoids produced 
by the adrenal cortex which are responsible for regulating sodium 
levels in the body, (2) the oestrogens produced by the ovaries,
(3) progesterone also produced by the ovaries and placenta and
(4) the androgens produced by the testes and adrenal cortex, all of 
winch control sexual development and reproduction, and finally,
(5) glucocorticoids produced by the adrenal cortex which help regulate 
carbohydrate, protein and lipid metabolian and also mediate in 
inflamnatory responses.
The glucocorticoids and their derivatives have two important 
pharmacological properties, they act as iimunosuppressants and also 
possess anti-inflairmatory activity. The former property is used 
clinically in the suppression of the T lymphocyte mediated
rejection of tissue grafts and organ transplants.
The latter property is used clinically in the treatment of a number of 
diseases associated with the inflanmation of tissues including psoriasis 
and rheumatoid arthritis. The action of the glucocorticoids and their 
clxmically synthesised derivatives are investigated in the following 
two chapters using an in vivo and in vitro assay system. This port of
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the work was carried out predominantly at Upjohn Limited as part of 
tlieir study on topical anti-inflammatory agents.
7.2 THE MECHANISM OF ACTION OF GLUCOCORTICOIDS
Glucocorticoids produce a lumber of diverse resjwnses depending 
upon tlte target tissue for the steroid (144). In many tissues such as 
muscle they stimulate catabolism whereas in other tissues they 
stimulate analwlian. In this respect they can be viewed as preparing 
the body for stress situations. Thus there is an inhibition of 
glucose uptake and utilisation in lymphoid cells, skin, connective 
tissue and adipose tissue. In these tissues and muscle there is a 
general increase in catabolism affecting carbohydrate, protein, fat 
and nucleic acid metabolism leading sometimes to cell death or growth 
inhibition. Other tissues such as brain, heart, liver and erythrocytes 
are spared this increase in catabolisn and are capable of using the 
increased glucose that is produced.
Hie glucocorticoids also play a role in the control of the 
cardiovascular process. In many cases their actions are permissive, 
i.e. certain cyclic AMP mediated hormonal effects require the 
presence of the glucocorticoid hormones (144, 145). They also 
induce several enzymes such as tryptophan pyrrolase and tyrosine 
transaminase in the liver.
Their inhibitory effect on the metalxilism of lymplioid cells 
resulting in lyniplioid cell death is the direct cause, of their 
immunosuppressive effect. Human lymphocytes are relatively resistant 
to glucocorticoid inhibition unlike mouse and rat lymphocytes. The 
latter have therefore been extensively used in experimental studies 
on immunosuppression. The major lymphoid targets are the T lymphocytes. 
In seme instances humoral immunity is also affected though in some
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cases this may be an indirect effect due to the inhibition of 
T helper cell activity (146). The sensitivity of lymphoid cells to 
glucocorticoids changes during lymphocyte development (144). Doth 
mature B and T lymphocytes appear to be sensitive to glucocorticoids 
but lose this susceptibility when stimulate! by an antigen to undergo 
antigen induced differentiation. T lymplloeyte progenitor cells are 
also resistant, therefore there appears to be a resistant-sensitive- 
resistant development sequence, at least for T lymphocytes.
Glucocorticoids have a pronounced effect on white blood cell 
distribution (146). They act on neutrophils by causing their release 
from tone marrow stores, prolonging their half-life in the 
circulation and blocking their migration and accumulation in inflanmatory 
loci. This may be due to the inhibition of lymphokine production by 
T lymphocytes. Ill is mechanism also prevents the accumulation of 
macrophages at inf 1 {minatory loci. The prevention of cellular 
accumulation at sites of inflamnation is probably one of the major 
anti-inflamnatory effects of glucocorticoids.
Another possible explanation for their anti-inflamnatory activity 
is their inhibitory effect on prostaglandin biosynthesis. Prostaglandin 
release is a contributory factor in the cause of inflamnation. The 
steroids act by preventing the release and/or activation of the 
enzyme phospholipase Ag. This enzyme releases fatty acids from 
phospholipids thus providing the precursors for prostaglandin 
biosynthesis so its inhibition results in a lack of substrates for 
prostaglandin biosynthesis (147, 148).
There is a unifying hypothesis which explains the mechanisn of 
action behind these diverse responses to glucocorticoids (145). This 
hypothesis states that the steroids pass through the cell membrane 
and enter the cytoplann where they are bound by cytoplasnic receptor
proteins. The receptor proteins exist in a state of equilibrium 
between a form which will not and one that will ultimately bind in 
the cell nucleus (144). Active glucocorticoids influence a shift in 
this equilibrium to a form that can spontaneously undergo a second 
activation step that exposes a nuclear binding site on the receptor. 
This steroid receptor complex then binds to the chromatin within the 
nucleus. The binding of the steroid-receptor complex to nuclear 
chrcmatin results in the stimulation of RNA transcription. It is 
thought that the steroid receptor is a dimeric protein. One of the 
monomers is thought to bind to a specific non-histone protein on the 
chromatin. The dimer then dissociates and the other moncmer interacts 
with DNA enabling RNA polymerase to associate with an initiation site 
on the DNA molecule so that a segment of the DNA can be transcribed. 
Ribosanal and transfer RNA synthesis are altered depending on the 
target tissue. There is also an increase in messenger RNA synthesis. 
This is reflected by increases in both RNA polymerases I and II. These 
changes lead to the synthesis of specific proteins within the tissue 
which in turn produce the observed metabolic changes. There is a great 
deal of experimental evidence to support this hypothesis though much 
of the detail of the cytoplasmic and nuclear events still has to be 
elucidated.
7.3 STEROID STRUCTURE-ACTIVITY RELATIONSHIPS AND THEIR 
ANTI-INFLAMMATORY EFFECTS
It is useful when designing a series of drugs based on one basic 
structure to correlate drug activity with the structural requirements 
needed to produce that activity. Steroids have to bind to cytoplasnic 
receptors in order to elicit an effect so a study of the steroid 
structure in relation to receptor binding is one method of correlating 
structure with activity (149). Another useful method is to correlate
I2r>
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structure with activity using an in vitro assay system. One such 
system involves measuring the degree of induction of the enzyme 
tyrosine transaminase in rat hepatoma cells. A theoretical approach 
to structure is also useful, based on such techniques as NMR, X-ray 
diffraction and energy optimisation by calculating internal strain 
relaxation in different steroid derivatives (150, 151). 'Ibis allows 
a correlation to be made between the three-dimensional structure of 
the steroid molecule and its effect on a target tissue. The binding 
of a steroid to its cytoplasmic receptor is dependent upon its spatial 
arrangement. The biochemical response produced by a steroid is also 
determined by its three-dimensional structure. Different substituents 
can radically alter the steric arrangement of the rings of the 
steroid molecule and radically alter its effect on a target tissue.
A theoretical study of three-dimensional structure can therefore be 
used to predict the cells response to a particular steroid.
Another important structural consideration is based upon the 
clinical requirements of the drug. Drugs that are to be used 
topically for the treatment of localised inflanmations have to be 
lipophilic so that they can be readily absorbed by the skin. Topical 
drugs also must ideally have a large local effect and very little 
systemic activity, i.e. the drug should have a maximum effect at the 
site of application rather than at a site removed frern the site of 
application (152).
As a result of such studies a nimlx'r of structural requirements 
which can enhance the pharmacological activity of steroids have been 
discovered. Receptor binding is enhanced by a 17 «-Oil group and tin 
11 B-OH group, whereas an 11 a-Oil group decreases receptor affinity. 
The pharmacological activity of cortisol can be increased by a double 
bond between C-l and C-2, by 2n and 6a-Cl!^ groups and halogens
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substituted lor hydrogen at C-6 and C-9. In the case oi topical 
steroids substituents, usually esters, at C-17 increase their 
lipophilicity, and hence their bioavailability, thus giving an 
increased local pharmacological effect (153). The structures of 
typical glucocorticoids an; shown in Fig. 6.2. Those are (1) the 
physiological glucocorticoid, cortisol, (2) 6-a-methyl prednisolone 
which is used as an inmunosuppressant in transplant surgery and as an 
anti-cancer drug, and the topical steroids, (3) clobetasol propionate 
and (4) clobetasone butyrate.
At Upjohn Limited an animal model assay system, in which I 
assisted, has been developed to test potential topical drugs. The
assay system makes use of female hairless mice. The mice are treated
2
with the drug which is spread over 3 cm of the anterior dorsal 
surface (neck) of the animal. The animal is then injected with 25 wCi
3
H-methyl thymidine subcutaneously in the right thigh. The animals 
are killed one hour later using ether and skin samples removed frem 
the neck and the left side of the back. The epidermis is then 
removed by placing the sample, dermis down, on a stainless steel plate 
at 57°C for 25 seconds after which the epidermis can lie easily removed 
frem the dermis with a scalpel blade. The epidermal samples are then 
sonicated in 0.24 M phosphate buffer pH 6.8 containing 8 M urea,
1% sodiun lauryl sulphate and 1 mM EOT A. The DNA is then extracted 
frem the sonicates by colunn chromatography on hydroxyapatite columns. 
Tlx; columns, consisting of 1 g of hydroxyapatite, an; washed with 
0.2 M phosphate buffer pH 6.8 containing 8 M urea. Tire epidermal 
lysates are applied to the columns and RNA and protein removed by 
washing with 50 mis of the same buffer. Urea is then removed by 
washing with 50 ml 0.14 M phosphate buffer pH 6.8. The double stranded 
DNA, which binds to the columns under conditions of low salt 
concentration, is then eluted with 0.48 M phosphate buffer pH 6.8 and
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a 2 ml sample collected.
The DNA specific activity of the samples is determined by measuring 
the DNA concentration using UV absorption at 260 nm. A concentration 
of 50 ag/ml DNA has an absorbance of one. The degree of radioactive 
Lhjmidine incor|joratod into the DNA is detennined by adding 0.5 ml of 
the sample to 12 mis scintillant cocktail (3 parts PCS (Searle): 2 parts 
toluene) and 0.2 ml M HC1 in scintillation vials and the radioactivity 
measured in a scintillation counter, Epidermal DNA synthesis activity 
is expressed as dpn/ug DNA.
This method has been used to compare the local and systemic 
effects of topically applied steroids by comparing the degree of 
inhibition of local and systemic (neck and back respectively) epidermal 
DNA synthesis by the drugs. Using this system it was found that 
clobetasol propionate has both a marked local and systemic effect. 
Clobetasone butyrate has negligible systemic effect but a good local 
effect, though to a lesser extent than clobetasol propionate (152, 154). 
These results suggest that the modification at the C-ll position on 
the steroid with either an alcohol or keto group can profoundly alter 
the pharmacological activity of the steroid. Using these studies as 
a basis for further work it was decided to carry out further studies 
into the anti-inflanmatory effects of these glucocorticoids.
7.4 THE DELAYED-TYPE HYPERSENSITIVITY REACTION
The term delayed-type hypersensitivity (Dill) was first applied to 
a group of cutaneous hypersensitivity reactions that showed a delayed 
response to a specific antigen. The response occurs on re-exposure 
to the antigen after the previous sensitisation of the cellular iimune 
system to that antigen. The types of antigen that elicit the DTH 
response are proteins or protein-hapten complexes, e.g. tuberculin,
which are injected subcutaneously, or topically applied contact 
sensitising agents such as picryl chloride or oxazolone (see Fig. 7.3).
11 îe UTH response is primarily a T lymphocyte mediated response, 
these being the major effector cells, though there is sumo evidence 
that a type ol 11 suppressor cell may play a role in the regulation of 
the UTll response (155, 156). The UI11 response can be transferred by 
the passive transfer of lymphocytes from a sensitised animal to an 
unsensitised animal. The latter will then exhibit a Ulll response 
to a challenge by the antigen thus confirming that UFH is a cell- 
mediated imnune response rather tlian a humoral ininune response 
(157, 158).
The UllI response is characterised by a local cellular 
infiltration of lymphocytes and macrophages which results in oedema 
and inflanmation (157). These phenomena are directly caused by 
lymphokines produced by the lymphocytes. Macrophage migration is 
inhibited by MIF leading to macrophage accumulation (9). The 
lymphokines also cause increased vascular permeability and promote 
oedema. The delayed-type hypersensitivity response exhibits 
circadian rhytlmicity probably due to the variations in circulating 
lymphocyte numbers thoughout the day (160, 161, 162). In man the 
lymphocyte count is high during the day and decreases at night. In 
nocturnally active rats the lymphocyte count increases at night and 
decreases during the day. This may prove to be an important 
consideration when scheduling drug regimens.
Hie DTH response can be produced in the laboratory using rats or 
mice sensitised with oxazolone (157, 163). It can be used as a model 
systtm for testing immunosuppressive and anti-inflamnatory drugs such 
as the glucocorticoids (164, 165). Tire principle of the assay involves 
sensitising the animals with oxazolone by applying it to the shaved
Fig 7«3 Oxazolone
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abdomen of the animals. After a period of about nine days a challenge 
dose of oxazolone is applied to the ear. This challenge dose causes 
the ear to swell as a result of local oedema and inflanmation caused 
by the DTH response. This increase in ear thickness can be used as a 
measure of the I mi response. The steroid to lx? tested can lx? applied 
at the same time as the challenge? dose of oxazolone and its effect on 
the M U  response monitored. Steroids given after the challenge have 
little or no effect on the M U  response (164).
7.5 MATERIALS AND METHODS *10
7.5.1 Materials
Oxazolone (4-ethoxymethylene-2-phenyl oxazolone) was obtained 
from BOH Chemicals Limited. Clobetasol propionate and clobetasone 
butyrate were obtained frcm Glaxo, 6a-nx?thyl-preclnisolone-21-sodium 
succinate (Solu-medrone) was obtained from Upjohn Limited. The 
animals used were male inbred CBA mice (Olac 1976), 30-35 g weight. 
The animals were housed in a room with a light cycle of 10 a.m. to
10 p.m. for at least two weeks prior to and during the study.
7.5.2 The delayed-type hypersensitivity assay
The procedure used for this assay was adapted from the method
of Asherson and Ptak (157). On the morning of Day 1 the animals were
anaesthetised with ether and their ventral abdominal region shaved
with electric clipjx’rs. The animals were sensitised to oxazolone by
applying 100 pi of 10% oxazolone in a 1:1 mixture of ethanol:acetone 
2
over 5 cm of the abdomen. At approximately the same time on Day 8 
the mice were again anaesthetised and the thickness of their left 
ears measured with an engineers micrometer screw guage, three 
measurements were taken each time and the mean determined. Following 
this a 20 pi challenge dose of 10% oxazolouc in n 4:1 mixture of
KM
acetone:olive oil was applied to the left ear and the change in thickness 
of the left ear measured at regular intervals up to 48 hours after 
challenge.
7.5.3 The effect of glucocorticoids on the dclayed-type 
hyporsensi t i v i ty response
6-a-methyl prednisolone, which is water soluble but insoluble in 
organic solvents and therefore unsuitable for topical application, was 
dissolved in physiological saline and administered by an intramuscular 
injection at a dose of 14 mg/kg. The steroid was aclninistered at the 
same time as the application of the challenge dose of oxazolone. The 
change in ear thickness was measured at 6, 12, 24 and 48 hours after 
oxazolone challenge.
The effect of the two topical steroids on the 17111 response was 
determined by applying 20 pi of the steroids at a concentration of 
0.05% in ethanol to the left ear of the animals at the same time as 
the oxazolone challenge dose. The control animals were similarly 
treated with 20 pi ethanol. The change in ear thickness was measured 
at 6, 12, 24 and 48 hours after oxazolone challenge.
The effect of increasing doses of clobetasol propionate, the 
most effective of the two topical steroids, was investigated. This 
was carried out by applying 20 pi of 0.001, 0.01, 0.05 and 0.2% 
steroid in ethanol to the left ear of the animals at the same time 
as the challenge dose of oxazolone. Hie control animals were 
similarly treated with 20 pi ethanol. The change in ear thickness 
was measured at 12 and 24 hours after challenge. Two other steroids 
synthesised by the Upjohn company were also tested using this assay. 
However due to the restrictions placed upon employees in industry 
these results must remain confidential and are therefore not shown.
iar>
7.6 RESULTS
7.6.1 The effect of 6-a-methyl prednisolone on the DTH 
response in mice
Within the first 12 hours the intramuscular injection of 6-a-methyl 
prednisolone markedly inhibited the extent of ear swelling in the mice 
caused by the oxazolone challenge (see Fig. 7.4). The degree of 
inhibition of ear swelling decreased after that time so that at 
24 hours after challenge the change-in ear thickness in the control 
and steroid treated animals is approximately the same. At 48 hours 
after challenge the ear thickness of both sets of animals had decreased. 
However the decrease in ear thickness was greater in the steroid 
treated mice than in the control mice.
7.6.2 The effect of topically applied steroids on the 
DTH response in mice
Both clobetasol propionate and clobetasone butyrate inhibited the 
extent of the ear swelling caused by the oxazolone challenge (see 
Fig. 7.5). However the degree of inhibition of ear swelling caused by 
clobetasol propionate is greater than that caused by clobetasone 
butyrate. The former inhibited the extent of ear swelling by 70% 
whereas the latter inhibited the extent of ear swelling by 40% at 
12 hours after oxazolone challenge. The ear thickness in the control 
and experimental animals decreased 12 hours after challenge but the 
ratios of change in ear thickness between the three groups of animals 
remained approximately the same throughout the 48 hours that
measurements were taken.
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7.6.3 The effect of increasing doses of clobotasol 
propionate on the DTH response in mice
Ibe graphs in Fig. 7.6 show two things. The first is that the 
degree of inhibition of ear swelling by clobotasol propionate is 
approximately the same, wittiin the limits of the errors, at 12 and 24 
hours after oxazolone challenge independent of the steroid concentration. 
The second is that the degree of inhibition of ear swelling increases 
with increasing doses of steroid so that though there is almost 
maximum ear swelling with 0.001% clobetasol propionate ear swelling 
has been almost completely inhibited by 0.2% clobetasol propionate.
7.7 DISCUSSION
i:«t
The glucocorticoids can act lx>th as immunosuppressants and anti­
inflammatory agents. Their anti-inflamnalory effect has been 
demonstrated by their ability to suppress epidermal 1)NA synthesis in 
hairless mice. The work in this chapter has also shown that they are 
capable of inhibiting the inflanmatory response to the contact 
sensitising agent oxazolone caused by the delayed-type hypersensitivity 
reaction. In seme cases the inmunosuppressant and anti-inflamnatory 
effects of steroids appear to be unconnected. However in the case of 
the inhibition of the DTH reaction the anti-inflamnatory action of 
the steroids is probably a direct result of the suppression of cell- 
mediated immunity by the drugs, the DTH reaction being predominantly 
a T lymphocyte mediated response.
The water soluble steroid, 6-a-methyl prednisolone, exhibits an 
inhibitory effect on the DTH response when adninistered by intra­
muscular injection but its effect is not as great as that exhibited 
by the topical steroids. The most obvious explanation for this is 
that 6-a-methyl prednisolone could not be adninistered locally but
n o
had to reach the site of action via the systemic circulation. Because 
of this it could not be concentrated at the site of the inflanmation 
like the topical steroids but would have been distributed throughout 
the animal's body. Another possible explanation is that 6-a-methyl 
prednisolone does not have a fluorine group at C-9 like the topical 
steroids. The presence of a halogen at C-9 lias been shown to increase 
the pharmacological activity of the glucocorticoids. However this 
probably has only a minor effect,as 6-a-methyl prednisolone is a known, 
and clinically used, inhibitor of cfell-mediated inmunity, though this 
assumes that the observed anti-inflammatory effect of the steroids in 
the DTH assay is directly connected with their inmunosuppressant 
activity.
The hairless mouse assay has shown that both clobetasol propionate 
and clobetasone butyrate possess good anti-inflainnatory activity. 
Clobetasol propionate inhibits local epidermal ONA synthesis in this 
system to a greater extent than clobetasone butyrate. However this 
drug also gives a pronounced systonic effect whereas this is negligible 
with clobetasone butyrate. This effect has been shown to be directly 
associated with the presence of the keto group at C-ll rather than the 
alcohol group. Because of the lack of systemic activity clobetasone 
butyrate is the better topical drug as its effect is localised to the 
site of application.
The greater effect of clobetasol propionate is again demonstrated 
in the UllI assay. Clobetasol propionate inhibits the ear swelling 
cause xl by the DTH response to oxazolone more effectively than 
clobetasone butyrate. This assay however gives no indication of 
systemic activity. The inhibitory effect of clobetasol propionate has 
been shown to be dose dependent, the degree of inhibition increasing 
as drug dose increases.
I'll
When designing an anti-inflamnatory drug for topical application 
two important considerations have to be borne in mind. The potential 
drugs have to be selected so that they have maximum local effect and 
minimun systemic effect. They must also be selected for their anti- 
i nil ¡minatory effect rather than their iiimunosuppressive effect. 
Continued use of steroids that depress the inmune res[)onse can lead 
to secondary infections of the lesions. By using more than one assay 
system for investigating the pharmacological activity of steroids 
these parameters can be compared with respect to steroid structure- 
activity relationships and the ideal drug selected.
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C H A P T E R  8
T h e  I m m u n o s u p p r e s s i v e  Ac t i v i t y  Of  Gl u c o c o r t i c o i d s :
î h j ’U i: >_St u d i e s
8.1 ISOLATED LYMPHOCYTES AS A MODEL SYSTEM
The DTH reaction discussed in Chapter 7 is a lymphocyte mediated 
response. Lymphocytes can be easily isolated from lymphoid tissues 
and blood and used to provide a useful in vitro analogue of the 
in vivo iimiunological assays. They also provide a useful system for 
the study of a number of biochemical events such as DNA (103, 166, 167), 
RNA (168) and protein synthesis (169). They have also been used 
extensively in the study of leukaemia (117, 170, 171).
Isolated lymphocytes can be stimulated in vitro to undergo mitosis 
and differentiation to blast cells by a variety of chemical substances 
known as mitogens. These bind to the glycosidic groups of glycoproteins 
in the lymphocyte membrane and elicit a number of biochemical responses 
leading to blast formation. Some mitogens specifically stimulate one 
lymphocyte sub-population whereas others can stimulate both B and T 
lymphocytes (172). The most conmonly used mitogens are the plant- - 
lectins, phytohaemagglutinin (PHA) and concanavalin A (conA). Other 
cannon1y used mitogens are pokeweed mitogen (PWM) and bacterial 
lipopolysaccharides (LPS). ConA and PHA selectively stimulate T 
lymphocytes whereas IPS selectively stimulates B lymphocytes, PWM 
stimulates both B and T lymphocytes. As well as inducing blastogenesis, 
mitogens can also induce B and T cell responses. For example PHA will 
induce lymphokine production in T cells and PWM will induce IgM 
secretion by B cells (173). The PHA response can also be modulated
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n:i
by the presence of different populations of cells in the culture 
such as suppressor T lymphocytes and monocytes (174, 175).
The mitogen used in the present studies was P11A, a protein 
isolaUxl from the red kidney bean Phan coin a vulgaris. Being an 
activator of T lymphocytes this should piovide an analogous system 
to the Dill assay which is a T lymphocyte mediated response. There are 
four separate steps in lymphocyte activation by PHA (176). These are 
(1) attachment to the cell membrane, (2) a reversible pre-activation 
step, (3) a step causing ccximitment to ccnmence mitosis and 
(4) a mitogen-independent activation step. After three days of 
exposure to P1IA isolated lymphocytes fonn blast cells, most of which 
are starting to undergo mitosis (177). The nucleus in these blast 
cells is larger than the nucleus in the precursor lymphocytes and 
this correlates with an increase in DNA synthesis (178). There are 
marked nucltolar changes four hours after exposure to PHA. There is 
an increase in nucleolar size followed by an increase in the amount 
of nucleolar chromatin. The nucleolar chromatin becomes more 
dispersed and is found concentrated on the nuclear membrane and 
throughout the nucleoplasm. 48-72 hours after exposure to P1IA there 
is an increase in cytoplasmic size and in the number of cytoplasmic 
components, e.g. lysoscmes. With some mitogens, e.g. PWM the cells are 
characterised by a well developed rough endoplasmic reticulun and 
Golgi apparatus. However with PHA blasts though there are well formed 
Golgi bodies there is sparse rough endoplasnic reticulum and many free 
ribosanes (179, 180).
The increase in DNA synthesis upon PHA stimulation can lie easily 
measured by tin: ina>rporation of radioactive thymidine into acid 
precipitable material. The increase in DNA synthesis corresponds to 
an increase in DNA polymerase <i levels three days after exposure to
P1IA (181, 182). The rate of UNA synthesis then decreases. A second 
wave of UNA synthesis has been reported 5-8 days after exposure to 
PUA (183, 184). This corresponds to an increase in UNA lipase and DNA 
polymerase B levels and may represent UNA repair. Prior to the onset 
of UNA replication there is an increase in UNA and protein synthesis 
(182). This implies that blast activation and the corresponding increase 
in DNA synthesis first requires the synthesis of new protein including 
the enzymes involved in UNA replication. One study suggests that the 
increase in DNA synthesis is due to an increase in the transport and 
uptake of precursors of DNA replication by the stimulated lymphocytes 
rather than by the activation of the DNA replication apparatus but this 
seens unlikely (103).
Another possible method for stimulating isolated lymphocytes to 
undergo blastogenesis is to use a hapten-carrier conjugate (185). The 
stimulation of isolated lymphocytes by an oxazolone-protein conjugate 
could be used as an analogue of tic IMU response in vitro. It is thought 
that in the in vivo situation, the oxazolone must bind to a protein in 
the skin before it can produce a response (186). Oxazolone is too 
snail a molecule to be an antigen in its own right and is therefore 
thought to behave as a hapten which binds to a large carrier molecule 
in the skin. This possibility was modelled by using an oxazolone-rat 
serun albumin conjugate. This was then used for the in vitro stimula­
tion of lynphocytes isolated from rat blood thus producing an in vitro 
assay system parallel to the in vivo 1/111 assay system.
The isolated lymphocyte system was used to investigate the effects 
of glucocorticoids on thymidine incorporation by stimulated lynphocytes. 
The glucocorticoids in general act in a cell cyclic specific manner 
being Gj/S phase inhibitors (187). Their in vivo action is also 
dependent upon the stage of development of the ljmplioeytes since they 
will only inhibit the metabolian of lymphocytes before they are
presen Ic'd will) an antigen (144). Translated to the in vitro situation, 
this means that the steroids will only inhibit the PIIA stimulation of 
lymphocytes if atini nistered in the first 24 hours after stimulation as 
PHA rapidly induces resistance to steroids (188, 189). It appears as if 
the glucocorticoids act as P11A antagonists and inhibit the mechanisa of 
PILA stimulated transformation of lymphocytes to lymphoblasts. The 
inhibition of lymphocyte transfonnation by steroids is also complicated 
by the fact that the response to glucocorticoids is modulated ard 
inhibited by interacting ceil populations in the lymphocyte culture« 
such as monocytes and macrophages (190, 191). Steroid receptors also 
appear to play a part in conferring resistance to steroids upon the 
transformed lympliocytes. 11 in important factor appears to be the 
affinity oí the steroid for the cytoplasmic receptor (191). It has 
also been shown that receptor numlwr increases with P11A stimulated 
transfonnation. However this seems to be unrelated to the steroid 
sensitivity of the transformed lymptocyte (192).
This is in contrast to the mechanisms of action of the drugs 
already studied. A comparative study was carried out using araC and 
aphidicolin. These drugs, which directly inhibit DNA synthesis, have 
a maximum effect when administered during the S phase of the cell 
cycle when the rate of DNA synthesis is at a maximim. Both drugs 
have been shown to be inhibitors of DNA synthesis in PHA stimulated 
isolated lymphocytes (103, 135).
8.2 MATERIALS AND METHODS
8.2.1 Materials
Dextran T-400 and Ficoll-Paciue were obtained from Pharmacia Fine 
Chemicals. Ficoll-Paque is an aqueous solution of density 
1.077 i 0.001 g/cm'* containing 5.7 g Ficoll 400 and 9 g sodium
Hi;
diatrizoate ix>r 100 ml. Phytohannugglut inin and rat serum albunin 
were obtained from Sipna Chemical Company. Sheep erythrocytes in 
Alsever’s solution were obtained fran Flow Laboratories. All materials 
required for the culture of isolated lymphocytes are the same as those 
described in 3.4.1.
8.2.2 Isolation of lymphocytes
Human peripheral lymphocytes were isolated from 30 ml or 40 ml 
blood samples taken from volunteers.- The blood samples were collected 
in EDTA or heparin solution. The blood samples were then diluted 1:1 
in sterile bottles with balanced salt solution and 10% Dextran 400 in 
0.9% sodium chloride to give a final concentration of 1%> Dextran.
The blood was then left to stand for at least one hour at 37°C during 
which time the ma.jority of the red blood cells sedimented to the bottom 
of the bottle. The sixiimentation of the red blood cells is enhanced 
by dextran. After sedimentation the upper planta rich layer was removed 
and centrifuged at 800 g, 10 mins, 18-20°C in a MSE Mistral 6L 
centrifuge. The supernatant was discarded and the pellet resuspended 
in a suitable volume of balanced salt solution, this volume being 
governed by the next step in the procedure.
The lymphocytes were then separated out from the cell suspension 
by layering the suspension on to Ficoll-Paque. The voline of Ficoll- 
Paque used depended upon the size of the centrifuge tube used. The 
relative height of the Ficoll-Paque layer compared to that of the 
sample layer is critical, the best height ratio was found to be 2.5 an 
Ficoll-Paque to 1.5 cm sample. This was then centrifuged at 400 g,
35 mins, 18-20°C. Differential migration through the Ficoll-Paque 
results in separation of the cells in the suspension. Granulocytes 
and erythrocytes sedimented to the bottom of the centrifuge tube and 
the lymphocytes collected at the interface between the two layers 
(193, 194).
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The "buffy" lymphocyte layer at the interface was removed and 
diluted with three volumes of balanced salt solution and the lymphocytes 
washed by centrifugation at 100 g, 20 mins, 18-20°C. The lymphocyte 
pellet was collected and resuspended in RPMI-1640 medium supplemented 
with I «—ft Ini :iiui n< ', :«)() pi'/iiil, | h'ii i (.* i 1 lin, 100 ll/ml, and streptomycin,
100 pg/ml. The cell viability was determined by the trypan blue 
exclusion test and the cells counted using a Neubauer haameytometor.
The cells were then diluted to 10^ cells/ml and the mediun supplemented 
with 10% new born calf serum and left to equilibrate for 24 hours. PHA 
was then added to a final concentration of 25 pg/ml of culture.
Rat peripheral lymphocytes were prepared from blood obtained from 
Wistar rats. Tbe rats were anaesthetised with ether and exsanguinated 
by withdrawing blood from the inferior vena cava into a heparinised 
syringe. The blood was then transferred to a sterile 20 ml bottle 
containing 2 ml heparin solution, 10 U/ml in 0.9?! saline. The average 
volume of blood obtained from a rat was about 10 ml. The blood was 
then diluted 1:1 with balanced salt solution and 10% dextran added to 
give a final concentration of 1%. Tbe diluted blood was then left to 
stand for one hour at 37°C to.allow the red blood cells to sediment.
Tbe upper plasma rich layer was removed and the lymphocytes isolated 
on Ficoll-Paque as previously described for the isolation of human 
peripheral lymphocytes. The lymphocytes were stimulated with either 
PHA, 25 pg/ml, or the oxazolone-rat serum albumin conjugate.
Lymphocytes were also isolated from rat and mouse spleens. The 
freshly removed spleens were sliced and then homogenised by passing 
them through a fine wire mesh and washing with balanced salt solution. 
Hie homogenate was left to stand on ice until all the debris had 
settled. The supernatant was then centrifuged at 800 g, 10 mins, 4°C. 
Tlx; pel let was resu.s|x;nd(xl in balanced salt solution and the lymplio- 
cytos isolated in Kieol l-Paque as previously descrilxxl.
i -its
All glassware list'd in this procedure was sterile and siliconised.
The balanced salt solution was freshly prepared each time from two
_5
stock solutions, A and B. Solution A consisted of 5 x 10 M CaClg^I^O,
9.8 x 10"4 M MgClg.eilgO, 5.4 x 10-3 M KC1, 0.1% glucose and 0.145 M 
Tris-HCl pH 7.6. Solution B consisted of 0.82^ NaCI. The balanced 
salt solution was prepared by adding 10 ml of solution A to 90 ml of 
solution B.
8.2.3 Sheep erythrocyte rosette test
Human lymphocytes isolated as described in 8.2.2 were tested for 
their ability to foim rosettes with sheep red blood cells. This test 
was used to detennine the percentage of T lymphocytes in the culture 
(187). 0.1 ml of lymphocytes, 10^ cells/ml, was mixed with 0.1 ml
sheep erythrocytes in Alsever's solution that had been previously 
diluted with balanced salt solution to give a suitable distribution of 
red cells when viewed on a haomocytometer under a light microscope.
The suspension was centrifuged at 200 g, 10 minutes at room temperature 
in a BTL micro-angle bench centrifuge and then incubated for one hour 
at 20°C in a water bath. The cells were then gently resuspended with 
a Pasteur pipette and diluted*1:1 with 0.4% trypan blue in 0.9% sodiun 
chloride. The number of rosettes that had formed were counted on a 
Neubauer haemocytometer. A rosette was defined as a lymphocyte with 
three or more adherent red blood cells. The percentage of T 
lymphocytes in the culture was then calculated.
8.2.4 Preparation of the oxazolone-protein conjugate
A hapten-carrier conjugate was formed between oxazolono and rat 
serum albimin in the following way (196). 20 mg oxazolone was dissolved
in 1 ml dioxan and added dropwise to 40 ml rat serum albumin solution,
1 mg/ml in 0.05 M sodiun cartionule/bicarbonnte buffer pH 9. The 
suspension was well mixed and left to stand overnight at 4°C. It was
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then centrifuged at 2000 g, 90 minutes, 4°C and the supernatant dialysed 
extensively against phosphate buffered saline pH 7.2 in order to remove 
the dioxan and any unbound oxazolone. The protein concentration of the 
conjugate was determined by the method described by lowry ct al. , using 
lx)vino sonun albumin as a standard (98). The antnml of oxazolone Ixxuui 
to the rat serum albumin was determined by UV s|x*:Lrophotcmetry. UV 
spectra over the range 240 nm to 400 nm ■*» re taken for oxazolone, rat 
s e m a  albumin and the conjugate and these spectra used to determine the 
amount of bound oxazolone (see 8.3.3).
3
8.2.5 The measurement of H-thymidine incorporation by 
isolated lymphocytes
3
1 ml cultures of lymphocytes were incubated with 10 pCi f H-methyll
thymidine sp. act. 47 Ci/nmol and the incorporation of radioactive
thymidine into acid précipitable material assayed as described in 3.4.5.
The optimal P11A concentration for the stimulation of rat peripheral
3
lymphocytes was determined by measuring H-thymidine incorporation 
72 hours after addition of different concentrations of PHA. The period 
of maximum thymidine incorporation after PHA stimulation in hunan and 
rat peripheral lymphocytes was determined by incubating the cells for 
one hour with radiolabelled thymidine at regular time intervals after 
stimulation. The effect of the different drugs on thymidine incorpora-
3
tion was determined by incubating the cells for 4 hours with H-thymidine 
at the period of maximum thymidine incorporation in the presence of the 
drugs at the required final concentrations. All drugs were dissolved in 
physiological saline except for aphidicolin which was dissolved in DMSO 
and added to the cultures so as to give a concentration of DMSO of not 
greater than 1%. The effect of the oxazolone-rat serum albumin
3
conjugate on H-thymidine incorporation by rat peripheral lymphocytes 
was investigate. The effect of PHA on thymidine incorporation by rat 
and mouse sphx'n lymphocyles was also investigated. All results are
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shown as a percentage inhibition of the maximum incorporation of 
thymidine into acid precipitable material.
8.3 RESULTS
8.3.1 Thymid i no incorporation by 1*11 A stimulated human 
lymphocytes
The lymphocytes isolated from human blood showed a viability of 
greater than 90% in most cases. The sheep erythrocyte rosette tests 
showed that the majority of the lymphocytes isolated using the Ficoll- 
Paque method were T lymphocytes, generally 90-95%- of the isolated 
lymphocytes were T lymphocytes.
Isolated human lymphocytes were pulsed with ^11-thymidine for one 
hour at 11, 23, 35, 47, 59, 71, 83 and 95 hours after the addition of 
P11A. A control experiment was carried out with lymphocytes which had 
not been treated with PIIA. The results, which are shown in Fig. 8.1, 
are representative results from a number of similar experiments. The 
period of maximum thymidine incorporation occurs at 72 hours after PUA 
stimulation, after which there is a decrease in the ability of the 
lymphocytes to incorporate thymidine. There is little thymidine uptake 
in unstimulated lymphocytes.'
3
Human lymphocytes treated with PHA were pulsed with H-thymidine
for 4 hours starting 68 hours after the addition of PHA. Methyl
prednisolone was added at final concentrations of 0, 10-12, 10
10 10 ® and 10  ^M at the same time as the PHA. The effects of the
drugs on thymidine incorporation are shown in Fig. 8.2. 37% inhibition
—8is obtained with 10 M methyl prednisolone and 92% inhibition is 
-4obtained with 10 M. The experiment was repeated with cytosine
12 ” 10 ” 8 ” 6arabinoside at final concentrations of 0, 10 ,10 , 10 , 10 and
_4 q
10 M. In this case the araC was uddod concurrently with the °H-thymidine.
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lymphocytes with time after the adlition of PHA (25ug/ml) at 
zero time ( a ) ,  (o ) is a control without PHA. Results are 6hown 
as the percentage of the maximum thymidine incorporation into 
acid percipitable material as described in 3.A.*»
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Hefhyl Pr*dnisolone io n t  IMl
Fig 8.2 Tilt; i n h i b i t i o n  of thymidine uptake in PH A stimulated 
human peripheral lymphocytes by 6-ot-methyl prednisolone. Results 
are shown a« the p e r c e n t a g e  inhibition of maximum thymidine 
incorûirkfci on into iicid nrnri t;ihl n m/itnrial u':
--------. . . .  ------  r
orporat
i.n 3.i|.l*. Krror bar represent S.E. n=h
0 1Q-12 1040 îo-® 10-6 10'C
araC. tone [Ml
Fig 8 . 3  The inhibition of 1^1 thymidino uptake in PHA stimulated 
human peripheral lymphocytes by cytokine arabinooide.. Results
are shown as the percentage inhibition ol' maximum thymidine 
incorporation into acid précipitable material as described 
in 3.i(./t. Krror bars represent fj.U. n=/|
154
FIg 8./| The inhibition of 'll thymidine uptake in PH A stimulât.;d human 
peripheral lymphocytes by aphidicolin. Penults are shown as the percoat- 
ae;o inhibition of maximum thymidine incorporation into acid 
précipitable material as described in 3 Krror b a r G  represent 
S.K. n=l|
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Thymidine incorporaiion in hiinan lymphocytes was more sensitive to
—8inhibition l»y cytosine arabi noside, 10 M giving 57,? inhibition and 
-410 M, 97" inhibition. This degree of inhibition is comparable with
the effect of araC on thymidine incorporation in Nitmalwa lymphoblasts
(see 9 .5 .1 ) .  The e f f e c t  o f  apliidicolin was also invest ii;ated at final
concentrai ions of 0, 10 10 10 ^ , 10 *', 10 and 10 * M.
Aphidicolin was added at the stime time as the '*11-thymidine, i.e. 68 hours
after P11A stimulation. The lymphocytes were less sensitive to
—8aphidicolin at low concentrations, 10 M giving only 23?” inhibition 
whereas 93% inhibition was obtained with 10 6 M drug. This result is 
again comparable with the effect of the drug on Namalwa cells.
8.3.2 Thymidine incorporation by PHA stimulated rat 
lymphocytes
The otpimum PHA concentration required for the stimulation of 
rat peripheral lymphocytes was determined by measuring thymidine 
incorporation 72 hours after addition of PIIA. The optimum PHA 
concentration was found to be 25 pg/ml, though stimulation was 
obtained with concentrations as low as 2.5 yg/ml and as high as 
50 pg/ml. Thymidine incorporation was then followed for 96 hours.
In order to do this the lymphocytes were pulsed with ^-thymidine 
for one hour at 23, 47, 71 and 95 hours after the addition of PHA.- A 
control experiment was carried out with lymphocytes that had not been 
exposed to PHA. The results are shown in Fig. 8.5. The period of 
maximun thymidine incorporation occurs at 72 hours after PHA 
stimulation after which there is a decrease in the ability of the 
lymphocytes to incorporate thymidine. As with human lymphocytes 
there is little thymidine uptake in unstimulated lymphocytes.
Rat peripheral lymphocytes treated with PHA were puls(Ki with
ll-thymidino for 4 hours starting 68 hours after PIIA stimulation.
3
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Fig 8.6 The inhibition of 1^1 thymidine uptake in PHA stimulated rat 
peripheral lymphocytes by 6-d-methyl prednisolone. Results are 
shown as the percentage inhibition of maximum thymidine incorporation 
into acid précipitable material as described in Error bars
represent 55.E. n = l*.
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Methyl prednisolone was added to the cultures at the same time as the 
PI1A at final concentrations of O, 10-9, 10-7, 10-6, 10 *’, 1 0 and
_3
10 M. Rat lymphocytes appeared to lx? more sensitive to the steroid
_q
than hyman lymphocytes as 10 ' M motliy 1 prednisolone nave 30ft 
inhibition while 90ft inhibition was ohtuimd with 10 ’ M methyl 
prednisolone!.
Attempts were made to look at the effects of the topical steroids, 
clobetasol propionate and clolx.'tasone butyrate, on PIIA induced thymidine 
incorporation by rat peripheral lymphocytes. However both these 
steroids are water insoluble and no suitable solvent was found at the 
time that did not itself cause inhibition of the PHA response. In the 
light of subsequent work on aphidicolin a possible solvent that could 
have been usixl is DM30. This does not have an effect in low 
concentrations on the PIIA rosjxinse.
Spleen lymphocytes were easier to isolate than the peripheral 
lymphocytes isolated from blood and they could be obtained in larger 
numbers. They showed comparable viability with peripheral lymphocytes 
(greater than 90ft) in both cases) when examined using the trypan blue 
exclusion test. However they showed an apparent resistance to PHA 
stimulation and so could not be used as a model system in this study.
8.3.3 The effect of the oxazolone-rat serum albumin 
conjugate on rat peripheral lymphocytes
The UV spectra of rat serum albumin, oxazolone and the oxazolone- 
rat serum albumin conjugate are shown in Figs. 8.7, 8.8 and 8.9 
respectively. The original protein concentration of the conjugate 
was 0.8 mg/ml. This was diluted ten fold to 0.082 mg/ml for the UV 
spectrum. 'The oxazolone concentration used was 0.05 mg/ml, i.e. that 
concentration assiming 100ft, binding of the oxazolone to the rat serum
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Wavelength Inm )
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Fig 8.8 UV spectrum of oxazolone 0.05 rag/ral.
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FlC 8*9 UV up'îCtrum of oxazolono - rat i¡ iriiin albiumln conjugate
0.n82 mg/rnl.
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albumin. Oxazolone had a maximum absorption at 330 nm. Two spectra 
wc.'re taken for rat serum albumin, one at 0.82 mi;/ml and one at 
0.082 mg/ml protein concentration as the peak height for the latter at 
280 nm was too anal 1 to give an accurate measurement. ' The absorption 
for llie O.S'.l mg/ml K|>eclniii was 10 Limes greater than that lor 
0.082 mg/ml thus confirming that the relationship lx;lween al)sorbance 
and concentration was a linear one. The amount of oxazolone bound 
to rat serum albumin in the conjugate was calculated by using the 
ratio of the peak heights of oxazolone to rat serum albumin of known 
concentrations and the ratio of the peak heights at 280 nm and 350 nm ’ 
in the conjugate (the oxazolone peak was shifted by 20 nm in the 
conjugate). The peak height at 280 nm in the conjugate was a function 
of the rat serum albunin concentration, the actual concentration of 
which was known frcm the Ijowry assay. The oxazolone concentration in 
the conjugate, which was a function of the height of the 350 nm peak, 
could therefore be calculated. Using this method the amount of 
oxazolone bound to the rat serum albumin was calculated to be 130 ug 
oxazolone/mg protein.
Fig. 8.10 shows the effect of increasing concentrations of the 
conjugate on thymidine incorporation by rat peripheral lymphocytes.
The conjugate was added in place of PHA and thymidine incorporation 
assayed 72 hours after exposure to the conjugate. This was done by 
incubating the cultures with ^II-thymidine for 4 hours, i.e. from 68-72 
hours after the addition of the conjugate. Maximum incorporation was 
achieved using a conjugate concentration of 8.2 ug/ml culture.
In order to show that it was the conjugate that was stimulating 
the lymphocytes and not oxazolone or rat serum albunin 1 ml cultures 
of the lymphocytes were incubated with (1) conjugate, 10 pg/ml, this 
concentration was decided upon after conducting the previous experiment,
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ul conjugate/ 
ml culture
ug conjugate/ 
ml culture
% Max activity
0 0 12.3-2.3
20 '(.1 67 *1.1,
'|0 8.2 100 *2.3
8o 16.If 92.3* if
Fig 8.10 The effect of increasing concentrations of the 
oxazolone-rst serum albumin conjugate on the thymidine uptake 
ability of rat peripheral lymphocytes 72 hours after addition of 
the conjugate to the lymphocyte cultures. Results are shown as 
the percentage of the maximum thymidine incorporation into acid 
précipitable material as described in 3*ii.,i. ’.rrors represent 
the spread of the results about the moan, n=2
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Ad li’t i oils to ru 1 til re Max. acti v:i ty
lOug/ml con up, ate 100 J-l.l
lOug/ml RSA 5.6*0.3
5ug/ml oxa&olonc 11.9*0.6
Saline 5.1-o.3
Fig 8.11 The measurement f H-thymidina uptake in rat 
peripheral lymphocytes- 7 2  hours after the addltl m  of 
i) oxazolone-rat serum albumin conjugate, lOug/ml, (ii) rat 
serum albumin, l'ug/ml, (iii) oxazolone, 5ug/ml, and (iv) online. 
Results .re shown as the percentage of the maximum thymidine incorp­
oration into acid pi-eci pi.tubl c material as described in 3.1|.1<>
Errors represent tli . spread of the results about the mean, n=2.
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lOug/ml conjugate 100 ±2.9%
1; ug/ral conjugate*
lO-^M metiiyl pr ;dnioolune 16 ±2.1%
.Taline (unstimulated control) 6.2 ±1.9%
Fig 8.12 The inhibition of H-thymidino uptake in oxazolono- 
protein conjugate stimulated rat peripheral lymphocyte by 
methyl pr dniuolnne. Rccults are rhov;n an the percentage of the 
maximum thymidine incorporation into acid pr cipitable mat .rial 
as described in irrors ropr sent the rpr.-ed of the
results about the mean, n=2.
!(>(>
(2) rat serum albumin, 10 pg/ml, (3) oxazolone, 5 pg/ml and
(4) a control with an equivalent volune of physiological saline (10 pi).
Thymidine incorporation was assayed after 72 hours as before. As can
be seen from Fig. 8.11 only the conjugate caused substantial thymidine
incorporation.
The effect of 6-a-methyl prednisolone on the stimulation of 
thymidine incorporation by the oxazolone protein conjugate was
investigated. Rat peripheral lymphocyte cultures were incubated with
-4(1) 10 pg/ml of conjugate, (2) 10 pg/ml of conjugate and 10 M
methyl prednisolone and (3) a control with an equivalent volume of
physiological saline (10 pi). Thymidine incorporation was assayed
at 72 hours as previously described. There was no substantial
incorporation by the control cultures. Thymidine incorporation by
the conjugate-stimulated rat peripheral lymphocytes was inhibited
-4by the steroid, 84% inhibition was obtained with 10 M 6-a-methyl 
prednisolone.
8.4 DISCUSSION
The stimulation of isolated hunan lymphocytes by PUA to undergo 
blastogenesis has been well characterised in terms of many of the 
biochemical responses that occur (see 8.1). It has been shown that a 
maximum nunber of lymphocytes undergoing mitosis usually occurs about 
72 hours after PHA stimulation. The results obtained here show that 
thymidine incorporation, used as a measure of DNA synthesis, of PHA 
stimulated human peripheral lymphocytes occurs 72 hours after 
stimulation and then rapidly decreases. The maximum DNA synthesis 
activity at 72 hours after stimulation therefore agrees with similar 
studies on this system by Locb et al. (181, 182).
TTie results presented here show that DNA synthesis in PUA
h i 7
stimulated human peripheral lymphocytes, as measured by thymidine 
incoporation into acid precipitable material, can be inhibited by 
6-a-methyl prednisolone. The results also demonstrate that this 
system can be used as an in vitro model for screening potential 
inmunosuppressive drugs such as the glucocorticoids. Thymidine 
incorporation is also inhibited by the DNA synthesis inhibitors, 
cytosine arabinoside and aphidicolin. Whereas steroids have to be 
administered during the early stages of PHA activation the DNA 
synthesis inhibitors were administered concurrently with the radio­
active thymidine. This difference reflects the different mechanisms 
of action of the drugs. The steroids appear to act as antagonists to 
PHA stimulation and in seme way affect the molecular processes that 
initiate blastogenesis. The DNA synthesis inhibitors act during the 
S phase of the cell cycle by inhibiting DNA polyiperase a and therefore 
their effect is best seen at the period of maximun DNA synthetic 
activity.
The PHA stimulation of rat peripheral lymphocytes has not been so 
well characterised in the literature as the PHA stimulation of human 
lymphocytes therefore this was an important and necessary starting point 
for the development of the in vitro assay system in rat lymphocytes.
The optimum PHA concentration was found to be 25 pg/ml and maxinun 
thymidine incorporation occurred at 72 hours after the addition of 
PHA, i.e. similar to that for human lymphocytes. Thymidine 
incor;¡oral.Ion into DNA by PHA stimulated rat lymphocytes was found to 
be sensitive to inhibition by methyl prednisolone. This degree of 
inhibition was comparable with the effect of the drug on PHA 
stimulated human lymphocytes.
There were several problans inherent in the rat lymphocyte 
system as compared to the human lymphocyte system. One major problem 
was that because of the small volume of blood obtainable from one rat
k ;k
only a small numlxjr of cells could be isolated from each blood sample. 
This made it difficult to carry out accurate dose/response assays over 
a large drug concentration range. The other major problem was that it 
was found that rat lymphocytes were often resistant to PHA stimulation 
unlike human lymphocytes which, generally speaking, are readily 
stimulated by PHA.
The problem of the resistance of rat spleen lymphocytes to P11A 
stimulation was not resolved. Though the trypan blue exclusion test is 
used to determine viability it can only be used as a guide as it only 
measures one aspect of lymphocyte metabolism It is possible that the 
spleen lymphocytes were more sensitive to the preparation procedure 
than the peripheral lymphocytes and were damaged in seme way that was 
not obviously detectable using the trypan blue test. This damage 
could have taken the form of damage to the cells' metabolic machinery 
such as the DNA synthetic machinery as there was no measurable 
thymidine incorporation following the addition of PHA to the cultures. 
Alternatively damage to the cell membrane resulting in loss of PHA 
receptors would also have prevented the PHA response. The presence of 
a large number of suppressor cells in the culture would also inhibit 
the response but this is unlikely to be the reason for the lack of 
response to PHA.
Work with the oxazolone-rat serum albunin conjugate' was mainly 
confined to trying to use the conjugate to stimulate the lynphocytes, 
rather than as an investigative tool to study the mechanism of 
blastogenesis and steroid inhibition. A two-pronged approach was 
adopted in studying lymphocyte stimulation by the conjugate. One 
approach was to determine an optimal conjugate concentration for 
lymphocyte stimulation. The other was to ensure that stimulation was 
actually being caused by the conjugate and not by free oxazolone or 
rat serum allnmin. This was done by sotting up cultures containing
IC!)
oxazolone and albumin as well as the conjugate. It was found that 
isolated rat peripheral lymphocytes could be stimulated by the 
conjugate. Tlie stimulation of thymidine incorporation by the 
conjugate was also shown to be markedly inhibited by 6-a-methyl 
prednisolone.
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ç  H A P I  E R 9
Ge n e r a l  D i s c u s s i o n
'11 ig  work presented in this thesis ccni|)ai'es the elfects of a niinber 
of dissimilar canpounds on the DNA metabolism and proliferation of 
lymphoblasts. The lymphoblast systems that I have used include 
transformed cell lines derived iron both B and T lymphocytes, and 
mitogen stimulated human and rat peripheral lymphocytes. A protozoan 
model system was also used. The in vivo effect of the inhibitory 
action of glucocorticoids on lymphocytes was also demonstrated using 
an animal model system based on the delayed-type hypersensitivity 
response to oxazolone.
The metabolism of the anti-leukaemia drug, cytosine arabinoside, 
was investigated in the EBV transformed B lymphoblastoid, Namalwa, 
cell line, in the CCRF-CEM T lymphoblastoid cell line and in the 
protozoan T. pyriformis. Cytosine arabinoside has to be phosphorylated 
to its triphosphate by a series of intracellular kinases before it 
exhibits cytotoxicity (69). However it can also be inactivated by 
deamination to its inactive derivative uracil arabinoside. The main 
site of deamination in the in vivo situation is the liver, though intra­
cellular deamination may also play a part in inactivating the drug.
The mechanism of clinical resistance to araC has not yet been fully 
defined but it is thought that araC deamination is an important 
contributory factor (197). One possible way to inhibit the inactivation 
of the araC by deamination is to acininisler the deaminase inhibitor 
letrahydrouridine in combination with araC.
It has been demonstrated here that araC is a potent inhibitor of 
UNA synthesis in Namalwa cells, 50% inhibition of thymidine incorporation
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into acid precipitable material being obtained with 5 x 10 M araC. 
This inhibitory effect is not affected by the addition of tetrahydro- 
uridine. This suggests either (1) there is no araC deaminase present 
in Namalwa cells or (2) Nainalwa cell araC deaminase is resistant to 
tetrahydrouridine. The metalxrlites of araC produced by Namalwa cells, 
CCRF-CEM cells and the protozoan T. pyriformis were identified using 
thin-layer chranatography. The effect of THU on the levels of these 
metabolites was also investigated. The levels of the enzymes araC 
deaminase and araC kinase were measured in cell hcmogenates produced 
iron these cell systems. It was shown that T. pyriformis possessed 
high levels of the deaminase and that this was readily inhibited by 
THU. There was no deaminase activity present in either the lympho- 
blastoid cell lines. However the latter possessed high levels of the 
kinase compared to the protozoan. AraC has a greater inhibitory 
effect in Namalwa cells than in T. pyriformis.
It appears as if the main determining factor for araC to 
efficiently inhibit DNA synthesis in an in vitro system, is a high 
intracellular kinase level and that high araC deaminase levels may 
confer resistance to the drug upon an in vitro cell system. However 
care must be taken in extrapolating these results to the in vivo 
clinical situation. The major site of araC deamination is the liver 
rather than in the leukaimic target cell. It is the plasma level of 
the drug, coupled with the araC kinase level in target cells that 
determines its therapeutic efficacy. The plasma levels of araC can 
be greatly reduced by deamination in the liver. There is little or 
no intracellular competition between the kinase and deaminase 
enzymes and intracellular deaminase levels may only play a small part 
in determining araC efficacy. However inhibition of the liver 
deaminase may help to increase the araC plasma levels therefore the 
TllU/araC combination m y  still prove to lx; effective in maintaining
-9
araC plasma levels and hence increasing araCIP target cell levels.
Despite the limitations involved in using in vitro cell systems 
they can still provide much useful information on the mechanism of 
araC metabolism and in that respect make useful model systems. One 
important conclusion derived from this study is that the lack of araC 
deaminase and the high araC kinase level in Namalwa cells make it an 
ideal model system for studying the effect of araC on eukaryotic DNA 
replication.
AraC is a known inhibitor of DNA synthesis and it is generally 
considered that this is its major mode of action as a cytotoxic 
agent. The actual cause of cytotoxicity as a result of the 
inhibition of DNA synthesis is still unclear. Woodcock et ail. , 
suggest that araC and other DNA synthesis inhibitors cause cell death 
by producing severe chrcmoscmal aberrations. These aberrations are 
postulated to be caused by the reinitiation of previously replicated 
sements of DNA resulting in the formation of two daughter helices in 
that section of DNA. This in turn would cause a deformation in the 
DNA double helix and resultant clircmosomal abnormalities (130, 198). 
Recently Mayor et ail. , have proposed that cell death is a direct 
result of the incorporation of araC into internucleotide linkages 
which in turn causes a decrease in elongation rate (199). Frcm the 
work presented here it is seen that cytosine arabinoside is 
incorporated into DNA and that it can also produce a decrease in 
elongation rate. However the proposition that the decrease in 
elongation rate is a direct result of araC incorporation and that 
this is also the cause of cell death seems unlikely in the light of 
the bulk of the evidence concerning the mechanism of action of araC 
(see 4.1).
It is generally considered that araC is a ccmpetitive inhibitor 
of DNA polymerase a with respect to dCIV and it is thought to exert
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its inhibitory effect on DNA replication primarily in this way (110,
121). Studies on its effect on DNA replication have indicated that 
it is an inhibitor of DNA chain elongation (123, 126, 127) as would 
be expected frcm an inhibitor of DNA polymerase u. In contrast to 
this Fridland has proposal that at low concentrations of araC its 
primary effect is as an inhibitor of replicón init iation (128, 129).
The results presented in this thesis indicate that even at low
concentrations araC is an inhibitor of elongation in Namalwa cells.
-95 x 10 M araC has toen shown to slow down the rate of DNA chain 
elongation. Though an effect on initiation cannot be totally 
discounted from these results it is suggested that any effect on 
initiation is a secondary effect caused by the inhibition of 
elongation. It is possible that the decrease in elongation rate may 
represent an inhibition of the ligation of DNA pieces between 12 S 
and 25 S. Hi is cannot be determined from the results presented here 
but in the light of other evidence concerning the effect of araC on 
DNA polymerase a it is suggested that any effect on ligation is a 
secondary effect caused by the inhibition of elongation. The results 
presented here agree with similar results presented by Dijkwel and 
Wanka (126) and also agree with the conclusions of Wist et al. (125) 
and Heligren et al. (127).
Ttie effect of aphidicolin on DNA replication in Namalwa cells was 
also investigated. Aphidicolin is an inhibitor of DNA synthesis and 
50% inhibition of Namalwa DNA synthesis was obtained with a concentration
_ 7
of 10 M of the compound. It is a known inhibitor of DNA polymerase a 
(137) and should therefore be a specific inhibitor of DNA chain 
elongation. The results obtained using sedimentation analysis on 
alkaline sucrose gradients indicate that this is the case. Hie 
gradient profiles obtained are similar to those obtained for araC 
under similar conditions. This is another indication that araC is
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acting at the level of DNA chain elongation.
The work presented by Fridland in favour of araC acting at 
the level of initiation is not altogether conclusive. He has 
analysed the; DNA produced by CCHF-C1M lymphoblasts in the presence of 
araC using alkaline sucrose gradient centrifugation, lie proposes 
that an inhibitor of initiation should produce a decrease in the 
amount of low molecular weight DNA precursors and an accumulation of 
high molecular weight DNA intermediates and his results appear to 
show this. However the conditions which he has used to separate the 
different size-classes of DNA only allow for good separation of high 
molecular weight DNA intermediates and they do not show the effect of 
araC clearly on low molecular weight intermediates. When looking at 
tire effect of inhibitors on the process of initiation under these 
conditions one should look at the formation of low molecular weight 
primary, Okazaki, pieces of DNA produced inmediately after initiation. 
Fridland however, by only looking at the formation of high molecular 
weight DNA, is only looking directly at the elongation process.
Therefore any conclusions drawn concerning the initiation process must 
be considered with reservation.
The experimental conditions used that have been described in this 
thesis allow for the study of the formation of low molecular weight DNA 
precursors. However in order to study the initiation process directly 
a more subtle approach must be adopted. A more ideal approach would be 
to use an isolated nuclei system such as that used by Krokan et al. (200), 
lk‘i>Ji(y at al. (201, 202) and Brun and Weissbach (45). Krokan et al., 
have used an isolated IleLa cell nuclei system to investigate the process 
of initiation and have used this to demonstrate the discontinuous 
synthesis of DNA via 2-4 S, Okazaki size, pieces of DNA (203). Brun 
and Weissbach have developed a method for reconstructing a system, 
capable of synthesising DNA, derived from Hein eel 1 nuclei (45). They
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have used this systtm to demonstrate the requirement of ribonucleotide 
triphosphates and the involvement of an RNA polymerase-like enzyme 
for the? initiation of Okazaki fragments. Tlie possibility of deriving 
an isolated nuclei system frem Namulwa cells was investigated during 
the course' of tins project .
The proposexl method lor isolating nuclei was based on that 
described by Birnie (204). Numalwa cells were lysed in buffer 
containing 10 nM Tris-llCl pH 7.5, 5 mM MgClg, 0.5 irM HIT and 1%
Triton X-100. The lysate was then layered on to 2.2 M sucrose in 
10 mM Tris-HCl pll 7-5, 5 mM MgClg, 0.5 rnM mT, 0.28 M NaCl and 
centrifuged at 18,000 g, 1 hour, 4°C and the nuclei resuspended in 
150 mM NaCl, 1.5 mM MgClg, 10 mM Tris-HCl pH 7.5. As yet this system 
has not been fully developed due to the unavailability of sufficient 
cells for the preparation of an adequate number of nuclei.
This approach sluxtld be used to pursue further the effect of araC 
on eukaryotic DNA replication. One proposed possible way of doing 
this would be to make the system limiting with respect to rNTPs so 
that initiation would cease when all the rNIPs were used up. By 
adding more rNIPs at this poilit a DNA replication system that is about 
to start new rounds of initiation would be achieved. Hie inhibitory 
effect of araCIP, the active phosphorylated form of araC, could then 
be investigated using this system.
In contrast to the specific mechanian of action of the two DNA 
polymerase inhibitors is the mechanism of action of the phosphoramide 
mustard derivatives. These bifunctional alkylating agents are 
chemically very reactive compounds that can interfere with a nunber 
of biochonical processes by alkylating biological molecules. They 
are thought to inhibit cell replication by cross-linking double 
stranded DNA. The inhibitory effects of phosphoramide mustard,
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cyclophosphamide and hydroperoxycyclophosphamide on DNA synthesis in 
Namalwa cells have been compared. Cyclophosphamide has little effect 
compared with the other two compounds. 5 x 10 M cyclophoshamide
_3
only gives 20% inhibition of DNA synthesis compared to 5 x 10 M
• -3phosphornmlde mustard which gives 6f>% inhibition and ft x 10 M
hydroperoxycyclophosphumide which gives 90% inhibition. This
differential effect is to be expected as in the in vivo situation
cyclophosphamide has to be activated by oxidative, hepatic microsomal
enzymes. The hydroperoxy compound is an analogue of the activated
4-hydroxycyclophosphamide. Cyclophosphamide, after oxidative
activation, breaks down slowly to give phosphoramide mustard which
is thought to be the active form of the drug. However the effect of
hydroperoxycyclophosphamide is much greater than that of phosphoramide
mustard. This may be due to secondary effects of the metabolites of
4-hydroperoxycyclophosphamide.
When the DNA produced by Namalwa cells in the presence of the 
alkylating agents was analysed on alkaline sucrose gradients DNA 
intermediates of an unusual size were found. It is suggested that 
these represent segments of DNA that have been alkylated by the drugs 
thus producing cross-linked DNA segments of unusual sizes. A more 
subtle method of investigating this possible cross-linking phencmenon 
would be to measure density changes in the DNA using CsCl buoyant 
density centrifugation coupled to incorporation studies with 
brcmodeoxyuridine (BrdUrd). Incorporating BrdUrd into the DNA of 
synchronised cells results in the production of DNA of a higher 
density than normal DNA, this can be detected on CsCl gradients. 
Cross-linking of DNA strands by alkylating agents should enhance this 
effect by preventing replication and the subsequent incorporation of 
BrdUrd into DNA.
Another approach would U> to use radiolnlx'lled derivatives of
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phosphor amide mustard and hydroperoxycyelophosphamide. The binding of 
the alkylating agents to the I)NA molecule could lx; followc<l using a 
similar method to that used for studying the incorporation of araC 
into DNA. The label should ideally be on the phosphorus atcm of the 
molecule or on one of the csuixm atoms on one or lx>th of the alkylating 
arms. Those radioact ive derivat ives could then lx; incubated with the; 
target cells and the ONA analysed on alkaline sucrose gradients. The 
incorporation of the radiolabel into one or more of the DNA inter­
mediates would indicate the interaction of the alkylating agent with DNA.
The study of the inmunosuppressive action of glucocorticoids was 
part of an industrial project concerned with the screening of 
potential topical anti-inflamnatory agents. The objective of the 
study was two-fold (a) to look at the inhibitory effect of a number 
of different steroids on an in vivo irrmunological assay, the oxazolone- 
induced, delayed-lype hypersensitivity response and (b) to develop an 
in vitro assay for screening potential iimunosuppressive steroids. The 
results presented show the effect of three different steroids on the 
Dili response. These were 6-a-methyl prednisolone, clobetasol 
propionate and clobetasone butyrate. It had already been demonstrated 
using an in vivo assay system for measuring epidermal DNA synthesis in 
hairless mice that the modification of the C-ll position on the steroid 
with either an alcoliol or a keto group could alter the pharmacological 
activity of the steroid (152, 154). It was shown using the DTH assay 
that the alcohol, clobetasol propionate, had a greater inhibitory 
effect on the DTH response than the ketone, clobetasone butyrate. The 
topical steroids were also shown to inhibit the 17111 response more 
efficiently that the water soluble steroid, 6-a-methyl prednisolone.
The substitution of a halogen at C-9 for a hydrogen has been shown to 
have an effect on the therapeutic response to imflanmation. It has 
been sliown that elolxjtusone Ixityrate is more effective than the
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unhalogenated steroid, hydrocortisone butyrate, against psoriasis (205). 
The lack of a halogen at C-9 in 6-a-methyl prednisolone may therefore 
be the reason for this difference.
The method of administering the drug is also important. Lipophilic 
steroids that c;ui lx? applied topically are more desirable as anti- 
inflanmatory agents. A more likely reason for the lower efficiency 
of 6-a-methyl prednisolone as an inhibitor of the DTH response is that 
it was administered as an injection into the muscle and therefore had 
to reach the site of action via the systemic circulation. Therefore 
it could not be concentrated at the site of the inflamnation like the 
topical steroids.
The DTH assay has several limitations. It is an inminological 
assay and as such primarily demonstrates the inrnunosuppressive response 
of steroids to inflammation. It also does not provide a method for 
comparing the systemic and local action of topically applied steroids 
like the hairless mouse assay which was used to show the pronounced 
systemic effect of clobetasol propionate. It also provides no insight 
into the cellular mechanian of steroid inhibition.
In order to overcome this latter problem an in vitro tissue culture 
system was set up using PHA' stimulated lymphocytes isolated from himan 
blood. PHA selectively acts on T lymphocytes. As the DTH response 
is primarily a T lymphocyte mediated response the tissue culture 
system provides a useful in vitro analogue of the in vivo assay. The 
lymphocytes were stimulated with PHA and the induction of DNA synthesis 
was characterisod by finding the period of maximum DNA synthetic 
activity. This was found to occur 72 hours after the addition of PHA
to the isolated lymphocyte cultures. DNA synthesis was measured by 
3
the incorporation of H-thymidino into acid prccipltable material. It 
was shown that this response to I’ll A could lx? inhibited by cytosine
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arabinoside, aphidicolon and 6-a-methyl prednisolone. 60% inhibition
was obtained will) 10 *’ M 6-(i-enc;Lhyl prednisolone, 10 ^ M  aphidicolin 
—8
and 10 M cytosine arabinoside. Cytosine arabinoside and aphidicolin
act at the period of maximum DNA synthetic activity since they are S
phase s|Hvilic inhibitors. Tlie steroid liowever luis to Ik ? added to
the cultures at Lite s ; u i k ;  time as Hie milogon. The steroids appear to
act as antagonists to the PHA response by affecting the molecular
processes which are activated by the mitogen. PHA acts by a four
step activation process which induces isolated lymphocytes to enter
the G1 phase of the cell cycle (176). Steroids act at the Gl/S phase
of the cell cycle (187) and this is probably one reason why they only
inhibit the PHA res)x>nse when acininistered soon after mitogen
addition. Isolated rat lymphocytes were similarly treated with PHA
and the period of maximum DNA synthetic activity after mitogen
stimulation was determined. This was found to occur 72 hours after
the addition of the mitogen. The response was also shown to be
inhibited by 6-a-methyl prednisolone, 90% inhibition being obtained 
-4with 10 M of the steroid.
In order to make the in vitro assay more representative of the
in vivo DTH system rat peripheral lymphocytes were treated with an
oxazolone-rat serum albumin* conjugate instead of PHA. It was shown
that this oxazolone-protein conjugate was capable of stimulating DNA
synthesis in isolated rat peripheral lymphocytes. This response was 
-4inhibited 84% by 10 M 6-a-methyl prednisolone. If developed 
further this modification of the in vitro assay system should provide 
a useful method for screening potential immunosuppressive gluco­
corticoids.
Further experiments should be performed in order to fully 
characterise this system. First, of all in order to demonstrate the 
validity of the in vitro assay lymphocytes should lx1 isolated frem
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rats sensitised to oxazolone and transferred to unsensitised animals.
These s h o u l d  t h e n  be challenged w i t h  oxazolone. If t h e  t r a n s f e r r e d  
l y m p h o c y t e s  are the n x x l i a t o r s  o f  t h e  I Till r e s | X )n s e  t h e  recipient a n im a l s  
s h o u l d  e x h i b i t  a mil response o n  b e i n g  challenged w i t h  oxazolone.
Another similar transfer cx|>erimcnt that could U >  |x>rfomxl would I xj  
to isolate lympliixytes linn uasensitised rats and treat the lymphocytes 
with the oxazolone-rat serum albumin conjugate. These treated 
lymphocytes can then be transferred to other unsensitised rats which 
can then be challenged with oxazolone. If the conjugate is mimicking 
in vitro the contact sensitising effect of oxazolone in vivo the 
animals should exhibit a OTll response on oxazolone challenge.
The system could be further developed by using mouse lymphocytes 
which can be readily isolated Iran mouse spleens. A satisfactory 
method for isolating viable rat and mouse spleen lymphocytes was in 
the process of being developed but was not carried to a successful 
conclusion. However, once these problems have been overcane, mouse
l
spleen lymphocytes could provide a useful system as they have been well 
characterised imnunologically in terms of their cell surface antigens.
j
If mouse lymphocytes could be induced to respond to treatment by an 
oxazolone-mouse serum albumin conjugate then the sub-population of 
lymphocytes responding to the conjugate could be identified. There 
are several ccmnercially available radio-inmunoassay techniques for 
identifying the different cell surface antigens on mouse lymphocyte 
cell membranes. These antigens can be used to identify different 
mouse lymphocyte populations. If an oxazolone-prc '•>1 n conjugate is 
mimicking the in vivo response to the contact sensitising effect of 
oxazolone the population of lymphocytes involved should lie T lympho­
cytes.
The work presented in this thesis has demonstrated the diversity 
of cytotoxic agents that affect the HNA replicat tve machinery. Sam;
I
INI
of these compounds are used clinically as anti-cancer and irnnuno- 
suppressive drugs. Their effect on lymphoblasts has been investigated 
and their different mechanisms of action discussed in the light of the 
results obtained. A biochemical study of drug action such as this can 
increase our understanding of lhe therapeutic activity of drugs and 
provide a biochemical rationale for thc;ir clinical use.
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A p p e n d i x  I
CALCULATION OF COUNTS DUE TO 3H AND * 14C IN DOUBLE ISOTOPE 
EXPERIMENTS
When detennining the radioactivity of a sample containing two
radioactive isotopes each isotope contributes to the total amount of
3 14radioactivity. In the case of the H and C isotopes each enitts 
radioactivity of different energies and so their radioactivities can 
be counted separately on a scintillation counter using two separate 
channels with different energy limits. However there is always seme 
overlap between the two channels therefore the amount of radioactivity 
in each channel is the sum of the radioactivity of the major isotope 
and leakage of radioactivity from the other channel. The counts due 
to 3II and in the double labelling experiments described in 
Chapters 4, 5 and 6 were calculated using the method described below 
which ccmpensates for this leakage frem one channel to another.
3
It was assumed that there was no leakage from the H channel to
14 14the C channel so that all the counts in the C channel are solely
14 * 14the result of the C isotope. The leakage from the C channel to
the 3H channel was calculated using a ^ C  standard. The ratio of 
3 14counts in the II channel and C channel was calculated for the 
standard, this ratio is called f and had a value of 0.19 under the 
conditions used.
14Iiet the counts in the C channel due to the standard be A 
3Let the counts of the H channel due to the standard be B
correction factor f = B/A = 0.19 for the conditions used.
14Total C counts due to the standard = A + A.f = A + B 
3 14The counts due to II and C for a sample were calculated thus:
l£t the counts in the C channel be A' and the counts in the 
channel be B'.
The total counts due to = A' + A'f where A'f is the nunber of counts
14 3
due to C in the H channel
Tlx? total counts due to ‘H = IV - A'f.
14
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A p p e n d i x  I I
CALCULATION OF SEDIMENTATION COEFFICIENTS
The size and molecular weight of HNA can Ik' calculated using 
sedimentation analysis on alkaline sucrose gradients (206). The size 
of a macrcmolecule can be defined using a sedimentation coefficient 
(s) which is defined as
u)2r
dr
dt (1 )
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where r (cms) is the distance of the molecule from the axis of 
rotation at time t (seconds) and oj is the angular velocity of the 
rotor (radians/second). Sedimentation coefficients are usually 
expressed in Svedburg units (S), one Svedburg unit is equal to 10- 
seconds. Sedimentation coefficients are dependent upon the experi­
mental conditions used and the properties of the centrifugation 
medium therefore all sedimentation coefficients are defined for a 
set of standard conditions. A standard sedimentation coefficient is 
obtained for a given macrcmolecule when sedimenting torough water at 
20°C and is expressed asS 20, w. Water is unsuitable as a centrifu­
gation medium so all coefficients are measured in density gradient 
media and converted to S 20, w. A convenient method for calculating 
values of S has been devised by McEwen (207). This allows for direct 
calculations of sedimentation coefficients using a set of precomputed 
tables. This method relies upon the gradients used being isokinetic. 
An isokinetic gradient is one in which a constant rotor speed will cause 
a given macrcmolecule to move with a constant velocity which is 
independent of the distance moved. Such a condition will be met if, 
as the particle sediments, the increased centrifugal force is
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balanced by the increased density and viscosity of the gradient medium. 
These conditions have been shown to exist in a linear, 5"-20% sucrose 
gradient such as the ones described in this thesis (see Chapter 4) (208).
Under these conditions the S 20, w of a molecule sedimenting at 
temperature T (°C) through a inediun of density pT,M tuid viscosity nT,M
S 20 w = —
a)2r dT ' n2 0 ,w(pp “ PT,M)
(2)
where P2 0,w an(l 0 2 0,w are density and viscosity of water at 20°C 
and pp is the density of the sedirpenting particle in that medium.
For the following calculations the density of DNA was assumed to be 
1 . 2  g/cm3.
Integration of (2) yields
S 20, w
'
w2 dt
h t ,M(pP - P 2 0, w ) 
n2 0 ,w(pp - p t ,M)
(3)
Assuning that the acceleration and deceleration times are 
negligible the time integral on the left becomes S 20, w u2t where 
t is the total time of centrifugation. When the gradient is linear 
the radiun can be expressed in terms of the sucrose concentration (Z).
dz _ Z - Zo 
dr T
Where Zo is the extrapolated value of the sucrose concentration at the 
centre of rotation. Thus the right hand side of the integral may be 
expressed in terms of the sucrose concentration if the temperature, 
particle density and Zo are known. If during centrifugation a 
particle moves from sucrose concentration Zj and time tj to a 
sucrose concnetraton Z^ at time t2 equation (3) can be written as
S  20, w.<o? ( t 2 -  t j )  = I ( Z 2 ) -  I ( Z j )
isr»
balanced by the increased density and viscosity of the gradient medium. 
These conditions have been shown to exist in a linear, 5a-20% sucrose 
gradient such as the ones described in this thesis (see Chapter 4) (208).
Under these conditions the S 20, w of a molecule sedimenting at 
temperature T (°C) through a mediun of density pT,M and viscosity nT,M
S 20 w = — . —  J1T. . M( pP Z.J12A., w )
u)2r dT ' H2 0 ,w (pP “ PT,M)
(2)
where P 2 0 ,w an(* 020 ,\v are the density and viscosity of water at 20°C 
and pp is the density of the sedirpenting particle in that medium.
For the following calculations the density of DNA was assuned to be 
1 . 2  g/cm^.
Integration of (2) yields
S 20, w ui2dt
h t ,M(pP - P2 0 ,w )
H2 0 ,w(pp - PT,M)« (3)
Assuming that the acceleration and deceleration times are 
negligible the time integral on the left becomes S 20, w w2t where 
t is the total time of centrifugation. When the gradient is linear 
the radiun can be expressed in terms of the sucrose concentration (Z).
dz _ Z - Zo 
dr T (4)
Where Zo is the extrapolated value of the; sucrose concentration at the 
centre of rotation. Thus the right hand side of the integral may be 
expressed in terms of the sucrose concentration if the temperature, 
particle density and Zo are known. If during centrifugation a 
particle moves from sucrose concentration Zj and time tj to a 
sucrose concnetraton Zg at time tg equation (3) can be written as
S 20, w.id2(tg - tt) = I(Zg) - I(Zj)
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The values of I(Z]) and I(Z2) are obtained from McEwens tables (207). 
Zo can be estimated from the knowledge of the dimensions of the rotor 
used.
Zo = Zlr 2 " Z2rl
Where r^ is the distance from the axis of rotation of sucrose 
concentraton Zj and is the distance from the axis of rotation of
2‘sucrose concentration Z,
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